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Chronic kidney disease (CKD) is associated with high cardiovascular morbidity and 
mortality.1 This increased risk is higher than expected taking into account the prevalence 
of traditional risk factors, such as hypertension, dyslipidemia and diabetes, suggesting that 
CKD specific factors may play a causal role. Disturbed calcium-phosphate metabolism, 
and especially Fibroblast Growth Factor 23 (FGF23) have appeared to a be associated with 
this increased risk for cardiovascular disease (CVD).2,3 FGF23 increases progressively as 
kidney function declines. This process starts already at stage 3 or even stage 2 of CKD.4,5 
SUMMARY OF FGF23 PHYSIOLOGY 
FGF23 was discovered two decades ago, in the search for an at that time unidentified 
phosphaturic hormone in patients with hypophosphataemic rickets and tumor-induced 
osteomalacia, both diseases characterized by disproportional urinary phosphate 
losses.6  FGF23’s main function is to maintain phosphate homeostasis, an important 
role as phosphate is an crucial mineral for several physiological processes such as 
membrane composition, nucleotide structure and cellular signaling, bone development 
and mineralization.7 
The principal cellular source of FGF23 production and secretion is the osteocyte. 
The active form of FGF23 consist of the full length protein with a unique C-terminal 
structure and specific three-dimensional configuration accounting for its systemic action.8,9 
FGF23 is one of the three regulators of phosphate homeostasis, together with PTH and 
1,25-dihydroxy Vitamin D (1,25(OH)2D). The first two hormones both have phosphate 
lowering effects by decreasing tubular phosphate reabsorption but have opposite effects 
on vitamin D activation, which is enhanced by PTH, but inhibited by FGF23. 1,25(OH)2D 
regulates phosphate metabolism through increasing intestinal phosphate absorption and 
inhibition of PTH secretion. (see figure 1). 
FGF23 binds to the distal tubule of the nephron and by unknown mechanisms 
inhibits phosphate reabsorption in the proximal convoluted tubule, by downregulation of 
the sodium dependent phosphate transporters (NaPi2a and NaPi2c).10 FGF23 binds with 
only modest affinity the FGF Receptors (FGFR) and mainly to FGFR type 1,3 and 4.11 Co-
expression of α-Klotho is generally considered to be necessary for high-affinity binding 
of FGF23 to the FGF23 receptors to induce intracellular signal transduction, at least so 
for the FGFR112-14 Klotho-FGFR complexes are mainly expressed in the parathyroid glands 
and the kidney, the key target tissues of FGF23.10,15,16 FGF23 decreases the release of PTH 
in the parathyroid gland through suppressed PTH secretion and PTH gene expression.17 
The other way around, there is evidence that PTH increases FGF23 concentrations,18,19 
thereby completing a negative endocrine feedback loop. 
FGF23 lowers circulating 1,25(OH)2Vit D concentrations. It does so by inhibition of 1 
α-hydroxylase, the enzyme necessary for activation of vitamin D, in the distal convoluted 
tubule.20-22 FGF23 further stimulates 24-hydroxylase, the enzyme responsible for 
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metabolic inactivation of vitamin D.23 This results in less 1,25(OH)2Vit D production and 
more degradation.24 Through vitamin D inactivation, FGF23 has also an indirect effect on 
serum phosphate, with less phosphate being absorbed from the intestinal tract. 
The exact mechanism for phosphate sensing and FGF23 synthesis and secretion have 
not been fully elucidated. FGF23 is stimulated by oral phosphate loading and inhibited 
by phosphate restriction, as was shown in a study in healthy individuals.25 In addition to 
phosphate as a stimulator, FGF23 synthesis is also stimulated by PTH, vitamin D and calcium. 
Iron deficiency also stimulates osteocyte FGF23 production, but generally only the cleaved 
FGF23 is released in this setting. Furthermore, osteocytes act as mechanoreceptors and 
FGF23 secretion is inhibited when osteocytes are under strain, as in exercise, to retain 
phosphate for bone formation.26 
FGF23 IN CKD
In CKD, FGF23 concentrations rise progressively as kidney function deteriorates.4 This 
increase of FGF23 is adaptive to maintain serum phosphate levels in the normal range, as 
outlined above, to compensate for decline phosphate filtration at the glomerular level. 
However, this adaptation comes with a price. While aiming to restore phosphate balance, 
FGF23 induces 1,25(OH)2 D deficiency, subsequent decline of serum calcium, which 
triggers hyperparathyroidism to develop.27 Long term secondary hyperparathyroidism leads 
Figure 1. Figure with permission adapted from Vervloet et al. Nature Reviews Nephrology 2017 




to osteodystrophy. Although FGF23 inhibits PTH production, this regulatory mechanism 
increasingly fails during progression of CKD and the parathyroid gland becomes resistant 
to FGF23.28 Since PTH induces FGF23 transcription and secretion, the increase of PTH 
leads to an amplification of FGF23 production.29 In addition to the effects of FGF23 
on phosphate and calcium metabolism, FGF23 overexpression may induces several ‘off 
targets effects’, notably on the immune and the cardiovascular system, but also on bone 
and on iron metabolism. The adverse (off-target) effects of increased FGF23 combined 
with its strong association with different cardiovascular outcome measurements leads to 
the hypothesis that FGF23 might be, in the causal pathway to the development of CVD 
and mortality. 
AIM AND OUTLINE OF THIS THESIS
This thesis focused on the question whether it is beneficial to modify FGF23 levels. If 
lowering of FGF23 leads to a reduced risk for adverse outcome, then interventions should 
aim at lowering FGF23 in order to improve patient outcomes.
Chapter 1.2 starts with a broader perspective on the possible clinical usefulness 
of FGF23 measurements in the near future. It reviews the literature on the reliability 
of the FGF23 measurement and provides an overview of studies examining FGF23 as 
a tool for improving patient risk classification. This chapter introduces the main question 
of this thesis, namely the discussion on whether lowering FGF23 might be beneficial. 
This chapter therefore reviews the current evidence indicating that FGF23 may be in 
the causal pathway to cardiovascular pathology, provides an overview of strategies to 
lower FGF23 levels and discusses the current evidence concerning the benefit of lowering 
FGF23. In Chapter 2 we search for evidence from epidemiological data that supports 
the hypothesis of FGF23 having a role in the pathogenesis to cardiovascular outcome. 
For this we investigate in chapter 2.1 the natural course of FGF23 in a CKD stage 3 
population to evaluate if change of FGF23 affects future cardiovascular events and 
mortality. In addition, in Chapter 2.2 the associations of FGF23 with different outcomes 
and in different populations are compared on magnitude and consistency to explore if 
FGF23 shows an exposure-responses relation to clinical outcome. Because it is postulated 
that very high FGF23 concentrations, as occurs during progression of CKD, merely reflect 
a state of resistance to FGF23, we investigate in chapter 3 if the association of FGF23 
and outcome is determined by FGF23 resistance. Because observational studies can only 
hint at a cause-effect relation between FGF23 and outcome, we performed in chapter 4 
a study to specifically target FGF23 and evaluate the effect of this intervention on arterial 
stiffness. We investigate in this chapter if FGF23 can be reduced by sevelamer, an oral 
phosphate binder, and whether this improves arterial stiffness measured by pulse wave 
velocity (PWV). As hemodiafiltration (HDF) has shown to be able to effectively lower 
FGF23 concentrations, we investigated in chapter 5 in a population on hemodialysis (HD) 
or HDF whether change of FGF23 over time influenced outcome. Chapter 6 summarizes 
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Chapter 1.2REVIEW: F IBROBLAST GROWTH 
FACTOR 23:  ARE WE READY TO 
USE IT  IN CLINICAL PRACTICE?
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Patients with chronic kidney disease (CKD) have a greatly enhanced risk of cardiovascular 
morbidity and mortality. Over the past decade it has come clear that a disturbed calcium-
phosphate metabolism, with Fibroblast Growth Factor-23 as a key hormone, is partly 
accountable for this enhanced risk. Numerous studies have been performed unravelling 
FGF23s actions and its association with clinical conditions. As FGF23 is strongly associated 
with adverse outcome it may be a promising biomarker for risk prediction or, even more 
important, targeting FGF23 may be a strategy to improve patient outcome. This review 
elaborates on the clinical usefulness of FGF23 measurement. Firstly it discusses the reliability 
of the FGF23 measurement. Secondly, it evaluates whether FGF23 measurement may 
lead to improved patient risk classification. Finally, and possibly most importantly, this 
review evaluates if lowering of FGF23 should be a target for therapy. For this, the review 
discusses the current evidence indicating that FGF23 may be in the causal pathway to 
cardiovascular pathology, provides an overview of strategies to lower FGF23 levels and 





Chronic kidney disease (CKD) is a major health concern, given its high prevalence and 
associated cardiovascular morbidity and mortality, leading to a high rate of health care 
consumption.1 This high burden of cardiovascular disease (CVD) is seen in CKD stage 
3 and beyond. Although traditional risk factors, such as hypertension, diabetes and 
smoking contribute to the development of CVD in CKD, they cannot fully explain the high 
incidence of cardiovascular mortality in these patients.2,3 Disturbances in calcium-
phosphate homeostasis are probably contributing to this high mortality risk.4 A key 
hormone, in the regulation of calcium-phosphate homeostasis is the 32-kDa peptide 
Fibroblast Growth Factor-23 (FGF23). This hormone was discovered in the early 2000s 
in patients with autosomal dominant hypophosphataemic rickets (ADHR).5 This disease 
is characterized by hypophosphatemia and hyperphosphaturia resulting in growth 
retardation, bone deformities and rickets.6,7 FGF23 appeared to be the humoral factor 
to induce this excess renal phosphate loss. FGF23 is secreted by osteocytes in bone and 
is one of the three regulators of phosphate homeostasis, together with PTH and 1,25 
dihydroxycholecalciferol (1,25(OH)2D3). The first two hormones both have phosphate 
lowering effects by decreasing tubular phosphate reabsorption by downregulation of 
the sodium dependent phosphate transporters (NaPi2a and NaPi2c),8 but have opposite 
effects on vitamin D regulation, which is activated by PTH, but catabolized by FGF23.9-12 
FGF23 acts on its main target organs, the kidney and parathyroid, by binding to the FGF23 
receptors with α-Klotho as a co-receptor. This co-receptor is generally considered to be 
necessary to induce intracellular signal transduction, at least so for FGFR1.13-15
Nowadays FGF23 has gained wide attention in chronic kidney disease associated 
mineral bone disease (CKD-MBD) and appears to be a candidate as missing link 
between chronic kidney disease and cardiovascular morbidity and mortality. FGF23 levels 
increase during progression of CKD.16,17 Although this, initially physiological, adaptation 
is crucial for maintaining phosphate balance in early CKD, prolonged exposure and 
extreme concentrations in advanced CKD may have deleterious effects, in particular 
on the cardiovascular system.18-20 Several observational studies showed an independent 
association between FGF23 levels and adverse outcome through all stages of CKD. 
Over the last decade a legion of studies has been published on FGF23, unravelling 
its biology, physiological actions and its association with clinical conditions. Some 
epidemiological data and experimental studies suggest that FGF23 not only acts as 
regulator of parathyroid hormone (PTH), vitamin D, or phosphorus, but may actually be 
in the causal pathway to cardiovascular pathology. However, definite proof of causality is 
lacking, since many questions still remain. This review will focus on the clinical usefulness 
of FGF23 as a biomarker and its potential use as a target for therapy.
RELIABILITY OF FGF23 MEASUREMENT
Currently, FGF23 is rarely measured in routine clinical practice. There are four 
immunoassays commercially available for measurement of FGF23: Immutopics (1st and 
20
1
2nd generation, San Clemente, USA), Kainos (Tokyo, Japan), Millipore (Billerica, USA) 
and DiaSorin (Saluggia, Italy). Most assays measure the intact 251 amino-acid protein 
(iFGF23) by simultaneous recognition of epitopes on the N- and C-terminal domains close 
to the proteolytic cleavage site. Additionally, Immutopics has an assay which measures 
both iFGF23 and the C-terminal fragment of FGF23 (cFGF23) by two antibodies against 
two epitopes within the C-terminal portion. 
The four assays differ substantially as they are using different antibodies targeting 
different epitopes on the FGF23 protein. Besides different reported units (iFGF23 in 
picograms per milliliter (pg/ml) and cFGF23 in relative units (RU) per milliliter), absolute 
values between the assays vary substantially due to different calibration, and no 
harmonization has ever been conducted.21,22 
If FGF23 would be used as a new biomarker certain issues need to be assessed. An 
ideal biomarker would be stable (no degradation ex vivo), show minimal diurnal variability 
and the analysis should be accurate, reproducible and affordable.23 
Stability of FGF23
There are several studies performed to assess the stability of FGF23, since intact FGF23 
may be degraded by proteases or modified after blood withdrawal. First of all, iFGF23 
is significantly more stable in plasma (EDTA) than in serum.24 Even if samples after 
venepuncture are directly centrifuged and processed, there is the possibility of direct 
post-venepuncture instability of FGF23. The latter was investigated by Dirks et al. who 
found no differences between FGF23 concentrations in normal EDTA collecting tubes 
compared to tubes pre-coated with a protease-inhibitor, suggesting that no immediate 
protein proteolysis occurs after normal blood withdrawal.25 
However, when centrifugation is delayed a significant decrease of intact FGF23 
concentrations was observed in several studies, both in healthy volunteers as well as in 
patients on dialysis, of 12% with the Immutopics assay, 7% with the Millipore assay and 
5% with the Kainos assay (all p< 0.05).25 This confirmed two earlier studies that showed 
23% reduction of FGF23 measured after a 8 hour delay of centrifugation (compared 
with prompt centrifugation) using the 2nd generation Immutopics assay.21 Comparable 
reductions were found with the Millipore and Kainos assays.21,26 With the DiaSorin assay 
no such decrease in FGF23 concentrations was found.27 
Also, post-centrifugal stability of intact FGR 23 has been tested. No decrease of 
intact FGF23 concentrations are observed when in directly centrifuged samples delayed 
measurement of intact FGF23 was performed (after8 hours or more) with all the four 
currently used assays.25,28,29 Besides, there are no indications of degradation of intact 
FGF23 after storage of processed samples at -80 C°.25 
Biological variability 
In healthy subjects, iFGF23 is subject to significant diurnal variation as iFGF23 




25%).30,31 In contrast, cFGF23 concentrations show only a modest non-significant 
increase during the day.31 The inequality of diurnal variation between iFGF23 and 
cFGF23 concentrations likely reflects the difference in clearance of the intact protein or 
its C-terminal fragment.32 iFGF23 concentrations increase after phosphate intake with 
a delay of at least 12 hours.31,33 Therefore it is preferable when measuring iFGF23 to use 
fasting samples or early morning samples as it is shown that iFGF23 concentrations in 
early morning samples are comparable to fasting samples.30 In contrast, cFGF23 shows no 
significant postprandial changes in healthy individuals or patients with early CKD.31,34,35 It 
is unlikely that a circadian rhythm is of clinical relevance in situations like advanced CKD, 
where FGF23 levels are extremely elevated.
Accuracy and reproducibility of methods for FGF23 measurement of 
different assays
In healthy adults, the 95% reference limits for plasma iFGF23 is 11.7–48.6 pg/mL and 
for cFGF23 21.6–91.0 RU/mL.30 The intra- and inter-assay coefficient of variation are 
respectively, <2.4% and < 4.7% for the 2nd generation Immutopics cFGF23, < 9.7% and 
< 14% for the Kainos assay,36 < 2,9% and < 6.% for the DiaSorin assay,28 and lastly, 
<10% and < 8% for the Millipore assay. These latter variations are values provided by 
the manufacturer. The Millipore assay also reports to have a wider functional analytical 
range, this comes at the expense of poor sensitivity at low concentrations.21 The first 
generation intact assay of Immutopics had an unacceptably high inter-assay coefficient 
of variation,36 that was substantially improved in the second generation assay to <5 %.37 
In patients on dialysis FGF23 concentrations become very high (frequently exceeding 
100,000 RU/mL in prevalent patients). As the functional analytical range of the available 
assays is limited, large dilutions may be necessary to bring the concentration within 
this range. Another problem is that in patients on haemodialysis substantial intra-
individual (week-to-week) variation in cFGF23 concentration has been reported.38,39 For 
all commercially available assays applies that they have not been validated for clinical use. 
Age- and renal function adapted reference ranges have not been established yet. 
Using intact or c-terminal FGF23 assay and when? 
The measurement of cFGF23 has, as earlier stated, the advantage of little diurnal variation 
and has more desirable variance characteristics with higher inter-individual than intra-
individual variation. Besides, cFGF23 is more consistently associated with outcome as 
shown in the meta-analysis of Xiao et al. in which c-term FGF23 was associated with 
mortality in HD patients whereas iFGF23 measurement did not correlate to mortality.40 
Furthermore cFGF23 is a better predictor for identifying patients with declining renal 
function,41 atherosclerosis associated cardiovascular disease and heart failure.42 
Therefore, the cFGF23 assay may outperform the iFGF23 assay for clinical use, especially 
for the purpose of patients individuals risk assessment.
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However, iFGF23 may better represent the biological effect of FGF23,43 especially 
since it is reported that the c-terminal fragments might have counter-regulator effects 
to the biologically active full-length hormone.32 A recent study on the effect of dietary 
phosphate restriction on FGF23 levels found a more pronounced effect on iFGF23, than 
on cFGF23.44 
FGF23 AS A RISK PREDICTOR
FGF23 is associated with progression of kidney failure and initiation of dialysis.41,45-49 This 
raises the question if FGF23 measurement might be a useful tool for risk prediction for 
progression of CKD and for other adverse outcome. Tangri et al. developed a model to 
predict progression of CKD that was validated in thirty-one cohorts, including 721,357 
participants with CKD stages 3 to 5 (including age, gender, eGFR, albuminuria, serum 
calcium, serum phosphate, serum bicarbonate, and serum albumin) with a good 
performance of overall C- statistics ( 0.90; 95% CI, 0.89-0.92). Several studies evaluated 
if FGF23 was able to improve this predictive value using specific statistics such as the area 
under the ROC curve and net reclassification index (NRI) statistics.50 However, only one 
small study found that adding FGF23 to a base model improved the agreement of 
predicted and observed probability of renal function decline,51 all other studies found 
no significant improvement of risk prediction for decline in renal function or ESRD with 
the addition of FGF23.49,52-54 
However, for the prediction of all-cause mortality it has been reported that FGF23 
might have added value in patients with CKD. 49,53,54 In a large study from the CRIC cohort 
by Edmonston et al. an improved prediction for all-cause mortality and hospital admission 
for heart failure was found when FGF23 concentration was added to the model, but 
the NRI did not reach statistical significance. For cardiovascular mortality no improved risk 
prediction was found.54 Furthermore, in patients on hemodialysis, addition ofFGF23 did 
not improve risk prediction for mortality.55,56
Concerning cardiovascular events, FGF23 does not consistently improve prediction 
of novel events in hemodialysis patients.57 Although one study showed that FGF23 
improved prediction of fatal and non-fatal cardiovascular events in predialysis patients,49 
another study showed small improvement of prediction only, yet without improved (NRI) 
classification. However, other studies showed no improvement at all.42,54 Interestingly 
the study by Emrich et al. found that when NT proBNP was added to the model the predictive 
value of FGF23 was largely eliminated and NT proBNP had a much stronger discriminating 
ability than FGF23.42 Overall, FGF23 only marginally improved the prediction for outcome. 
An overview of several risk predicting studies is provided in table 1.
Future studies should evaluate whether multiple measurements of FGF23 may be 
advantageous compared to a single measurement for individual patients risk assessment 
in those with CKD, as it was shown that especially increasing FGF23 concentrations over 



























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Apart from being a risk predictor, FGF23 might serve as an useful tool to identify 
patients to benefit from certain therapy. Udell et al. showed in their study among patients 
with stable ischemic heart disease that FGF23 was able to identify patients profiting 
from angiotensin-converting enzyme inhibitor therapy resulting in reduced cardiovascular 
death or incident heart failure.60
INDICATIONS OF FGF23 TOXICITY FROM 
EPIDEMIOLOGICAL STUDIES
The question however arises if FGF23, besides being a potential risk predictor for adverse 
outcomes, might also have an instrumental role in the pathogenesis of complications. 
A great number of epidemiological studies sought an answer to this question.
Mortality
One of the first studies to report an association between FGF23 and mortality was the study 
by Gutierrez et al.61 In this nested case control study among incident haemodialysis 
patients, a concentration dependent effect of FGF23 levels on mortality was observed. 
Even more interesting, this association became stronger after multiple adjustments, 
including adjustment for serum phosphate. This observation was confirmed in subsequent 
studies that followed, mainly in incident HD patients.62-65 However, this finding is not 
consistent, as other studies found no association between FGF23 and mortality in patients 
on haemodialysis.66-70 Overall, when 8 studies in patients on haemodialysis were pooled, 
a relative risk for the highest third of FGF23 versus the lowest third of FGF23 of 1.5 (95% 
CI 1.29-1.73) for all-cause mortality and of 1.42 (95% CI 0.96-2.39) for cardiovascular 
mortality was found the meta-analysis by Marthi et al.71 Remarkably, the association of 
FGF23 with mortality is stronger in CKD patients not on dialysis despite much lower 
absolute levels of FGF23.45,46,49,53,72-75 Concerning the general population, although there 
are a few studies that found no association of FGF23 with all-cause mortality,.(76,77 most 
epidemiological studies (some consisting of great number of participants) report modest 
associations, even when adjusted for eGFR.75,77-80 
Cardiovascular Disease; Myocardial infarction and Stroke
In a post-hoc analysis of the EVOLVE trial (vide infra) by Moe et al. among nearly three 
thousand patients on dialysis, FGF23 was statistically significantly associated with 
the incidence of myocardial infarction,81 an association also found in CKD 45,75 and in 
the general population.82,83 However, for ischaemic stroke, no consistent association 
with FGF23 was found in in patient on dialysis,81 nor in the general population.75,84 
Although some reports do suggest an association may exist with haemorrhagic stroke 
or thromboembolic stroke.82,85,86 Concerning patients with pre-dialysis CKD, one cohort 
consisting of nearly four thousand patients found an association between FGF23 and 
a composite endpoint including myocardial infarction, stroke and peripheral vascular 
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disease87, an observation confirmed in other CKD cohorts and in the meta-analysis by 
Marthi et al.45,71,75 
Left Ventricular Hypertrophy 
There are epidemiological data linking FGF23 and left ventricular hypertrophy (LVH). 
The relatively small studies by Hsu et al. in 2009 and by Kirkpantur et al. in 2011 found an 
positive association between FGF23 and left ventricular mass in haemodialysis patients.66,88 
However, in a sub analysis of the Evolve trial, among nearly three thousand haemodialysis 
patients, there was no association of FGF23 with heart failure.71,81 In CKD patients not 
on dialysis, the association with heart failure is more consistent. Although the study by 
Bouma - de Krijger et al. in in the Masterplan cohort found no association between FGF23 
and congestive heart failure,73 other studies did report such an association.18,75,87,89,90 Most 
epidemiological studies in the general population, one consisting of eleven thousand 
participants,79 also found an association between FGF23 and heart failure.79,83,91-93 
Combining several population studies,79,83,84,91 the meta-analysis by Marthi et al. calculated 
a relative risk of FGF23 on heart failure of 1.24 (95% CI 1.29-1.69) for the highest versus 
the lowest tertile of FGF23.71 
IS  THERE EVIDENCE THAT FGF23 CAN DIRECTLY 
INDUCE TISSUE PATHOLOGY LEADING TO ORGAN 
DAMAGE?
Apart from its associations with clinical events in etiological driven epidemiological 
analyses, numerous experimental studies investigated potential mechanisms by which 
FGF23 might induce cardiovascular pathology. 
FGF23 as a cause for left ventricular hypertrophy
Left ventricular hypertrophy (LVH) is an important contributor to cardiovascular morbidity 
in patients with CKD and LVH is associated with high FGF23 concentration.18 Several 
studies explored the potential mechanisms by which FGF23 might induce LVH. For 
this, Faul et al. administered recombinant FGF23 (rFGF23) to isolated cardiomyocytes 
and to wild type and klotho deficient mice, where subsequently hypertrophic growth 
of the myocytes and cardiac hypertrophy in mice was observed, even so in the klotho 
knock-out animals.18 FGF23 activated the FGF Receptor leading to calcineurin and nuclear 
factor of activated T cells (NFAT) signalling in cardiomyocytes. When a pan-FGF Receptor 
blocker was added to the CKD mice model, LVH was attenuated.18,94 Subsequent studies 
identified FGFR4 as the klotho-independent receptor for FGF23 on cardiomyocytes.95 
Specific blockade of FGFR4 by an antibody inhibited hypertrophy in the isolated cardiac 
myocytes and mice lacking the FGFR4 did not develop LVH in response to FGF23,96 
establishing FGFR4 as the receptor involved in FGF23-induced LVH.97 However, these 
findings are not consistently reported, as in a transgenic mouse model of CKD, with high 




Interestingly, LVH itself causes cardiac expression of FGF23. Matsui et al developed 
two mice models of LVH. In both the transgenic and the pressure overload models, 
increased expression of FGF23 in the cardiomyocyte (inducing NFAT signaling) followed 
the development of LVH, while bone expression of FGF23 remained normal.99 These findings 
were confirmed in an experimental animal models and in humans where, after myocardial 
infarction, expression of FGF23 in the heart is described.100,101 The upregulation of FGFR4 
receptor, the culprit receptor for FGF23-induced cardiotoxicity, in the myocardium might 
further contribute to hypertrophy, which would imply a feedforward loop.102 
However, contradictory to the above findings, are the results of different mouse 
models of x-linked hypophosphatemia (XLH). Mice models of XLH have excess FGF23 
production, yet those mice do not develop cardiac hypertrophy.103,104 This finding is 
confirmed in XLH patients, where no cardiac hypertrophy is observed.105 There are several 
possible explanations for these contractionary findings. Unlike the situation in CKD, XLH is 
accompanied with low serum phosphate, normal blood pressure, serum calcium and renal 
function, and the absence of vascular calcification, and this very different phenotype may 
explain the discordancy. Also, in end stage CKD, FGF23 concentrations can reach values 
that are more than 1000 fold above normal, and as such much higher than in patients 
with XLH. Also, the different animal models of LVH had a variety of systemic alterations, 
such as high phosphate, uraemia or hypertension. It is possible that the deleterious effect 
of high FGF23 levels might result from a synergy between those abnormalities. 
FGF23 and vascular calcification
Another mechanism contributing to the high burden of cardiovascular disease and 
mortality in CKD is arterial stiffness.106 This can be worsened, among other causes, by 
vascular calcification or endothelial dysfunction. Arterial stiffness, regardless of its cause, 
increases pulse wave velocity, promotes the development of left ventricular hypertrophy, 
and can result in heart failure. An unresolved question is whether FGF23 can directly 
act on vascular cells to promote or inhibit matrix calcification. Two studies, by Scialla et 
al and Lindberg et al, performed with vascular smooth muscle cells in vitro, showed no 
calcification when FGF23 was added.107,108 Also aortic rings or ex vivo mesenteric arteries 
of mice showed no calcification or changed vasoreactivity in response to FGF23.107,108 On 
the other hand, Zhu D et al. reported that addition of recombinant FGF23 had a protective 
effect on calcification in cultured murine SMCs.109 In contrast, Jimbo et al. showed that 
FGF23 amplified Pi-induced calcification in cultured human vascular SMCs overexpressing 
α-Klotho.110 Other studies focussed on the presence of α-klotho expression, necessary 
for FGFR1-mediated FGF23 action, in the vasculature. However, these results are also 
conflicting. Although some studies reported α-klotho expression and FGF23 signalling 
through FGFR1s receptor activation in the arterial wall,109-111 more compelling evidence 
refutes its presence. 107,112,113 
28
1
FGF23 and endothelial dysfunction
As outlined, besides medial layer calcification, endothelial dysfunction can also contribute 
to arterial stiffness. Yilmaz et al. found a negative association between FGF23 and flow-
mediated vasodilation (FMD) accompanied by increased concentrations of asymmetrical 
dimethyl arginine (ADMA), an endogenous competitive inhibitor of the vasodilator nitric 
oxide (NO).114 Since FGF23 and ADMA are both associated with progression of CKD, 
ADMA was added to a statistical model and was found to attenuate the effect of FGF23 on 
FMD. In two cohorts of CKD patients Tripepi et al. found a strong competitive interaction 
between FGF23 and ADMA suggesting that FGF23 is a modifier for ADMA levels, leading 
to dysregulation of the nitric oxide system associated with CKD progression.115 
Different experimental models have been used to explore this aspect of potential 
FGF23 toxicity. In an ex vivo model of isolated mice aortic rings, addition of recombinant 
FGF23 increased superoxide levels and reduced the bioavailability of nitric oxide in 
endothelial cells resulting in impaired relaxation.116 When a pan FGF23 blocker was 
administered this effect was eliminated. Another experimental study suggested that 
the effect of FGF23 on endothelial cells is mediated by reactive oxygen species (ROS) 
that negatively influence arterial vasodilator capacity.117 In that study mouse and human 
aortic rings (the latter obtained after aortic valve bypass surgery) and umbilical cord 
subjected to high concentrations of recombinant FGF23, recombinant soluble Klotho or 
phosphate in parallel showed increased ROS production. Addition of sKlotho attenuated 
the effect of FGF23 and Pi through increasing NO production, thereby protecting 
the vessel to some extend against the potentially noxious effects of high phosphate or 
FGF23 concentrations. In the study by Verkaik et al. resistance arteries from mice with 
renal failure and healthy mouse were studied ex vivo. They showed that pre-treatment 
with recombinant FGF23 impaired acetylcholine (Ach)-induced vasodilatation, which was 
restored after administration of FGF23 blocking antibodies regardless of the presence of 
renal failure.
Collectively, there is evidence that FGF23 induces arterial stiffness. This can be 
attributed to a large extent to impaired endothelial function, but unlikely to arterial 
calcification. This effect on endothelial layer mediated arterial stiffness would provide 
a rationale to target FGF23 as treatment goal. Obviously, before implementing such an 
approach, this needs clinical proof from prospective trials.
IS  FGF23 MODIFIABLE?
There are several potential strategies for reducing excess FGF23 levels or bioactivity, 
principally through dietary phosphate restriction or use of oral phosphate binders, by 
inhibiting FGFR signalling, by FGF23 blocking agents, and by the use of calcimimetics. In 




Dietary phosphate restriction to lower FGF23 
Several studies evaluated if FGF23 could be reduced by the use of dietary phosphate 
restriction. Most studies in healthy individuals with normal kidney function reported 
a decline of intact FGF23 with dietary phosphate restriction and an increased iFGF23 after 
a phosphate-enriched diet.35,118,119 Studies in CKD found also a reduction of intact FGF23 
with a phosphate restricted diet and increased FGF23 with dietary phosphate loading.120-
122 Interestingly, studies that measured C-terminal FGF23 did not report modification of 
cFGF23 with either phosphate loading or restriction, in healthy participants,31,34,35 as well 
as in patients with CKD.123,124 A possible explanation for this different findings for iFGF23 
and cFGF23 was postulated by Smith et al. in their review on the different FGF23 assays.23 
They hypothesized that dietary phosphate loading might lead to enhanced FGF23 stability, 
thus a greater proportion of biologically active intact compared to the C-terminal peptide, 
in order to restore phosphate homeostasis. Of importance is that not only the absolute 
phosphate content in food counts, but also the source of phosphate matters, since 
bioavailability of phosphate is different between organic and inorganic phosphate. 
Phosphate as a food additive (for taste or conservation) is inorganic phosphate and is 
easily absorbed (bioavailability above 90%) compared to organic phosphate derived from 
vegetables such as in peas, nuts and cereals (absorption between 40-60%). The study 
by Moe et al. in CKD patients, elegantly showed that a vegetarian diet compared to 
a meat diet, despite both diets containing comparable amounts of phosphate, induced 
a decrease in iFGF23, whereas iFGF23 increased in the meat diet.125 
Lowering FGF23 by phosphate binders
Table 2 provides an overview of several different intervention trials using phosphate 
binders that also reported effects on FGF23 levels. When calcium-containing phosphate 
binders were used, all of six studies reported no decrease of FGF23.126-131 Block et al. 
even found in their placebo controlled trial among 148 patients with moderate CKD 
(eGFR 20–45 mL/min/1.73 m2 ), an increase of intact FGF23 with the use of calcium 
acetate as a phosphate binder.129 In that study, in which patients were randomized to 
either placebo, lanthanum carbonate, calcium acetate or sevelamer carbonate, only 
the group of patients receiving sevelamer carbonate had a significant decline of intact 
FGF23 compared to placebo. Interestingly, these findings were assay-dependent as 
these results were not found when the c-terminal assay was used. Other prospective 
intervention studies that evaluated non-calcium based oral phosphate binders showed 
a similar pattern. Most studies in CKD patients measuring the intact FGF23 assay found 
a decrease of FGF23 with the use of either sevelamer,126-128,130 or lanthanum carbonate131-
133 in CKD stage 2-5 D patients. Ketteler and colleagues did report a 64% reduction of 
intact FGF23 using sucroferric oxyhydroxide (Velphoro) in patients on dialysis.134 However, 
other studies in predialyis CKD did not find a reduction of FGF23 levels with the use of 
sevelamer carbonate measuring intact FGF23.135-138 In addition, when c-terminal FGF23 
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CKD
Oliveira  
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40 Randomized trial, 
up titration med. 
every 2 weeks
6 weeks 50 35 3.5 97 pg/mL Intact (Kainos) Fixed 615 mg protein/d Calcium acetate 1.32g/d-> 2.64 
g/d-> 5,3 g/d
No change 
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16 2x2 factorial 
placebo 
controlled trial
2 weeks 62 40 3.2 158 c-term 
(Immutopics)
Pi diet 750 mg/d placebo No change
Pi diet 1500 mg/d Lanthanum carbonate 3g/d No change
Pi diet 750 mg/d Lanthanum carbonate 3g/d No change
Pi diet 1500 mg/d placebo Increase
Gonzalez-Parra 
et al. 2011 130
18 Open label trial 4 weeks 70 42 3.5 212 RU/mL c-term 
(Immutopics)
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100 Randomized 
open label trial
8 weeks 45 24 7.7 40 pg/mL Intact (Kainos) NA Sevelamer 1.6g/d, up titrated to 
Pi< 5.5 mg/dL
Reduction (27%) r
Calcium acetate 3g/d, up titrated 
to Pi< 5.5 mg/dL
No change
Bleskestad  
et al. 2012 137
21 Open label cross-
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66 37 3.3 90/110 pg/mL Intact (Kainos) Ad Libitum diet Alfacalcidol 0.25ug/d-> 
Sevelamer 1.6g/d
No change
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61 38 4.0 95 ug/mL NA (Genzyme 
diagnostics)
Ad Libitum diet, mean Pi 
intake 967 g/d
Sevelamer 4.8 g/d-> Calcium 
carbonate 3.6 g/d
No change
Calcium carbonate 3.6 g/d -> 
Sevelamer 4.8 g/d
Reduction in group with 
FGF23 baseline > 70 ug/mL
Block  
et al. 2012 127





Ad Libitum diet Calcium acetate av. 5.9 g/d Increase 
Lanthanum carbonate av. 2.7g/d No change
Sevelamer av. 6.3 g/d Reduction of iFGF23,  
No change of cFGF23
Placebo No change
Isakova  
et al. 2013 122




12 weeks 55 38 3.6 129 RU/mL c-term 
(Immutopics)
Ad Libitum diet placebo No change
Pi diet 900 mg/d Lanthanum carbonate 3g/d No change
Ad Libitum diet placebo No change
Pi diet 900 mg/d Lanthanum carbonate 3g/d Reduction
Seifert  
et al. 2013 135
38 Double blind RCT 12 months 62/61 47/45 3.5/3.3 69/55 pg/mL Intact (Kainos) Ad Libitum Placebo No change
Lanthanum carbonate 3g/d No change
Chue  
et al. 2013 133
109 Double blind RCT 36 weeks 55 50 3.2 69 pg/mL Intact (Kainos) Ad Libitum Placebo No change
Sevelamer 1.6g/each meal No change, reduction 
only when adherence to 
medication was ≥80% 
Spatz  
et al. 2013 138
40 Prospective open 
cohort study
12 weeks 70 21 4.8 602 RU/ml c-term 
(Immutopics)
Verbal instruction for low 
Pi diet
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Placebo + Lanthanum carbonate 
3g/d
No change
Placebo + placebo No change
Dialysis
Koiwa  
et al. 2005 128
46 Open label 
randomized trial
4 weeks 57 dialysis 5.9 9000 ng/L Intact 
(manufacturer 
NA)
NA Sevelamer 3 g/d+ Calcium 
carbonate 3 g/d
Reduction
Calcium carbonate 3 g/d No change
Brandenburg 
et al. 2010 139
75 Open label cohort 
study
8 weeks 65 dialysis 6.4 7244 RU/mL c-term 
(Immutopics)
NA Sevelamer titration on top of 
usual Pi-binder medication to 
serum Pi < 5.5 mg/dl
No change
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25 Open label 
randomized trial
8 weeks 56/61 dialysis 6.8/6.5 8678/ 8565 
pg/mL
Intact (Kainos) Pi diet 600-800 mg/d Lanthanum carbonate up 
titrated to serum Pi
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randomized trial
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(Biochamp 
China)
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titrated to serum Pi < 5.5 mg/dl
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No Change
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et al. 2018 132 
1059 Multi centre open 
label phase 3 
study
24 weeks and 
a subset of 
no. 549 up to 
1 year
56 dialysis 7.4 39600 pg/mL Intact 
(Immutopics)
NA sucroferric hydroxide 1-3 g/d Reduction at 24 and at  
52 weeks
Sevelamer 2.4-14.4g/d Reduction at 24 and at  
52 weeks
Pooled analysis 64% 
reduction at 52 weeks
Overview of studies with phosphate binders with or without dietary phosphate restriction to lower FGF23.
FGF23; Fibroblast growth factor 23, factor-23; eGFR, estimated glomerular filtration rate; iFGF23; intact FGF23, 
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was measured, most studies found no reduction after treatment with either lanthanum 
carbonate or sevelamer carbonate, some even when combined with a low phosphate 
diet.123,137,139-142 Only one of the studies measuring c-terminal FGF23 found a reduction of 
FGF23 with dietary phosphate restriction.124 However, the group with FGF23 reduction 
in this study had a higher baseline FGF23 concentration than the other groups making 
interpretation difficult. Another factor, besides the assay that might influence whether or 
not FGF23 reduction was achieved in the different studies, is the duration of phosphate 
binder use. Duration of therapy possibly should be 3-6 months or more since it is 
demonstrated that in kidney transplant patients high FGF23 levels may sustain for this 
period even when overt hypophosphatemia exists,143,144 suggesting autonomous FGF23 
production, which vanishes only after time. As outlined in table 2, most studies were of 
relatively short duration.
FGF23 antibodies and FGF23 receptor blockers 
Burosumab is an FDA approved monoclonal antibody targeting FGF23 and was developed 
for the treatment of XLH. In FGF23-mediated hypophosphataemic disorders it improves 
hypophosphatemia and bone abnormalities in children.145 However, there are no data on 
its use in CKD and its use might be even induce harm by disturbing the adaptive response 
of FGF23, as was shown in an experimental model of CKD.146 In that animal study, FGF23 
antibodies resulted in decrease of FGF23 and ameliorated uremic hyperparathyroidism. 
However, urinary phosphate excretion decreased and hyperphosphatemia developed, 
promoting vascular calcification and increased mortality. The same observations were 
found in an experimental study with a pan-FGFR inhibitor,147 showing that FGF23 remains 
necessary to maintain serum Pi levels within range, at least in non-dialysis dependent 
CKD. A more promising strategy might be to specifically inhibit FGFR4 signalling to 
prevent the development of LVH associated with high FGF23 levels.96 However, this was 
only tested in an animal model and there are currently no data available to suggest 
a clinical benefit for patients with CKD. 
Calcimimetics 
Several studies showed that FGF23 concentrations can be reduced by the use of cinacalcet 
or etelcalcetide. In a randomized trial by Wetmore et al. it was demonstrated that patients 
assigned to cinacalcet compared to low dose calcitriol had a decrease of serum FGF23 
concentrations.148 However, it was not clear if this was caused by the relatively low dose 
of active vitamin D in the cinacalcet treatment arm, considering active vitamin D being 
a strong stimulator of FGF23. The study by Koizumi et al. found that the decrease of 
FGF23 during cinacalcet treatment was independent of active vitamin D.149 Also data 
from the Evolve trial showed that cinacalcet is a potent suppressor of FGF23.81 The newer 
intravenously used calcimimetic etelcalcetide appears to be an even more potent 
suppressor of FGF23 compared to cinacalcet.150 However, the mechanism by which 




sensing receptor on osteocytes or a decline of the calcium-phosphate product may have 
accomplished this effect. 
Haemodiafiltration (HDF)
Previous studies have shown that FGF23 with its 32 kDa middle molecular size can be 
cleared by HDF and not by low-flux HD.151 Several studies have shown a reduction of 
serum FGF23 within a single HDF session of around 50% (± 25%), with FGF23 detected 
in spent dialysate samples.152-154 The study by Bouma et al. showed a sustained decline 
FGF23 over time, of greater size with higher convection volume.70 
IS  IT  USEFUL TO MEASURE SERIAL FGF23 
CONCENTRATIONS?
Whether change of FGF23 better reflects risks and possibly impacts on outcomes is an 
open question. There are some studies that do shed some light on this issue. Probably 
the best of these is the study by Isakova on the CRIC cohort, consisting of 1135 patients 
with a mean eGFR of 46.3 (±14.7) ml/min per 1.73 m2. Although, the majority of patients 
from this cohort had stable FGF23 concentrations during the 5 years of follow-up, 
patients with rapidly increasing FGF23 concentrations had an exceptionally high mortality 
risk.58 Also, in a sub analysis of the CONTRAST study in prevalent haemodialysis patients, 
increasing levels of FGF23 were associated with increased mortality.70 Both studies found, 
in different populations, that increasing FGF23 is disadvantageous. However, the study 
by Jovanovich in over 900 dialysis patients showed that, although over 24 month 
stable low FGF23 concentration was associated with a favourable outcome compared 
to stable high FGF23 concentrations. The group with high FGF23 in which FGF23 
further increased over time, had no further increased risk for all-cause mortality.59 More 
importantly, this study also showed that in patient with high baseline, and subsequently 
decreasing FGF23 concentrations had no improved risk for mortality . Likewise, in 
the sub analysis of the CONTRAST study, a decrease in FGF23 was not associated with 
improved mortality compared to a stable FGF23 concentration. A secondary analysis of 
the EVOLVE trial155 analysed the impact of cinacalcet-induced reductions in FGF23. This 
analysis, different from the studies discussed above, did suggest that decreasing FGF23 
might be beneficial.81 Here, a more than 30% reduction of FGF23 in 20 weeks among 
participants allocated to cinacalcet, was associated with a reduced risk on the composite 
outcome of cardiovascular mortality, sudden cardiac death and heart failure. Remarkably, 
in the placebo treated group there were also (yet fewer) patients with more than 30% 
FGF23 reduction, but in those patients no association with reduced risk on outcome was 
found. This suggests that not the decline of FGF23 itself, but the way it was achieved, 
determined the more favourable outcome. Since the main outcome of the EVOLVE trial 
demonstrated no improvement of the primary combined outcome in cinacalcet treated 
patients, FGF23 reduction probably just identified patients who might benefit more 
from cinacalcet treatment.155 Since FGF23 has been implicated with the development 
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of LVH, Seifert et al. studied CKD patients with an increase of LVH over 12 months. This 
worsening of LVH was not associated with an increase of FGF23.156 Moreover, Chue et 
al. identified in their study, among CKD patients treated with sevelamer, a subgroup with 
a decrease of FGF23, which was however not accompanied with a change in arterial 
stiffness, left ventricular mass or cardiac function.135 Therefore, there is currently no 
compelling evidence that FGF23 reduction leads to improved outcome and this leaves 
the role of FGF23 in the pathway to adverse outcome still under debate. 
FGF23 ARE WE READY TO USE IT  IN CLINICAL 
PRACTICE? (CONCLUSION)
In conclusion, FGF23 is a promising biomarker in CKD. Although the different FGF23 assays 
should be harmonized and assay specific reference intervals should be established, FGF23 
measurement has shown to be consistently associated for adverse outcome in different 
populations. Furthermore, FGF23 measurement was shown, and validated, to predict 
mortality in CKD. However, FGF23 has limited value in predicting progression of renal 
failure in CKD or in risk prediction in patients on dialysis. Future studies should evaluate 
the predictive validity of repeated FGF23 testing. Increasing FGF23 concentrations over 
time, both in CKD and dialysis patients are associated with dismal outcomes.
Considering the fact that there is currently no, or very limited, evidence that FGF23 
reduction leads to improved outcome, it is preliminary to use FGF23 concentrations as 
target for therapy in everyday clinical practice, despite the ability of dietary phosphate 
restriction and phosphate binders to lower FGF23 concentrations in CKD. For patients on 
haemodialysis both calcimimetics, non-calcium containing phosphate binders and HDF 
are effective modes to lower FGF23. The availability of interventions that lower FGF23 
sets the stage for clinical trials that target FGF23 (and not phosphate concentrations) and 
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A single time point fibroblast growth factor-23 (FGF23) level is a strong, well established 
risk factor for clinical events in chronic kidney disease (CKD). This study investigated 
whether repeated measurements of FGF23 after 2 years, allowing the calculation of time-
averaged FGF23 and the rate of change in FGF23, provided a better prediction of clinical 
events in CKD than a single time-point value.
Methods  
A post hoc analysis was performed in a subset of 439 adult patients of the prospective 
multicentre MASTERPLAN study in which paired samples to measure FGF23 were available. 
The primary outcome was defined as a composite of myocardial infarction, stroke and 
cardiovascular mortality and secondary endpoints, which were overall mortality, congestive 
heart failure (CHF) and start of renal replacement therapy. Only events occurring after 
Month 24 were included in the analysis.
Results 
Analysis of different FGF23 measures showed that a single time-point value and time-
averaged FGF23 were positively associated with the primary endpoint, and also with 
overall mortality, start of renal replacement therapy and CHF. The adjusted hazard ratios 
of a single value of FGF23 and of time-averaged FGF23 for the composite endpoints 
were 1.71 (CI 1.20-2.43) and 1.91 (CI 1.29-2.82) respectively. Change in FGF23 was not 
associated with any outcome except for the initiation of renal replacement therapy. 
Conclusion 
Our study confirms that FGF23 is an important cardiovascular risk factor. Two measurements 
of FGF23 have no added value over a single value to predict the cardiovascular outcome. 
This study demonstrates that, under routine clinical practice, the variability of FGF23 in 2 
years’ time is small. Concomitantly, this study showed no benefit of consecutive FGF23 
testing for estimating the risk of a clinical event in an individual patient.




Over the past decade, it has become clear that patients with chronic kidney disease (CKD) 
have a greatly enhanced risk of cardiovascular morbidity and mortality.1 Disturbances in 
calcium-phosphorus metabolism may play a major role in this enhanced risk.2;3 Fibroblast 
growth factor-23 (FGF23) is a recently discovered 32-kDa peptide secreted by osteocytes 
in bone. It is now evident that FGF23  is the key hormone regulating phosphorus 
homeostasis by modulating renal phosphorus handling, PTH secretion by the parathyroid 
glands and vitamin D metabolism in the kidney.4-8 It is signaled by the FGFR1 receptor,9;10 
with Klotho as an obligate co-receptor.11;12
FGF23 levels increase during the progression of CKD,13 and many studies have shown 
that a single time-point value of FGF23 is associated with mortality,14;15 left ventricular 
hypertrophy 16;17 and progression of kidney failure.18-20  Multivariable adjustment for 
factors such as PTH, vitamin D and phosphorus, and other established cardiovascular risk 
factors, did not attenuate the strength of the association of FGF23 with these clinical 
outcomes. Moreover, FGF23 was also associated with several cardiovascular risk factors 
such as endothelial dysfunction and arterial stiffness, in the general population as well as 
in early CKD.21-23 
These epidemiological data suggest that FGF23 not only acts as a regulator of PTH, 
vitamin D or phosphorus, but may also actually be in the causal pathway to cardiovascular 
pathology. This hypothesis is further substantiated by recent experimental compelling 
evidence that FGF23 can induce left ventricular hypertrophy.24 Therefore, it is conceivable 
that targeting FGF23 in clinical practice may improve clinical outcome. It is still unknown 
whether modifying FGF23 levels alters this elevated risk. In this study we explored to 
what extend the course of FGF23 levels in time is predictive for cardiovascular events and 
mortality and if so, whether this course is more predictive than just a single value FGF23. 
We hypothesize that if average FGF23, as a measure for exposure to FGF23 over time, is 
more predictive than a single value, targeting FGF23 might be beneficial. Support for this 
assumption can be provided by determining the association between time-varying levels of 
FGF23 and clinical outcome. We assessed this in the prospective MASTERPLAN CKD cohort.
SUBJECTS AND METHODS
Population
This study was a post hoc analysis of the MASTERPLAN study. Masterplan (ISRCTN 
73187232) is a randomized controlled clinical trial that was performed in nine 
Dutch hospitals in adult patients with CKD with an estimated creatinine clearance of 
20-70 ml/min/1.73m2.25 Patients with acute renal failure, rapidly progressive 
glomerulonephritis and patients with a malignancy < 5 years before inclusion were 
excluded. Patients were randomised to receive either usual care by the nephrologists or 
intensified treatment with added nurse practitioner support. The study was approved by 
central and all local medical ethics committees, and all participants provided informed 
52
2
consent. Enrolment started in April 2004 and ended in December 2005. Participants 
were followed for events up tot May 2010. Its primary endpoint findings have 
recently been reported.26 
Of the original 788 participants of MASTERPLAN, those who had a medical history of 
renal transplantation were excluded (n=110). Of the remaining 678 patients, 239 were 
not included because of missing paired samples. One hundred and forty-six patients had 
a regular visit at 2 years; however, stored blood samples from baseline visit (n=64) or from 
the 2-year visit (n=82) were not available. Ninety-three patients did not attend the visit 
at 2 years, for the following reasons: death (n=22), start of RRT (n=16), unknown (n=49) 
and lost to follow-up (n=6). A flow chart of patient inclusion is shown in Figure 1a in 
Appendix 1. The clinical characteristics of these 239 patients are given in Table 1A in 
Appendix 2. Not unexpectedly, the patients with missing samples were slightly older, and 
had a lower eGFR, higher blood pressure, more metabolic abnormalities and higher FGF23 
levels. These differences were, however, limited, and not significant after Bonferroni 
correction for multiple testing. We included in our analysis only the 439 subjects with 
paired plasma samples  at Month 0 and 24. The calculated events were those recorded 
from Month 24 and onward.
Changes in FGF23 and average FGF23 in the first 24 Months were key 
dependent variables.
Design of the study
This analysis  was designed to evaluate whether  two measurements of FGF23 have an 
additional value  on predicting cardiovascular outcome. For this reason, only patients with 
paired FGF23 samples were included and only events that occurred after Month 24 after 
the  start of the Masterplan-study were analysed. From Month 24, we looked  back in time 
to see if the previous FGF23 level (at Month 0) was of additional value to predict outcome. 
Primary and secondary outcome definitions
The primary endpoint was defined as a composite of myocardial infarction, stroke and 
cardiovascular mortality, occurring after Month 24. Secondary endpoints were overall 
mortality, CHF and renal replacement therapy in the same time period. 
Myocardial infarction was defined as evident new ischaemic changes on an ECG 
or an established rise and fall pattern of cardiac enzymes. Stroke was defined as 
characteristic clinical symptoms of stroke accompanied by signs of recent ischaemia using 
an appropriate imaging technique (computed tomography scan or magnetic resonance 
imaging). Cardiovascular mortality was defined as death due to myocardial infarction, 
stroke, ruptured abdominal aneurysm and terminal heart failure. Sudden death was also 
considered as cardiovascular mortality. The diagnosis CHF was based on clinical criteria 
and confirmation of diminished ventricular function established in a normovolemic 
condition via ultrasound or radionuclide imaging. Renal replacement therapy was defined 
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by either kidney transplantation or the start of a dialysis modality. All suspected events 
were evaluated by an independent endpoint-committee. 
Data collection
The patients completed several questionnaires recording medical history, lifestyle factors 
and medication use. Regular physical examination, involving measurement of height, 
weight and blood pressure was performed. These measurements were repeated annually. 
The underlying diagnosis of kidney disease was determined by the treating physician 
using available history, clinical course and histopathology (if available) and categorized 
using the European Renal Association (ERA)-EDTA registration criteria. Proteinuria was 
determined in 24-h urine collections. To obtain one value for proteinuria in all patients, 
albumin values were converted into proteinuria value using the same approach as applied 
by KDIGO (i.e. by multiplying albumin values by 3/2).27 Renal function was estimated by 
the four-point MDRD formula and by the Cockroft-Gault formula. 
Laboratory measurements
Blood samples were taken at baseline and annual visits. Routine laboratory measurements 
were performed in local laboratories. In addition, material was stored at -80° C until 
use. FGF23 was measured in stored plasma samples using the sandwich ELISA assay 
(Immutopics San Clemente, CA, USA) measuring the c-terminal FGF23. The intra- and 
inter-assay coefficient of variation of this assay are <5 and <16%, respectively.28
Data analysis
Baseline characteristics of the analysis set are presented as proportions or means with 
their corresponding standard deviations. For variables with a skewed distribution, 
results are presented as medians and interquartile values. Since FGF23 has a severely 
skewed distribution, the natural logarithm of FGF23 was used in the analyses (lnFGF23). 
The correlation between baseline and 2-year FGF23 was assessed using the Spearman 
correlation coefficient. 
To evaluate the effect of changes in FGF23 over time on endpoints compared with 
single time-point values, several measures representing this change were constructed 
from the paired FGF23 measurements. We analysed the relation of FGF23 on outcome 
using the single time-point FGF23 level at Months 0 and 24. The rate of change in FGF23 
was constructed by the 2-year value minus the baseline and next to all, a value of 3000 
was added in order to have positive values and subsequently the natural logarithm was 
used, because of a skewed distribution. In addition, we analysed the rate of change 
in FGF23 as a percentage. Cox proportional hazard models were constructed to assess 
the relation with primary and secondary endpoints. Data for participants were censored 
at their date of death, date of last visit (for those still alive at the end of the follow-up 
period) or date when last known to be alive (for those with unknown vital status). 
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Results are presented as hazard ratios (HRs) with corresponding 95% confidence limits. 
To adjust for confounding in the most optimal way in a dataset with a small number of 
events (N between 20 and 40), a propensity score was used. 29;30 The propensity score 
was build using the 614 participants of whom FGF23 data was available at the start of 
MASTERPLAN data collection. To adjust for potential confounding factors we selected 
factors of possible influence on FGF23 on physiological grounds and what is known from 
the literature. All the variables summarized in Table 1 were included. The factors that 
were incorporated into the model resulted from multivariable linear regression modelling 
and a backward selection procedure with a liberal P-value (0.15).31 The created propensity 
score includes information on gender, causes of CKD, history of cardiovascular disease, 
history of diabetes, baseline values of triglycerides, haemoglobin, calcium, PTH, waist-
to-hip ratio, smoking, creatinine, eGFR by the MDRD formula, proteinuria, sodium in 
the urine and the use of blood pressure lowering drugs, RAAS inhibitors, glucose lowering 
drugs or coumarin.
The primary and secondary endpoints were defined by events that occurred after 
Months 24. All P-values were two-sided, and p values of<0.05 were considered to 
indicate statistically significant. 
RESULTS
Study population
Characteristics of the study-population at Month 24 (the starting point of the current 
event analysis) are summarized in Table 1 (n=439). Mean age was 62 years, most of 
the patients were Caucasian, and mean eGFR was 36 ml/min/1.73m2. In the previous 2 
years, average decrease in eGFR was 2 ml/min/1.73m2. On average patients had a normal 
phosphorus level with a median of 1.09 mmol/l and a PTH of 7.95 pmol/l. The majority of 
patients used calcium containing phosphate binders and around half of all patients used 
active vitamin D. 
Changes in FGF23 over 2 years
The crude distribution of FGF23 after 2 year follow-up and the change in FGF23 from 
baseline are given in Figure 1. In most patients FGF23 levels were relatively stable over 
time. The Spearman correlation between baseline FGF23 and the 2 years FGF23 was 0.77. 
From baseline until 24 Months median FGF23 increased from 109 RU/ml to 149 RU/ml. 
The mean change in FGF23 in 2 years’ time was an increase of 126 RU/ml, ranging from 
a decline of 2800 RU/ml to an increase of 7420 RU/ml (Table 2).
Primary and secondary endpoints
Our results apply to those patients who lived up to the second measurement of FGF23. 
Of all the patients with a measurement of FGF23 at Months 0 and 24, none reached 
end-stage renal disease before Month 24. The primary and secondary endpoints were 
FGF23 and its association with clinical outcome
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Table 1. Clinical features of the patients at 2 years (N = 439)
Age (years) 61.7 ± 12.2
Gender (male) (%) 71




Glomerulonephritis/ interstitial nephritis 19/09
Congenital disease 11
Unknown 21
Diabetes1 (%) 23 
Current smoking (%) 17 
Prior cardiovascular disease by questionnaire (%) 27 
Creatinine ( μmol/l) 173 (135-228) 
eGFR2 (ml/min per 1.73 m²) 36.3 ± 15.1
Mean systolic blood pressure based on dynamap(mmHg) 130 ± 18
Mean diastolic blood pressure based on dynamap(mmHg) 75 ± 10
Body mass index (kg/m²) 27 ± 4
Hemoglobin (mmol/l) 8.2 ± 1.0
Total cholesterol (mmol/l) 4.4 ± 0.9
HDL cholesterol (mmol/l) 1.27 ±0.41
LDL cholesterol (mmol/l) 2.34 ±0.79
Triglycerides (mmol/l) 1.5 (1.0-2.1)
Ca (mmol/l) 2.35 (2.29-2.45)
Pi (mmol/l) 1.09 (0.95-1.26)
PTH (pmol/l) 8.0 (5.1-13.0)
Proteinuria (g/24h) 0.83 (1.5)
Sodium in the urine (mmol/24 h) 160 ±61
Use of vitamin D (%) 44
Use of calcium containing phosphate binder (%) 74 
Use of non-calcium containing phosphate binder (%) 53 
Use of RAS inhibitors (%) 88 
Use of beta blockers (%) 47 
Use of erythropoietin (%) 14 
Use of statins (%) 85 
Use of coumarin (%) 13.8
Use of glucose lowering drugs (%) 16.8
FGF23 (RU/ml) 149 (87-241)
lnFGF23 5.00 (4.47-5.48)
events that occurred after Months 24. After Month 24, 28 patients reached the primary 
endpoint. In addition there were 35 non-cardiovascular deaths, 46 patients who started 
renal replacement therapy, and 21 with CHF. There was no interaction by group assignment.
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Figure 1. Distribution of FGF23 at Month 0 and Month 24 












Months 24 and 0 
Percentage 
change in FGF23 
between Months 
24 and 0
Mean 174.8 300.8 237.8 126.0 87.7 
Standard Deviation 382.0 706.9 464.6 654.2 247.1 
Median 109.0 149.0 136.5 32.3 33.9 
Minimum 19.0 18.6 19.0 -2800.0 -93.8 
Maximum 6790.0 7640.0 5390.0 7420.0 3372.7 
Percentages
10 36.2 47.6 46.8 -33.2 22.9 
20 51.5 76.1 67.4 -5.0 4.9 
30 71.5 97.6 90.2 7.0 8.1 
40 90.0 123.0 110.0 18.0 23.1 
50 109.0 149.0 136.5 32.3 33.9 
60 134.0 178.0 157.0 49.0 54.8
70 168.0 216.0 197.0 73.0 78.5
80 207.0 293.0 254.5 109.0 105.8
90 288.0 491.0 392.0 232.0 184.0
FGF23 and its association with clinical outcome
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Impact of FGF23 changes on outcome 
Single time point values and average FGF23, were positively associated with the primary 
endpoint, and also with all-cause mortality, starting of renal replacement therapy and 
CHF, though not all significantly (see Table 3). Adjustments for factors related to outcome 
and for confounders of FGF23 did not substantially change the relations. The applied 
adjustment in the model is done by adding the propensity score variable to the model. 
Table 3 summarizes the relation between various FGF23 measures and risk of clinical 
events. The HRs are presented by an increase in standard deviation. 
The average FGF23 represents exposure to FGF23 during the 2-years preceding 
baseline. HRs of the average FGF23 on outcome were of a similar magnitude compared 
with a single time-point measurement (Table 3). The adjusted HRs of a single value of 
FGF23 at Month 24 and of average FGF23 on composite endpoint were 1.71 (CI 1.20-
2.43) and 1.91 (CI1.29-2.82) respectively. Only for heart failure average FGF23 reached 
significance whereas single time-point FGF23 did not. The rate of change in FGF23 was 
not predictive for the composite endpoint, mortality or CHF. We observed a positive 
association of change in FGF23 with initiation of renal replacement therapy, even after 
the correction for baseline eGFR. However, the adjusted HR was smaller compared with 
HRs of the single and time-averaged FGF23 values. When analysing the rate of change in 
FGF23 in percentages, the relations to outcome were comparable with change in FGF23 
in absolute values. Therefore these data are not shown.
Table 3. Hazard ratios of various FGF23 parameters with clinical events. 
Clinical event
Single FGF23 at 
Month 24
Average FGF23  
(Months 0 and 24)
Change in FGF23  
(Month 0 → 24 )
Composite
Crude 1.83 (1.41-2.37) 1.91 (1.47-2.49) 0.87 (0.73-1.05)
Adjusted 1.71 (1.20- 2.43) 1.91 (1.29-2.82) 0.93 (0.80- 1.08)
All -cause mortality
Crude 1.68 (1.29-2.19) 1.67 (1.27-2.20) 0.93 (0.73-1.19)
Adjusted 1.47 (1.03-2.10) 1.48 (1.00-2.18) 0.96 (0.81-1.15)
Initiation of renal replacement 
Crude 3.17 (2.54-3.96) 2.59 (2.12-3.16) 2.31 (1.93-2.77)
Adjusted 2.61 (1.93-3.54) 1.99 (1.45- 2.71) 1.78 (1.44-2.19)
CHF
Crude 1.51 (1.05- 2.19) 1.71 (1.20-2.44) 0.99 (0.66-1.49)
Adjusted 1.38 (0.86-2.23) 1.73 (1.05-2.87) 1.00 (0.75-1.32)
Values are HRs and their 95% confidence limits obtained from a Cox proportional hazards model. 
Adjusted means that the propensity score variable has been added to the model (see Results). The HRs 
reflect the change in Ln(FGF23)  values of the parameters divided by its standard deviation in order to 
facilitate the  comparison of direction and strength between the various FGF23 measures.
CHF- congestive heart failure. 
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Table 4 presents the association between groups defined by the categorical classification 
of  FGF23 change on outcome. Most patients had a persistently low or high FGF23 during 
the follow-up.  Patients with a persistently high FGF23 had an increased risk on composite 
endpoint and on mortality. This effect disappeared when adding the propensity score 
to the model. 
DISCUSSION
In the current analysis we explored if two values of FGF23 better predict a cardiovascular 
risk, compared to a single time-point value of FGF23. This would provide an additional 
argument in favour of targeting FGF23 in CKD. In the analysis we focused on two measures 
to express FGF23 levels over time: the average FGF23, which represents exposure to 
FGF23 levels in the 2-years’ time period and the rate of change in FGF23, a potential 
marker for progressive disease. First of all, we found in the Masterplan cohort on average 
a low amplitude of change in FGF23 under routine clinical practice, in which phosphorus 
and PTH levels were generally within the target. 
We found that HRs of the average FGF23 on the composite endpoint and all-cause 
mortality were of a similar magnitude compared with a single time point measurement 
(Table 2). Although we expected that the average FGF23 would have a higher predictive 
value for subsequent clinical events than a single time point, this was not the case.
Table 4. Groups with a persistently low, persistently high or an increase or decrease in FGF23 from 










N= 439 N=172 N=47 N=46 N=174
Percentage (%) 39.2 10.7 10.5 39.6
Composite
Crude 1.07 (0.22-5.17) 0.55 (0.07-4.51) 3.41 (1.46-7.95)*
Adjusted 1.00 (0.21-4.86) 0.50 (0.06-4.16) 2.32 (0.86-6.30)
All-Cause mortality
Crude 0.73 (0.16-3.34) 0.38 (0.05-2.94) 2.21 (1.05-4.67)*
Adjusted 0.67 (0.15-3.09) 0.33 (0.04-2.65) 1.42 (0.56-3.56)
CHF
Crude 0.0 (0.0-0.0) 0.62 (0.08-5.15) 2.49 (0.96-6.49)
Adjusted 0.0 (0.0-0.0) 0.60 (0.07-5.13) 2.03 (0.64-6.42)
Values are HRs and their 95% confidence limits obtained from a Cox proportional hazards model. Low 
and high is defined as above or below median FGF23.
Adjusted means that the propensity score variable has been added to the model (see rResults). 
The risk of initiation of renal replacement therapy is not described in the table since there were too little 
events (in the reference group (low-low) and in the high-low group)  to calculate a HR with precision. This 
was also the case for CHF in the low-high FGF23 group. 
* Significant
CHF, congestive heart failure. 
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The small variability of FGF23 levels within subjects also resulted in the finding that 
the change in FGF23 had not a significant relation with the composite endpoint. It is 
possible though that potential effects of the rate of change in FGF23 on the composite 
endpoint would require more pronounced differences in FGF23 in individuals over time. 
The study has several limitations: given the high correlation between FGF23 levels 
in 2 years’ time, a larger sample size, longer follow up and thus more events might be 
needed to detect a relation between changes of FGF23 in time on outcome, if such an 
relation exists. Interventions directly targeting FGF23 levels might increase differences 
between two subsequent levels and might also require a longer follow-up. The small 
number of events limits the conclusions of the study. Another limitation is that although 
this was a multicentre study, it was performed in a single country which may reduce 
the applicability to other populations.
Based on the fact that the primary research question was to assess the usefulness of 
subsequent FGF23 testing 2 years apart, our analysis was necessarily limited to patients 
who had survived >2 years. Therefore, our conclusions are applicable only to those, thus 
further limiting the generalizability of our conclusions.
When considering risk for the CHF, averaged FGF23 emerged (significantly) as 
a risk factor, with an higher HR compared with (the non-significant HR for) single time 
point. Although the HR’s of time-averaged FGF23 and the single point value were not 
significantly different, exposure to FGF23 over time as a cause of subsequent CHF, might 
have a pathophysiological base. Faul et al. demonstrated that in rodents, FGF23 directly 
induces myocardial hypertrophy, the clinical correlate of which is CHF.24 Therefore, 
prolonged exposure to high FGF23 might worsen these pathological myocardial changes 
and increase the risk of developing CHF.
The change in FGF23 had a strong and positive association with future initiation 
of renal replacement therapy. Remarkably  this risk factor remained significant after 
correcting for the propensity score which included eGFR.  An explanation for this could 
be that patients with a more progressive increase in FGF23 had more non-GFR related 
arguments to initiate RRT, like disturbed mineral  metabolism. Additional analysis showed 
a positive association between FGF23 and initiation of renal replacement even after 
adjustment of change in eGFR (data not shown). The decision to initiate RRT (dialysis 
or transplantation) is generally not only based on a combination of eGFR and several 
other ill-defined parameters, including other laboratory markers than creatinine, but also 
the presence of complaints and overall well-being.32 Therefore it is possible that rate of 
change in FGF23, the same as the other measures of FGF23, predicts the development of 
these other components involved in deciding to initiate RRT.
Our findings are consistent with other studies in which a single value of FGF23 is 
associated with an increased risk for cardiovascular events and mortality.18-20 This study 
in 439 patients with CKD Stages 3 and 4 confirmed that a single value of FGF23 is 
associated myocardial infarction, stroke and cardiovascular mortality. Like others,19;20 we 
also found an association with progression to end stage renal disease. In the Heart and 
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Soul study Ix et al. found an association between FGF23 and congestive heart failure,33 as 
we did in this cohort of CKD stage 3 and 4. 
Our findings are in line with recently published data  of the AASK trial.34 In this 
study the Hazard Ratio for ESRD and mortality was 2.24 for the highest quartile of 
FGF23.  FGF23 levels increased the most in patients with a  more rapidly declining GFR 
(measured by the 125 I-iothalamate method). Thus, the severity of CKD progression 
affects the observed change in FGF23. Our study adds important  information to suggest 
that increasing levels of FGF23 are associated with initiation of renal replacement therapy, 
also after adjustment for eGFR decline. 
FGF23 increases progressively as kidney function declines. This process starts already 
at Stage 3 or even Stage 2 of CKD.13 In CKD raised levels of FGF23 are associated with 
progression of CKD,18-20 left ventricular hypertrophy,16;17 vascular dysfunction21;35 and 
with mortality. 19;20 These associations are independent of serum phosphate. As kidney 
function deteriorates a high serum phosphate develops and a high serum phosphate is 
also associated with adverse cardiovascular outcome,2;3;36;37 but FGF23 is elevated long 
before serum phosphate increases.38;39 For this reason FGF23 might be a more appropriate 
target for treatment than serum phosphate. Our study could not confirm that changes of 
FGF23 over time alter clinical outcome and so the question remains if specific targeting 
FGF23 levels might be beneficial on cardiovascular outcome.
In conclusion, this study confirms that FGF23 is an important cardiovascular risk 
factor. However, follow-up testing of FGF23 has no added value over a single value to 
predict cardiovascular outcome. Although we expected that changing levels of FGF23 in 
the natural course of disease will change outcome, this study provides no clear evidence 
for this. The absence of such an effect  might be explained by the relative short follow up, 
the characteristics of this cohort of CKD Stage 3 and 4 patients, in which on average FGF23 
did not change substantially in 2 years. The latter is due to the fact that FGF23 was not 
specifically targeted in our study and rather reflects its natural course as CKD progresses. 
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Appendix Figure 1a.  Flow chart patient inclusion
Appendix Table 1a. Clinical characteristics of  the Masterplan population (patients with a renal 








age (years) 62.1 ± 13.1 59.6 ± 12.3
Gender (male) (%) 67 71
Race (caucasian) ( %) 90 93
Nephrological diagnosis (%)    
Diabetic nephropathy (%) 12 10
Renovascular (%) 33 30
Glomerulonephritis (%) 15 19
Interstitial nephritis(%) 11 09
Congenital disease  (%) 9 11
Unknown (%) 21 21
Diabetes¹  (%) 31 21
Prior cardiovascular disease by questionaire (%) 35 27
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Current smoking (%) 21 21
systolic pressure  based on dynamap (mmHg)² 139.0 ± 22.6 134.3 ± 19.2
diastolic pressure based on dynamap  (mmHg)² 78.3 ± 11.4 78.2 ± 10.8
Total cholesterol (mmol/l ) 4.87 ± 1.16 4.80 ± 0.99
HDL cholesterol (mmol/l ) 1.32 ± 0.52 1.29 ± 0.40
LDL cholesterol (mmol/l) 2.85 ± 1.02 2.73 ± 0.89
triglycerides (mmol/l) 1.83 ± 1.10 1.85 ± 1.16
Hemoglobin (mmol/l) 8.12 ± 1.05 8.32 ± 0.95
Ca (mmol/l) 2.38 (2.27-2.45) 2.38 (2.29-2.47)
Pi (mmol/l) 1.12 (0.98-1.28) 1.09 (0.94-1.22)
PTH (pmol/l) 8.5 (5.2-15.0) 8.0 (5.0-13.0)
Creatinine ( μmol/l) 174 (138-243) 164 (134-209)
eGFR(ml/min per 1.73 m²) 35.8 ± 16.4 38.7 ± 13.7
Proteinuria (g/24h) 0.40(0.10-1.32) 0.30 (0.10-0.87)
sodium in 24 h urine (mmol) 153 ± 60 157 ± 61
Body mass index (kg/m²) 27.5 ± 5.0 27.1 ± 4.2
use of vit D drug (%) 26 20
use of blood pressure lowering drugs (%) 93 95
use of RAS inhibitors (%) 78 83
use of beta blockers (%) 47 48
use of statins (%) 63 68
use of non-calcium containing phosphate binders (%) 4.6 1.6
Use of calcium containing phosphate binder  (%) 12.6 4.6
use of epodrug (%) 11 7
use of glucose lowering drug (%) 26 17
use of coumarines (%) 8 13
FGF23 131 (75-240) 109 (62-183)
Ln FGF23 4.92 ± 0.95 4.69 ± 0.86
Diabetes defined as using blood glucose lowering medication of fasting glucose > 7.0mmol/l
2 eGFR based on the MDRD formula.Values are expressed as median (IQR) or mean (± SD). See text 
paragraph Subjects and Methods for a comparison between the two groups
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Fibroblast growth factor-23 (FGF23) has been  hypothesized to play a role in the increased 
risk of cardiovascular disease in patients with CKD.
Methods
We identified prospective studies reporting associations between FGF23 and risk of 
cardiovascular events. Maximally adjusted risk ratios (RRs) were extracted for each 
outcome and scaled to a comparison of the top versus bottom third of the baseline FGF23 
concentration, and the results aggregated. 
Results
Depending on assay type used, median study FGF23 concentrations were 43-74 RU/mL 
and 38-47 pg/mL in 17 general populations cohorts; 102-392 RU/mL in nine cohorts of 
patients with CKD not requiring dialysis; and 79-4212 RU/mL and 2526-5555 pg/mL in 
eight cohorts of patients on dialysis. Overall, comparing participants in the top and bottom 
FGF23 concentration thirds, the summary RRs (95% confidence intervals [95%CI]) were 
1.33 (1.12-1.58) for myocardial infarction, 1.26 (1.13-1.41) for stroke, 1.48 (1.29-1.69) 
for heart failure, 1.42 (1.27-1.60) for cardiovascular mortality, and 1.70 (1.52-1.91) for 
all-cause mortality. The summary RR for noncardiovascular mortality, calculated indirectly, 
was 1.52 (95 %CI, 1.28-1.79). When studies were ordered by the average differences 
in FGF23 concentration between the top and bottom thirds, there was no trend in RRs 
across the studies.
Conclusions
The similary-sized associations between increased FGF23 concentration and cardiovascular 
(atherosclerotic and non-atherosclerotic) and of noncardiovascular outcomes, together 
with the absence of any exposure-response relationship, suggest that the relationship 
between FGF23 and  cardiovascular disease may be noncausal.




Cardiovascular disease risk increases as kidney function declines and this elevated risk 
is apparent even in early chronic kidney disease (CKD).1-3 Cardiovascular disease in 
people with CKD is characterized particularly by arterial stiffening and left ventricular 
hypertrophy, which becomes increasingly marked as CKD progresses.4-6 People with CKD 
are also at increased risk of atherosclerotic heart disease. It has been suggested that some 
of the excess cardiovascular risk in CKD may be mediated through disordered calcium-
phosphate metabolism due to reduced kidney function.7-9 
Blood fibroblast growth factor-23 (FGF23) concentration rises early in CKD, and 
increases exponentially in relation to estimated glomerular filtration rate, functioning 
to maintain phosphate homeostasis as the capacity for urinary phosphate excretion 
declines.10 FGF23 possesses an atypical heparin-binding domain which results in a low 
binding affinity to most FGF receptors.11 Its physiological actions may therefore be 
limited to the parathyroid glands and kidney where its co-receptor Klotho is abundantly 
expressed. In the kidney, FGF23 downregulates renal proximal tubular sodium-phosphate 
co-transport function, enhancing urinary phosphate excretion, and reduces vitamin D 1-α 
hydroxylation leading to less intestinal calcium and phosphate absorption.12 However, 
FGF23 could have Klotho-independent actions in other tissues, including the heart,13 and 
may contribute to the etiology of structural heart disease in patients with CKD.14,15 If so, 
interventions targeting FGF23 might hold therapeutic potential.
We conducted a systematic review and meta-analysis of the evidence from prospective 
studies for associations between FGF23 and the risk of different cardiovascular diseases. 
We compared the evidence for associations among cohorts of people unselected for CKD 
(general population cohorts) with those in patients with CKD who were not receiving 
dialysis at the time of recruitment (nondialyzed CKD cohorts) and in patients on dialysis. 
We assessed for evidence of an exposure-response relationship both within and across 
each of these 3 separate populations.
METHODS
Search strategy/selection strategy
A systematic and comprehensive search for English language publications with mention 
of FGF23 or equivalent terms was performed in MEDLINE (1948-April 2017) and EMBASE 
(1974-April 2017, see Webtable 1 for terms). Abstracts were reviewed and cohort studies 
in adults were selected for inclusion in the meta-analysis if: (i) FGF23 was a key exposure 
of interest; (ii) at least one clinical cardiovascular disease outcome was assessed, and (iii) 
outcomes were ascertained prospectively. Cardiovascular outcomes of interest included 
myocardial infarction, stroke, heart failure and peripheral arterial disease as well as 
mortality attributed to cardiovascular disease. Full-texts of publications which appeared 
to meet inclusion criteria were reviewed. Duplicate studies and those that included less 
than 200 participants were excluded. The quality of remaining studies was assessed using 
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the Newcastle-Ottawa scale16 and studies excluded if their results were at moderate-to-
high risk of bias (score of <6/9). A study of terminal heart failure was excluded post-hoc 
as the population was at exceedingly high risk.
Data extraction
Three authors (AM/KD/CR) extracted the following data from full-text articles: study and 
study population characteristics, FGF23 assay type (C-terminal, reported in RU/mL, or 
intact, reported in pg/mL), measures of FGF23 distribution, details of statistical models, 
covariates used for multivariate adjustments, follow-up duration, and hazard ratios/risk 
ratios (RRs) for relevant cardiovascular outcomes for all reported models, and where 
reported, all-cause and cardiovascular mortality. Where necessary, further data were 
requested from study investigators.
Statistics
To assess the FGF23 associations across the wide range of FGF23 concentrations 
encountered in different populations, meta-analysis was pre-specified to be performed 
overall and within three study population types: (i) general population (i.e. unselected 
individuals), (ii) nondialyzed CKD (defined as an estimated glomerular filtration rate 
[eGFR] <60 mL/min/1.73m2), and (iii) dialysis patient cohorts.
For each study, we aimed to extract from the primary publication, for each outcome, 
the hazard ratio or RR yielded by the model that included the greatest number of covariates. 
These covariates included incrementally: basic demographics (+); cardiovascular risk 
factors (including diabetes, body-mass index and smoking (++); kidney function (+++); and 
markers of CKD-mineral bone disorder (++++). On account of the usually skewed nature 
of FGF23 distributions, studies reported associations for top versus bottom quintiles, 
quartiles or thirds of the FGF23 distribution, or less frequently, per standard deviation or 
a unit increase in log-transformed FGF23. To enable comparisons and synthesis of data 
across the studies, these associations were converted (where necessary) to a measure 
of association corresponding to the top versus bottom third of the baseline FGF23 
concentration using established methods (see Supplementary methods and Webtable 
2 for more detail).17,18 Where non-cardiovascular mortality was not reported, RRs were 
derived indirectly from cardiovascular and all-cause mortality results assuming that on 
the natural logarithm scale, the RR for all-cause mortality is an inverse-variance weighted 
average of the RRs for cardiovascular and non-cardiovascular mortality.
The heterogeneity between studies (both within each population and overall) was 
summarized. Random-effects meta-analytical methods (DerSimonian and Laird)19 were 
used to combine the RRs for the top versus bottom third of baseline FGF23 concentration 
in each study, yielding a summary RR for all studies.
As the median baseline FGF23 concentration correlated strongly with interquartile 
range, standard tests for linear trend (on a log scale) across studies ordered by median 
FGF23 and its association with clinical outcome
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(or, if not reported, mean) baseline FGF23 concentration (within each population and 
across all the individual studies) were used to assess whether larger absolute differences 
in FGF23 concentration between top and bottom third were associated with larger 
RRs. Trend tests were also performed across population-specific summary RRs following 
meta-analysis of RRs from the contributing studies. In sensitivity analyses, to allow for 
potentially different relationships in dialysis populations, the trend tests across individual 
studies were repeated after excluding dialysis patient studies.
Primary analyses of disease associations did not take account of whether studies 
employed C-terminal or intact assays, which is equivalent to the assumption that the results 
between the two assays are approximately comparable. However, this assumption may not 
necessarily hold as, for example, intra-person biological variability of intact FGF23 may be 
higher than C-terminal FGF23.20 To investigate the sensitivity of results to this assumption, 
analyses were performed repeating trend tests, firstly after converting intact FGF23 
concentration to an approximately equivalent C-terminal concentration using a formula 
developed from a small healthy general population: iFGF23=0.110*cFGF23+32.2,21 and, 
secondly, after excluding all studies that only reported intact FGF23. To further assess 
whether associations in individual studies could have been affected by within-person 
FGF23 variability, regression dilution ratios were calculated from individual studies 
which had repeat FGF23 measurements22-24 using McMahon’s non-parametric quintile 
method.25 RRs for cardiovascular and non-cardiovascular outcomes were compared by 
heterogeneity tests.26 Analyses were performed using R version 3.2.1 (www.R-project.
org) using the “metafor” package v1.
RESULTS
Our literature search (Supplemental Table 1) identified 2477 abstracts of which 45 met 
the inclusion criteria (Figure 1). Three studies were excluded after a standard assessment 
for bias (Supplemental Table 3).27-29 Eight studies reported associations which could not be 
extracted or reliably expressed as RRs comparing the top versus bottom third of baseline 
FGF23 concentration30-37 (see Supplemental Table 4 for results from these and the other 
excluded studies). Of 34 studies included in primary analyses, 17 were a predominantly 
general population cohort,22,38-53 nine were in patients with CKD not on dialysis,23, 54-61 
and eight in dialysis populations24,62-68 (Figure 1). For dialysis patients, a single large trial 
(EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events [EVOLVE], n=2985) 
provided all the data on myocardial infarction, stroke, and heart failure (outcomes which 
were all confirmed by clinician adjudicators).24 
Table 1 describes the characteristics of included studies. Most of the studies (26 out of 
34) measured FGF23 concentrations using a C-terminal based assay, with the remainder 
(8 out of 34) using an intact assay. Measures (median or, if unavailable, mean) of FGF23 
concentration were lowest in general population cohorts (43-74 RU/mL and 38-47 pg/mL 
for the respective assays); higher in nondialyzed CKD (102-392 RU/mL), and substantially 
higher in dialysis cohorts (79-4212 RU/mL and 2526-5555 pg/mL: Table 1). 
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Across these three populations, the estimated absolute difference in mean FGF23 
concentrations between the top versus bottom third of the FGF23 distributions ranged 
from 72 RU/mL in general population studies, to 433 RU/mL in nondialyzed CKD, to 8644 
RU/mL in dialysis population studies (C-terminal studies only).
It was notable that the ten general population cohorts had a mean age of 65 






Figure 1. Study selection flowchart. FGF23=fibroblast growth factor-23; CKD=chronic kidney 
disease. RR=risk ratio.
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in all populations, with evidence of higher mortality with reduced kidney function. For 
example, the average all-cause mortality ranged from 1.9%-5.3% per annum (p.a.) 
across the general populations; 2.0%-14.2% p.a. in nondialyzed CKD populations; and 
2.0%-21.0% p.a. in dialysis populations.
Association between FGF23 and risk of cardiovascular events
Six studies assessed the association between FGF23 and risk of myocardial infarction 
(three in general populations,22,44,49 two in nondialyzed patients with CKD,44,56 and one in 
patients on dialysis 24). Overall, comparing participants in the top versus bottom third of 
baseline FGF23 concentration, there was a 33% increased risk of myocardial infarction 
(summary RR 1.33, 95% confidence interval [95%CI] 1.12-1.58), but no evidence of 
linear trend across the different patient populations studied (trend p=0.32: Figure 2). 
For the studies reporting an interquartile range of baseline FGF23 concentrations, there 
was good correlation between median baseline FGF23 concentration and the interquartile 
range (correlation coefficient 0.99), so ordering studies by increasing baseline FGF23 
concentration effectively orders the studies by increasing absolute difference between 
the means of FGF23 concentrations in the top versus bottom third of each study’s FGF23 
distribution. Tests for linear trend in the RRs for myocardial infarction across the ordered 
Figure 2: Association between FGF23 and risk of cardiovascular disease event by population type.  
 





Figure 2. Association between FGF23 and risk of cardiovascular disease event by population 
type. CI=confidence interval; CKD=chronic kidney disease; FGF23=fibroblast growth factor 23. 
Heterogeneity tests across the su mary risk ratios for the 3 outcomes: All populations combined 
p=0.23; general populations =0.59; nondialyzed CKD p=0.75; and dialysis populations p=0.47. * 
number of events not reported in one study
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studies were non-significant both within the three separate populations and across all 
individual studies (trend across all individual studies p=0.22: Supplemental Figure 1).
Associations between FGF23 and risk of stroke of any type were reported in nine 
studies, including six in general populations,22,44,45,48,49,52 two in nondialyzed CKD,44,56 and 
1 in dialysis populations.24 Overall, comparing those in the top versus the bottom third of 
baseline FGF23 concentration, there was a 26% increased risk of stroke (RR 1.26, 95%CI 
1.13 to 1.41). This increase in risk was consistent between populations (trend p=0.17; 
Figure 2), and there was no significant trend towards larger RRs with higher median 
FGF23 difference both within each population considered separately (where relevant) 
and across all studies (trend across all individual studies p=0.95: Supplemental Figure 2).
Four general population studies (n=1251 events)22,45,48,52 and a small nondialyzed CKD 
study (n=43 events)56 reported ischemic stroke events. Overall, no significant association 
between FGF23 and risk of ischemic stroke was observed for the top versus the bottom 
third of baseline FGF concentration (RR 1.08, 95%CI 0.92 to1.27: Supplemental Figure 3).
Associations between FGF23 and risk of heart failure were reported in ten studies, 
including five in a general population,42,44-46,49 four in patients with nondialyzed 
CKD,23,44,58,59 and one in patients on dialysis.24 Overall, comparing patients in the top 
versus the bottom third of baseline FGF23 concentration, there was a 48% increased 
risk of heart failure (RR 1.48, 95%CI 1.29 to1.69). There was no evidence of trend 
across populations (trend p=0.89; Figure 2) and no clear trend towards larger RRs with 
higher median FGF23 difference both within each population considered separately and 
overall (trend across all individual studies p=0.76: Supplemental Figure 4). There was 
also no good evidence that FGF23 was more strongly associated with heart failure than 
myocardial infarction or stroke, overall (heterogeneity p=0.23) or in any of the 3 separate 
populations (Figure 2).
Associations between FGF23 and risk of peripheral artery disease and some other 
noted cardiovascular outcomes are provided in Supplemental Table 5.
Association between FGF23 and mortality
Twenty-three studies reported associations between FGF23 and all-cause mortality: seven 
in a general population,39,40,44,47,49,51,53, eight in nondialyzed CKD,23,44,54,56,57,59-61 and eight 
in a dialysis population24,62-68. Overall, comparing patients in the top versus bottom third 
of baseline FGF23 concentration, there was an increased risk of death from all causes 
(RR 1.70, 95%CI 1.52 to 1.91). There was no good evidence of a trend across the three 
populations (trend p=0.76; Figure 3) or towards larger RRs with higher median FGF23 at 
baseline (trend across all individual studies p=0.97: Supplemental Figure 5).
Eleven studies reported associations between FGF23 level and cardiovascular mortality 
(seven studies in general populations,39,40,44,46,47,51,53 two in nondialyzed CKD,44,54 and two 
in dialysis patients24,68). Overall, comparing patients in the top versus bottom third of 
the baseline FGF23 concentration, there was a 42% increased risk of cardiovascular 
mortality (RR 1.42, 95%CI 1.27 to 1.60) with no evidence of trend across populations 
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(trend p=0.53: Figure 3) and no trend towards larger RRs with higher median FGF23 
(trend across all individual studies p=0.49: Supplemental Figure 6).
Among dialysis patients in the EVOLVE trial,24 comparing patients in the top versus 
the bottom third of the baseline FGF23 concentration, there was a 27% (RR1.27, 
95%CI 1.02 to 1.58) increased risk of non-cardiovascular mortality (n=514 deaths), 
which was similar to RR for cardiovascular mortality in this trial (RR 1.26, 95%CI 1.00 to 
1.57, n=607 deaths). Only one of the other nine studies (a general population cohort) 
reported RRs for cardiovascular mortality (RR1.76, 95%CI 1.34 to 2.32, n=474) as well 
as for non-cardiovascular mortality (RR 1.47, 95%CI 1.17 to 1.85, n=612 deaths).53 For 
the remaining eight studies RRs for non-cardiovascular mortality were derived indirectly 
using associations for cardiovascular and all-cause mortality.39,40,44,46,47,51,54,68 The overall 
combined RRs for all studies for non-cardiovascular mortality for the top versus the bottom 
third of the baseline FGF23 concentration was 1.52 (95%CI 1.28 to 1.79) with results 
suggesting that for each of the separate populations, the RRs for cardiovascular and non-
cardiovascular mortality were comparable (Figure 4).
Sensitivity analyses and assessment for publication bias
The results of trend tests remained non-significant after exclusion of studies in dialysis 
patients (Supplemental Figures1,2 and 4-6), after exclusion of studies which only reported 







Figure 3. Association between FGF23 and risk of all-cause and cardiovascular mortality by population 
type. CI=confidence interval; CKD=chronic kidney disease; FGF23=fibroblast growth factor 23. * 
Number f events not reported for one study.
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Repeat measurements within groups of FGF23 were highly correlated in all 3 types of 
populations studied (regression dilution ratios all >0.8, Supplemental Table 6),22-24 so 
adjustment for regression-dilution bias was not performed. All-cause and cardiovascular 
mortality associations were not substantially affected by adjustment for other markers of 
CKD-mineral bone disease (Supplemental Figure 7).40,46,49,54,55,59,66
Funnel plots of associations between FGF23 and all-cause mortality by type of 
population suggested evidence for publication bias for the general population cohorts 
(Egger regression test p=0.005) and that RRs for all-cause mortality may be slight 
overestimates (Supplemental Figures 5 and 8). There was no important heterogeneity 
between studies with respect to other outcomes (Supplemental Figures 1-4 and 6).
DISCUSSION
This systematic review and meta-analysis assessed the epidemiological associations 
between FGF23 concentration and cardiovascular outcomes, as well as associations with 
cardiovascular and all-cause mortality in populations with and without known kidney 
disease. Overall, we found that, irrespective of a population’s level of kidney function, 
a difference in FGF23 concentration corresponding to that between top and bottom 
thirds of baseline FGF23 concentration was associated with about 30% increased risk of 
myocardial infarction and stroke, 40% increased risk of cardiovascular mortality and 50% 
increased risk of heart failure. In the studies where it was possible to estimated effects 
on both cardiovascular and non-cardiovascular mortality, we found that the strength of 







Figure 4. Association between FGF23 concentration and risk of cause-specific mortality overall 
and by population type. CI=confidence interval; CKD=chronic kidney disease; FGF23=fibroblast 
growth factor-23. 
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The Bradford Hill criteria for causality of a disease risk factor include the presence 
of epidemiological associations which are both consistent and specific for that disease, 
evidence of a biological gradient (i.e. greater exposure leads to increased effect, which 
we refer to as exposure-response), temporality (i.e. the cause precedes the effect), and 
biological plausibility.69 
In support of raised FGF23 concentration being a cause of cardiovascular disease, our 
study found consistent moderate associations between FGF23 and disease risks. FGF23 
concentration also rises before any other marker of CKD-mineral bone disorder,10 so it 
temporally mirrors the rise in cardiovascular risk as CKD progresses.1 In addition, there 
is biological plausibility since cardiac myocytes exposed to FGF23 become hypertrophied 
and develop electrophysiological disturbances (sometimes referred to as “off-target” 
effects as they appear to be Klotho-independent).13,14,15 
We also observed that FGF23 was strongly associated with non-cardiovascular causes 
of death, reflecting a lack of specificity of the associations between raised FGF23 and 
disease risk. This observation could reflect pleiotropy of FGF23 in disease causation. 
It has previously been reported that raised FGF23 is associated with a higher risk of 
end-stage kidney disease,55 acute kidney injury (RR for top versus bottom quartile 1.99, 
95%CI 1.04 to 3.80),70 fractures (RR 1.56, 95%CI 1.11 to 2.20),71 and serious infection 
(RR 1.59, 95%CI 1.14 to 2.22).62 There is emerging evidence that FGF23 may promote 
inflammation through direct effects on hepatocytes,72 and predispose to infection 
through downregulation of monocytic expression of 1,25 dihydroxycholecalciferol73 or 
other effects.74 A mechanistic study has also suggested FGF23 may promote progression 
of prostate cancer.75 
An alternative, more plausible, explanation for the observed non-specificity of 
associations across a range of disease outcomes is residual confounding. This may arise 
because of imprecise or incomplete measurement of baseline prognostic factors other 
than FGF23. Examples of such factors include level of kidney function (which is measured 
with greater error at high eGFR), duration of CKD, and risk factors which correlate with 
low kidney function. 
Furthermore, we found no evidence for a log-linear exposure-response relationship 
such as that which is commonly observed for known causes of cardiovascular disease (e.g. 
LDL cholesterol76,77 and blood pressure78). Indeed, the RRs corresponding to a difference 
between top and bottom thirds of FGF23 distribution were of similar magnitude in each 
of the three populations despite the absolute difference in FGF23 varying by two orders 
of magnitude across these populations. Such a pattern could potentially be explained 
by a ‘log-log’ relationship with flattening of the exposure-response curve at high FGF23 
concentration. But this would imply that, if FGF23 is a cause of cardiovascular disease, 
therapeutic agents designed to reduce FGF23 would need to achieve large absolute 
reductions in FGF23 in those with high levels in order to achieve worthwhile risk reductions. 
A limitation of this meta-analysis is that we were, for the most part, restricted to 
published summary data. The availability of individual participant level data from all 
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eligible studies could allow for more granular estimation of associations and perhaps 
a more sensitive analysis of any exposure-response relationship using a standardized 
method with fewer assumptions. It would also allow for the inclusion of the studies 
which could not be reliably converted onto a top versus bottom thirds scale. However, 
the studies excluded due to inability convert associations showed positive associations 
between FGF23 and disease risks which were similar in size to those observed by 
the included studies (Supplemental Table 4).30-37 Furthermore, given the lack of trends 
across the three population types despite a two-fold increase in the absolute difference 
in FGF23 concentration, it is unlikely that individual participant data would identify an 
important log-linear trend missed by our tabular meta-analysis. Individual participant level 
data would also not overcome residual confounding, which is the main limitation of this 
meta-analysis. Finally, not all relevant studies reported associations for all outcomes of 
interest (which may have introduced bias) and there was a lack of detailed data on non-
cardiovascular causes of death, so it was not possible to examine whether there were 
deaths (e.g. from cancer) that were particularly strongly associated with FGF23.
In summary, this systematic review and meta-analysis has demonstrated that across 
a wide range of levels of kidney function, higher FGF23 concentration was consistently 
associated with modest increased risks of myocardial infarction, heart failure, stroke and 
cardiovascular death. However, higher FGF23 was also associated with an increased risk 
of non-cardiovascular causes of death. Our findings suggest that associations between 
FGF23 and particular diseases, both in populations with CKD and those without known 
disease, may not signify cause and effect.
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Webtable 1: Literature search terms 
EMBASE/MEDLINE search 
#1 Search (((((((((("fgf23*.mp.") OR "fgf 23*.mp.") OR "Fibroblast Growth Factor 23.mp.") OR 
"Fibroblast Growth Factor23.mp.") OR "ifgf 23*.mp.") OR "ifgf23*.mp.") OR "cfgf23*.mp.") OR "cfgf
23*.mp.") OR "fgf-23*.mp.")) AND English[Language]
# 2 Search (exp animal/ or nonhuman/) not exp human/
# 3 Search (#1 NOT #2)
# 4 limit 3 to (conference abstract or conference paper or conference proceeding or "conference 
review")
# 5 3 not 4
#6 limit 5 to reviews
#7 5 not 6
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Webtable 4: Regression-dilution ratios by study population
Study 
population
Study Time from 
baseline
Regression dilution ratio for 
log[FGF23]
General EPIC – Germany[1] 4 months 0.84
CKD MASTERPLAN [2] 2 years 0.90
Dialysis EVOLVE [3] 20 weeks 0.88
Notes: RDR calculated using MacMahon’s non-parametric method through quintiles. EPIC= 
European Prospective Investigation into Cancer and Nutrition; MASTERPLAN=Multifactorial approach 
and superior treatment efficacy in renal patients with the aid of nurse practitioners; EVOLVE= 
Evaluation of Cinacalcet Hydrochloride Therapy to Lower Cardiovascular Events 
References 
1. di Giuseppe, R., et al., Plasma fibroblast growth factor 23 and risk of cardiovascular disease: 
results from the EPIC-Germany case-cohort study. Eur J Epidemiol, 2015. 30(2): p. 131-41.
2. Bouma-de Krijger, A., et al., Time-averaged level of fibroblast growth factor-23 and clinical 
events in chronic kidney disease. Nephrology Dialysis Transplantation, 2014. 29(1): p. 88-97. 
3. Moe, S.M., et al., Cinacalcet, FGF23 and Cardiovascular Disease in Hemodialysis: The 
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Chapter 3IMPACT OF FRACTIONAL 
PHOSPHATE EXCRETION ON 
THE RELATION OF FGF23 WITH 
OUTCOME IN CKD PATIENTS
Annet Bouma - de Krijger*, Anneke P, Bech*,  Arjan van Zuilen, 
Michiel Bots, Jan A. van den Brand, Peter.J. Blankestijn, 
Jack F.M. Wetzels, Marc G. Vervloet, (*first authors)





Cardiovascular risk is increased in patients with chronic kidney disease (CKD). Fibroblast 
growth factor 23 (FGF23) has emerged as an important, independent predictor of outcome 
in CKD patients. High FGF23 may, however, be a reflection of renal tissue resistance to 
its actions, reflected by a low fractional excretion of phosphate (FePi). We evaluated 
the modifying effect of FePi on the association between FGF23 and outcome in patients 
with CKD stage 3-4. 
Methods
An analysis was performed in a subset of 166 adult patients of two participating centers 
of the MASTERPLAN trial of whom urine samples at baseline were available to calculate 
FePi. Outcome was defined as a composite of death, renal failure (defined as need for 
renal replacement therapy or doubling of serum creatinine) and cardiovascular events 
(myocardial infarction, cerebrovascular accident, percutaneous transluminal coronary 
angioplasty or coronary artery bypass graft). Patients were categorized by FGF23 and 
FePi. A product term was added to Cox regression and RERIs were calculated. 
Results
Patients had a median estimated glomerular filtration rate (eGFR)  of 36 ml/min/1.73m2 
[interquartile range (IQR) 27-44], serum phosphate 1.04 [IQR0.92-1.20], FGF23 140 RU/
ml [IQR81-236] and FePi 0.32 [IQR0.25-0.44]. A total of 96events occurred during 5 
years of follow-up. LnFGF23 was a significant, independent predictor for the composite 
outcome (hazard ratio (HR)2.13 [95% confidence interval (CI)1.53-2.95]. FePi did not 
modify the relation between FGF23 and outcome in these patients with CKD.
Conclusions
Our study shows that FGF23 itself, but not its renal tissue resistance as reflected by FePi, 
is an important risk factor for clinical events in subjects with CKD stage 3-4.




Chronic kidney disease (CKD) is associated with a high risk for cardiovascular disease and 
mortality.1  This increased risk is attributed to various traditional and non-traditional risk 
factors such as hypertension, diabetes,2 proteinuria,3 uric acid 4 and acidosis.5 In recent 
years the role of disorders in calcium and phosphate metabolism have been emphasized, 
with studies reporting increased cardiovascular risk associations with higher serum 
phosphate,6-12 higher calcium,11 higher parathormone (PTH),13 and lower vitamin D levels.14 
Most recently focus has shifted to fibroblast growth factor 23 (FGF23), a phosphaturic 
hormone mainly produced by the osteocyte.15 FGF23 is associated with cardiovascular 
morbidity and mortality in patients with CKD,16-18 and is an independent predictor for 
progression of kidney failure.16;17;19;20 Moreover, elevated FGF23 levels have been shown 
to be a risk factor for cardiovascular disease and mortality in the general population.18;21;22 
FGF23 is involved in phosphate metabolism. It inhibits expression of the sodium-
phosphate transporters in the proximal tubuli of the kidneys, thus promoting renal 
phosphate excretion.23 Elevated FGF23 levels in patients with CKD may partially be 
the result of FGF23 resistance. FGF23 resistance can be defined as a state in which 
the kidney and the parathyroid glands, the primary sites of FGF23 action, do not respond 
optimally to FGF23 by excreting less phosphate and suppressing PTH less efficiently 
compared to healthy persons, which drives FGF23 to increase. Classical FGF23 action 
requires binding to its receptor, using Klotho as co-factor.24;25 It is believed that tissue 
Klotho levels of the kidney decline with CKD and may thus be the mechanism behind 
FGF23 resistance.26-31 Although FGF23 is thought to  have  effects also independently 
from klotho,32 it is possible that elevated FGF23 concentrations reflect renal tissue 
Klotho deficiency, and that FGF23 resistance itself contributes to the increased relative 
risk on outcome. This indeed was suggested by Dominguez et al who used fractional 
excretion of phosphate (FePi) as a marker of FGF23 resistance,33 and observed that FePi 
modified the association of FGF23 with outcome in 872 patients with relatively mild 
CKD (mean eGFR 71 ml/min/1.73 m2). Those considered to be more FGF23 resistant had 
worse outcome. We questioned if the same could be observed in patients with more 
severe CKD, a situation associated with increased CV mortality, progression of CKD and 
higher FGF23 concentrations. 
PATIENTS AND METHODS
Patients
We used baseline data of patients who participated in the MASTERPLAN study 
(multifactorial approach and superior treatment efficacy in renal patients with 
the aid of nurse practitioners).34 MASTERPLAN was a randomized controlled clinical trial 
(ISRCTN73187232) performed in nine Dutch hospitals in which patients with CKD (eGFR 
20-70 ml/min/1.73 m2) were randomized to either receive usual care by the nephrologist 
or intensified treatment with added nurse practitioner support. Inclusion started in April 
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2004 and ended in December 2005. In two centers baseline 24 h urine were collected 
and samples were stored at -80 ˚C. Only patients from these centers were included in 
the current analysis as urinary analyses were required.
Data collection
Details of the study methods have been described.34 In brief, baseline measurements 
included a questionnaire recording smoking behavior and medication use. Physical 
examination consisted of measurement of height, weight and blood pressure. Laboratory 
assessment included fasting serum creatinine, calcium, phosphorus and PTH. Stored blood 
samples were used at a more recent date for measuring FGF23 using the sandwich ELISA 
assay (Immutopics San Clemente, CA, USA) measuring the c-terminal FGF23.35 The intra- 
and inter-assay coefficient of variation of this assay are < 5% and < 16%, respectively.36 
Urine samples were thawed, acidified, and creatinine, calcium, and phosphate were 
measured using standard automated techniques. Glomerular filtration rate was estimated 
(eGFR) with the four-point MDRD formula.37 Fractional excretion of phosphate was 
calculated as (urine phosphate x serum creatinine)/(serum phosphate x urine creatinine). 
The clinical outcome of MASTERPLAN has been described elsewhere.38 A composite 
end-point was defined consisting of the combination of death, cardiovascular events 
(myocardial infarction, cerebrovascular accident, percutaneous trans luminal coronary 
angioplasty or coronary artery bypass graft) and renal failure (defined as need for renal 
replacement therapy, doubling of serum creatinine or death).
FGF23 resistance 
FGF23 increases phosphate excretion through reduced phosphate re-absorption. Thus, 
FGF23 resistance can be considered if a high FGF23 exists together with a low FePi. 
Statistical analysis
Baseline characteristics are reported as median values with interquartile range (IQR) for 
skewed data and as mean values with standard deviation for normally distributed data. 
Medians between groups are compared using the non-parametric independent samples 
median test. Natural logarithm transformation was applied for the skewed data. Spearman 
correlation coefficients were used to perform univariate analyses. Survival analyses were 
performed using Cox regression analyses in order to adjust for possible confounding by 
gender, age, systolic blood pressure, eGFR, PTH, proteinuria and smoking. In order to 
evaluate if FGF23 resistance expressed as FePi increased the risk of FGF23 on outcome, 
patients were categorized by FGF23 above and below the median combined with FePi 
above and below the median into four categories. A product term for the categorized 
FGF23 and FePi was added again to Cox regression. In the presence of a positive 
interaction, the sum of hazard ratios (HR) for the combination of a high FGF23 and low FePi 
would be higher than the theoretical calculated HR of a high FGF23 and high FePi times 
Impact of fractional phosphate excretion on the relation of FGF23 with outcome in CKD patients
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the ratio of the HR of a low FGF23 and low FePi divide by the HR of the reference group. 
A second method to calculate the presence and direction of interaction was performed by 
calculating the Relative Excess Risk due to Interaction (RERI).39;40 The confidence interval 
(CI) of the RERI was estimated using jackknife resampling. A positive additive interaction 
is present if the RERI is >0 and is statistically significant. Statistical significance was defined 
as a two sided p-value of <0.05. Statistical analyses were performed using SPSS 20.0 (IBM 
SPSS software, IBM Corp, Armonk, NY, USA) and Stata 11.2 (StataCorp, College Station, 
TX, USA) software packages.
RESULTS
The two participating centers included 194 patients in the MASTERPLAN study. Urine 
samples were available of 166 patients. Baseline characteristics of these 166 patients 
grouped by FGF23 and FePi are shown in Table 1. The median age was 53 (IQR 45-62) 
years, most patients were Caucasian and the median eGFR was 36 (IQR 28-44) ml/
min/1.73 m2. The median of proteinuria was 0.40 (IQR 0.20-1.20) g/day, FePi 0.32 (IQR 
0.25-0.44) and FGF23 140 (IQR 81-236) RU/ml. People with higher FGF23 levels more 
frequently used vitamin D compounds.
Correlations 
Univariate analysis between FGF23 and parameters of kidney function and phosphate 
metabolism showed a significant inverse correlation between FGF23 and eGFR 
(R= - 0.43 p<0.01). We observed a significant positive correlation between FGF23 and 
serum phosphate (R=0.29, p<0.01), FePi (R=0.36, p<0.01), urine phosphate/creatinine 
ratio (R=0.17, p=0.03) and PTH (R= 0.30, p<0.01). Of note, there was no significant 
correlation between FGF23 and serum calcium. In multivariate analysis including sex, 
body mass index (BMI), age, PTH, eGFR, FePi, serum phosphate, serum calcium, total 
cholesterol, systolic blood pressure, proteinuria, diabetes and smoking, only eGFR and 
smoking were independent predictors of FGF23. 
FGF23 resistance
Clinical characteristics of the patients divided by the combination of FePi and FGF23 are 
reported in Table 1. Compared to patients with FGF23 concentrations below the median, 
the patients with higher concentrations had more proteinuria, a higher PTH, a higher 
phosphate and a lower eGFR. Patients with high FGF23 were also more frequently 
diabetics and more likely to smoke. Patients with a low FePi had lower serum phosphorus 
levels, a lower PTH, total cholesterol and were more likely female.
Outcome
After a median of 4.8 years of follow up, 96 of the 166 patients (59%) reached an 















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































therapy or doubling of creatinine (74/166).  In the multivariate Cox regression analysis 
only lnFGF23, proteinuria and systolic blood pressure remained independent predictors 
of the composite outcome (Table 2). FePi was not associated with outcome. Moreover, 
the hazard ratio for LnFGF23 for outcome did not change after adjustment for FePi 
(Table 2). Figure 1 shows the Kaplan-Meier curve for the composite outcome according 
quartiles of FGF23 after adjustment for baseline covariates. 
Table 2. univariate and multivariate Cox regression analysis for combined outcome
Univariate Multivariate *
HR CI P value HR CI p value
LN FGF23 2.17 1.65-2.84 <0.01 2.13 1.54-2.95 <0.001
FePi 3.39 0.86-13.47 0.082 0.23 0.04-1.52 0.13
Serum phosphate 3.57 1.72-7.45 <0.001 2.13 0.87-5.19 0.10
Proteinuria 1.27 1.15-1.41 <0.001 1.25 1.11-1.41 <0.001
MDRD 0.97 0.96-0.99 0.005 0.99 0.97-1.02 0.59
Age 0.99 0.97-1.00 0.158 0.99 0.97-1.00 0.11
Gender (male) 1.32 0.85-2.09 0.215 0.67 0.40-1.11 0.12
Smoking 1.75 1.08-2.84 0.022 0.98 0.54-1.75 0.93
Systolic blood pressure 1.02 1.00-1.04 0.001 1.02 1.00-1.03 0.02
PTH 1.02 1.00-1.03 0.017 1.00 0.98-1.02 0.98





  Univariate    Mul ivariate * 
  HR  CI  P value    HR  CI  p value 
LN FGF23  2.17  1.65‐2.84  <0.01    2.13  1.54‐2.95  <0.001 
FePi  3.39  0.86‐13.47  0.082    0.23  0.04‐1.52  0.13 
Serum phosphate  3.57  1.72‐7.45  <0.001    2.13  0.87‐5.19  0.10 
Proteinuria  1.27  1.15‐1.41  <0.001    1.25  1.11‐1.41  <0.001 
MDRD  0.97  0.96‐0.99  0.005    0.99  0.97‐1.02  0.59 
Age   0.99  0.97‐1.00  0.158    0.99  0.97‐1.00  0.11 
Gender (male)  1.32  0.85‐2.09  0.215    0.67  0.40‐1.11  0.12 
Smoking  1.75  .08‐2.84  0.022    0.98  0.54‐1.75  0.93 
Systolic blood pressure  1.02  1.00‐1.04  0.001    1.02  1.00‐1.03  0.02 












Figure 1. Cox c r  for quartiles of FGF23 on composite utc me. Cox c rv  f r quartiles f FGF23 
and the effect on composite outcome. Adjusted for age, sex, smoking, systolic blood pressure, 
proteinuria, eGFR, TmP/GFR, serum phosphate and PTH. For abbreviations see table 1.
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Table 3 and 4 further show the hazard ratios for the associations between FGF23 
and FePi categories and outcome. Cox regression, which was adjusted for age, sex, 
smoking, systolic blood pressure, proteinuria, eGFR and PTH, revealed a hazard ratio for 
the combination of high FGF23 and low FePi of 4.15 (95% CI 1.85 - 9.30) on the combined 
outcome (Table 3). In the absence of hazard ratio modification, one would have expected 
the joint effect of a high FGF23 and low FePi to give a HR of 8.14 [=eln(2.56) + ln(3.18)]. Likewise 
the RERI was -0.60 (95% CI -4.81 to 3.70). Similarly, the hazard ratio of a high FGF23 
combined with low FePi on renal outcome was 3.44, lower than expected from the sum 
of both individual factors, HR=7.77 [=eln(2.40)+ln(3.22].
DISCUSSION
In this study we tested the hypothesis that FGF23 resistance may contribute to the increased 
risk for morbidity and mortality associated with elevated FGF23 levels in patients with 
advanced CKD. This hypothesis was based on a recent study showing interaction between 
FePi and FGF23 levels on outcome in patients with mild CKD.33 Our study showed that 
Table 3. multivariate cox regression on combined outcome for categories defined by FGF23 below 
and above the median combined with FePi below and above the mean. 
Combined survival participants events HR 95 % CI
Low FGF23/high FePi 31 11 1 reference
Low FGF23/low FePi 52 25 2.56 1.13-5.80
High FGF23/high FePi 51 37 3.18 1.47-6.87
High FGF23/low FePi 32 23 4.15 1.85-9.30
This model included FGF23 and FePi as categorical variables and their product term.
The model was adjusted for factors shown and age, sex, smoking, systolic blood pressure, proteinuria, 
eGFR, PTH 
Hazard ratio product for the product term is  0.51 (95% CI 0.19-1.34), p = 0.17
RERI is -0.60 (95 % CI -4.81-3.70), p = 0.79
RERI relative excess risk due to interaction, for other abbreviations see other tables
Table 4. multivariate cox regression for categories defined by FGF23 below and above the median 
combined with FePi below and above the mean with renal outcome. 
Renal survival participants events HR 95% CI
Low FGF23/high FePi 31 9 1 reference
Low FGF23/low FePi 52 20 2.40 0.81-6.34
High FGF23/high FePi 51 34 3.22 1.31-7.84
High FGF23/low FePi 32 18 3.44 1.37-8.62
This model included FGF23 and FePi as categorical variables and their product term. The model was 
adjusted for factors shown and age, sex, smoking, systolic blood pressure, proteinuria, eGFR, PTH 
Hazard ratio product for the product term is  0.44 (95% CI 0.14-1.41)
RERI is -1.18 (95% CI -8.10 to 5.73), p = 0.74 For all abbreviations, see previous tables
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there was no interaction between FGF23 levels and FePi on this outcome, and thus we 
could not confirm this hypothesis in subjects with more advanced CKD and higher FGF23. 
This suggests that in patients with advanced CKD, FGF23 itself and not FGF23 resistance 
determines the risk for adverse outcome. This study confirmed that FGF23 is an independent 
predictor of outcome. Moreover, multivariable adjustments that included FePi did not 
mitigate the HR of FGF23. FGF23 concentrations increase during progression of CKD and 
several studies have shown that FGF23 is associated with mortality in haemodialysis patients 
as well in patients with CKD. 16;17;41-43 Also in our analysis FGF23 remained a predictor of 
outcome after adjustment of eGFR. Interestingly, the HR of eGFR itself on the composite 
outcome that included progression of CKD was lost in the multivariable model. This 
suggests that the well-established risk of CKD may actually be accounted for by high 
levels of FGF23 that accompany CKD. Obviously, increased FGF23 levels might merely 
reflect the severity of other unmeasured risk factors. Cohort studies, for instance, have 
reported associations of FGF23 with left ventricular hypertrophy,44;45 progression of kidney 
failure,16;19;20 and with several cardiovascular risk factors, such as endothelial dysfunction 
and arterial stiffness, in the general population as well as in early CKD, in the absence of 
clinically evident disturbances in phosphate metabolism.21;46;47
Our findings appear to contrast with the report by Dominguez et al who concluded that 
the association of FGF23 with outcome was reinforced if high FGF23 was accompanied 
with a low FePi, suggesting that kidney FGF23 resistance modifies the association between 
FGF23 and outcome.33 There are several possible explanations for this discrepancy. 
The most important factor is the obvious difference in patient population and outcome. 
Dominguez et al studied patients that participated in the Heart and Soul study, which 
included patients with prevalent occlusive coronary artery disease and normal to slightly 
decreased eGFR, mainly attributed to vascular disease. Importantly, in the eGFR range of 
the Heart and Soul study (stage II CKD), CKD is not an important contributor to overall 
risk.1 In contrast, our patients had moderate-severe CKD and often defined kidney disease 
whereby outcome was mainly determined by renal failure. The second explanation could 
be the difference in methodology. We performed interaction analyses by calculating 
the direction of the interaction using the low FGF23 and high FePi as reference group. 
Dominguez documented the p-value though the direction seems opposite and used low 
FGF23 and low FePi as reference group. 
Another study examined the association of a poor phosphaturic response to FGF23, 
as a sign of FGF23 resistance, on abdominal aortic calcification in CKD stages 3-4.48. 
In this study FGF23 correlated well to FePi except in the group of patients with severe 
aortic calcification, while eGFR and PTH correlated well to FePi irrespectively the amount 
of calcification, suggesting an association with FGF23 resistance and severe aortic 
calcification.  A shortcoming of this study however is that the ratio of FePi to FGF23 (FePi/
FGF23) was used as a marker of resistance where this ratio was mostly determined by 
the denominator FGF23  as there was no difference in FePi between groups. Therefore, 
Impact of fractional phosphate excretion on the relation of FGF23 with outcome in CKD patients
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outcome on calcification score was mainly determined by FGF23. Overall, we cannot 
exclude the possibility that FePi values might indeed modify FGF23 related risk in patients 
with early-stage CKD. In patients with more severe CKD however the increased risk is 
predominantly determined by the higher FGF23 levels, and not by kidney resistance of 
its effects.  Furthermore, FePi was not associated with outcome in either univariate or 
multivariate analysis. Previous studies showed that FePi also was not associated with 
mortality and cardiovascular events in a model adjusted for FGF23 and eGFR.17;33;49 This 
might be because in CKD other (non-defined) risk factors might outweigh the risk of 
tubular resistance to FGF23, or that more advanced tubular damage inhibits phosphate 
reabsorption by other mechanisms than the physiological effects of FGF23, as can be 
observed, for instance, in Fanconi’s syndrome. 
Our results thus refute a significant contribution of FGF23-resistance on outcome in 
patients with CKD3-4. In addition to the arguments described above, it should, however, 
be borne  in mind that there lacks a good representative parameter and validated 
measure of FGF23-resistance, in that both TmP/GFR (ration of the maximum rate of 
tubular phosphate reabsorption to the glomerular filtration rate) and FePi might not 
reflect FGF23-resistance optimally, especially in the setting of more advanced CKD. 
Our study has some limitations, all being the consequence of the post-hoc nature of 
the current analysis. The main limitation is the relatively small number of patients included. 
Although the event rate was high, the events were mainly in the group of patients with 
highest FGF23 levels. Especially for the interaction analysis that we performed, a larger 
number of patients would have been preferable. Due to the small number of patients we 
used a composite end-point. Our study had a low power to evaluate single end-points 
with adjustment for competing risks. Another limitation of the study is that the study 
is a post-hoc analysis of mostly Caucasian patients with more severe CKD and results 
might not be directly applicable to other populations. Furthermore, although serum 
phosphate was measured in a fasting state, FePi was calculated from 24h urine samples, 
and not a timed specimen around blood sample collection. This might have led to higher 
FePi values, and an underestimation of FGF23 resistance because fasting phosphate 
concentrations are generally lower than the average daytime value. A final limitation is 
that we used a composite endpoint, and that in larger studies outcomes may differ for 
individual components of the currently used composite endpoints.
Strengths of our data are the prospectively collected data, and the inclusion of 
primarily patients in a stage of CKD, where CKD has proven impact on clinical outcome.
CONCLUSION
In conclusion, in this study in patients with a median eGFR of 36 (IQR 27-44) ml/min/1.73 
m2, FePi did not modify the association of FGF23 with outcome. Therefore, in advanced 
CKD, the role of FGF23 resistance expressed by FePi is negligible compared to the risk 




1. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY (2004) Chronic kidney disease and the risks 
of death, cardiovascular events, and hospitalization. N Engl J Med 351: 1296-1305
2. Culleton BF, Larson MG, Evans JC et al (1999) Prevalence and correlates of elevated serum 
creatinine levels: the Framingham Heart Study. Arch Intern Med 159: 1785-1790
3. Hemmelgarn BR, Manns BJ, Lloyd A et al (2010) Relation between kidney function, proteinuria, 
and adverse outcomes. JAMA 303: 423-429
4. Madero M, Sarnak MJ, Wang X et al (2009) Uric acid and long-term outcomes in CKD. Am J 
Kidney Dis  53: 796-803
5. Raphael KL, Wei G, Baird BC, Greene T, Beddhu S (2011)Higher serum bicarbonate levels 
within the normal range are associated with better survival and renal outcomes in African 
Americans. Kidney Int 79: 356-362
6. Dhingra R, Sullivan LM, Fox CS et al (2007) Relations of serum phosphorus and calcium levels 
to the incidence of cardiovascular disease in the community. Arch Intern Med 167: 879-885
7. Tonelli M, Sacks F, Pfeffer M, Gao Z, Curhan G (2005) Relation between serum phosphate level 
and cardiovascular event rate in people with coronary disease. Circulation 112: 2627-2633
8. Kestenbaum B, Sampson JN, Rudser KD et al (2005) Serum phosphate levels and mortality risk 
among people with chronic kidney disease. J Am Soc Nephrol 16: 520-528
9. Foley RN (2009) Phosphate levels and cardiovascular disease in the general population. Clin J 
Am Soc Nephrol  4: 1136-1139
10. Narang R, Ridout D, Nonis C, Kooner JS (1997) Serum calcium, phosphorus and albumin levels 
in relation to the angiographic severity of coronary artery disease. Int J Cardiol 60: 73-79
11. Kalantar-Zadeh K, Kuwae N, Regidor DL et al (2006) Survival predictability of time-varying 
indicators of bone disease in maintenance hemodialysis patients. Kidney Int 70: 771-780
12. Russo D, Bellasi A, Pota A, Russo L, Di Iorio B (2014) Effects of phosphorus-restricted diet and 
phosphate-binding therapy on outcomes in patients with chronic kidney disease. J Nephrol, 
Epub ahead of print
13. van Ballegooijen AJ, Reinders I, Visser M, Brouwer IA (2013) Parathyroid hormone and 
cardiovascular disease events: A systematic review and meta-analysis of prospective studies. 
Am Heart J 165: 655-64, 664
14. Kendrick J, Targher G, Smits G, Chonchol M (2009) 25-Hydroxyvitamin D deficiency is 
independently associated with cardiovascular disease in the Third National Health and Nutrition 
Examination Survey. Atherosclerosis 205: 255-260
15. Riminucci M, Collins MT, Fedarko NS et al (2003) FGF-23 in fibrous dysplasia of bone and its 
relationship to renal phosphate wasting. J Clin Invest 112: 683-692
16. Kendrick J, Cheung AK, Kaufman JS et al (2011) FGF-23 associates with death, cardiovascular 
events, and initiation of chronic dialysis. J Am Soc Nephrol 22: 1913-1922
17. Isakova T, Xie H, Yang W et al (2011) Fibroblast growth factor 23 and risks of mortality and 
end-stage renal disease in patients with chronic kidney disease. JAMA 305: 2432-2439
18. Ix JH, Katz R, Kestenbaum BR et al (2012) Fibroblast growth factor-23 and death, heart failure, 
and cardiovascular events in community-living individuals: CHS (Cardiovascular Health Study). 
J Am Coll Cardiol 60: 200-207
19. Fliser D, Kollerits B, Neyer U et al (2007) Fibroblast growth factor 23 (FGF23) predicts 
progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study. J 
Am Soc Nephrol 18: 2600-2608
20. Titan SM, Zatz R, Graciolli FG et al (2011) FGF-23 as a predictor of renal outcome in diabetic 
nephropathy. Clin J Am Soc Nephrol 6: 241-247
21. Mirza MA, Larsson A, Lind L, Larsson TE (2009) Circulating fibroblast growth factor-23 is 
associated with vascular dysfunction in the community. Atherosclerosis 205: 385-390
Impact of fractional phosphate excretion on the relation of FGF23 with outcome in CKD patients
119
3
22. Mirza MA, Larsson A, Melhus H, Lind L, Larsson TE (2009) Serum intact FGF23 associate with left 
ventricular mass, hypertrophy and geometry in an elderly population. Atherosclerosis 207: 546-551
23. Gattineni J, Bates C, Twombley K et al (2009) FGF23 decreases renal NaPi-2a and NaPi-2c 
expression and induces hypophosphatemia in vivo predominantly via FGF receptor 1. Am J 
Physiol Renal Physiol 297: F282-F291
24. Kuro-o M, Matsumura Y, Aizawa H et al (1997) Mutation of the mouse klotho gene leads to 
a syndrome resembling ageing. Nature 390: 45-51
25. Kurosu H, Ogawa Y, Miyoshi M et al (2006) Regulation of fibroblast growth factor-23 signaling 
by klotho. J Biol Chem 281: 6120-6123
26. Shimamura Y, Hamada K, Inoue K et al (2012) Serum levels of soluble secreted alpha-Klotho are 
decreased in the early stages of chronic kidney disease, making it a probable novel biomarker 
for early diagnosis. Clin Exp Nephrol 16: 722-729
27. Koh N, Fujimori T, Nishiguchi S et al (2001) Severely reduced production of klotho in human 
chronic renal failure kidney. Biochem Biophys Res Commun 280: 1015-1020
28. Faul C, Amaral AP, Oskouei B et al (2011) FGF23 induces left ventricular hypertrophy. J Clin 
Invest 121: 4393-4408
29. Sun CY, Chang SC, Wu MS (2012) Suppression of Klotho expression by protein-bound 
uremic toxins is associated with increased DNA methyltransferase expression and DNA 
hypermethylation. Kidney Int  81: 640-650
30. Komaba H, Goto S, Fujii H et al (2010) Depressed expression of Klotho and FGF receptor 1 in 
hyperplastic parathyroid glands from uremic patients. Kidney Int 77: 232-238
31. Sakan H, Nakatani K, Asai O et al (2014) Reduced renal alpha-Klotho expression in CKD patients 
and its effect on renal phosphate handling and vitamin D metabolism. PLoS One 9: e86301
32. Olauson H, Lindberg K, Amin R et al (2013) Parathyroid-specific deletion of Klotho unravels 
a novel calcineurin-dependent FGF23 signaling pathway that regulates PTH secretion. PLoS 
Genet 9: e1003975
33. Dominguez JR, Shlipak MG, Whooley MA, Ix JH (2013) Fractional excretion of phosphorus modifies 
the association between fibroblast growth factor-23 and outcomes. J Am Soc Nephrol  24: 647-654
34. van Zuilen AD, Wetzels JF, Blankestijn PJ et al (2005) Rationale and design of the MASTERPLAN 
study: Multifactorial approach and superior treatment efficacy in renal patients with the aid of 
nurse practitioners. J Nephrol  18: 30-34
35. Bouma-de KA, Bots ML, Vervloet MG et al (2014) Time-averaged level of fibroblast growth 
factor-23 and clinical events in chronic kidney disease. Nephrol Dial Transplant 29: 88-97
36. Heijboer AC, Levitus M, Vervloet MG et al (2009) Determination of fibroblast growth factor 23. 
Ann Clin Biochem 46: 338-340
37. Levey AS, Coresh J, Greene T et al (2006) Using standardized serum creatinine values in 
the modification of diet in renal disease study equation for estimating glomerular filtration 
rate. Ann Intern Med 145: 247-254
38. van Zuilen AD, Bots ML, Dulger A et al (2012) Multifactorial intervention with nurse practitioners does 
not change cardiovascular outcomes in patients with chronic kidney disease. Kidney Int 82: 710-717
39. Knol MJ, van dT, I, Grobbee DE, Numans ME, Geerlings MI (2007) Estimating interaction 
on an additive scale between continuous determinants in a logistic regression model. Int J 
Epidemiol  36: 1111-1118
40. de Mutsert R, Jager KJ, Zoccali C, Dekker FW (2009) The effect of joint exposures: examining 
the presence of interaction. Kidney Int 2009; 75: 677-681
41. Ix JH, Shlipak MG, Wassel CL, Whooley MA (2010) Fibroblast growth factor-23 and early decrements 
in kidney function: the Heart and Soul Study. Nephrol Dial Transplant 2010; 25: 993-997
120
3
42. Jean G, Terrat JC, Vanel T et al (2009) High levels of serum fibroblast growth factor (FGF)-23 
are associated with increased mortality in long haemodialysis patients. Nephrol Dial 
Transplant 24: 2792-2796
43. Gutierrez OM, Mannstadt M, Isakova T et al (2008) Fibroblast growth factor 23 and mortality 
among patients undergoing hemodialysis. N Engl J Med 2008; 359: 584-592
44. Gutierrez OM, Januzzi JL, Isakova T et al (2009) Fibroblast growth factor 23 and left ventricular 
hypertrophy in chronic kidney disease. Circulation 119: 2545-2552
45. Hsu HJ, Wu MS (2009) Fibroblast growth factor 23: a possible cause of left ventricular 
hypertrophy in hemodialysis patients. Am J Med Sci 337: 116-122
46. Mirza MA, Hansen T, Johansson L et al (2009) Relationship between circulating FGF23 and 
total body atherosclerosis in the community. Nephrol Dial Transplant 2009; 24: 3125-3131
47. Yilmaz MI, Sonmez A, Saglam M et al (2010) FGF-23 and vascular dysfunction in patients with 
stage 3 and 4 chronic kidney disease. Kidney Int 78: 679-685
48. Craver L, Dusso A, Martinez-Alonso M, Sarro F, Valdivielso JM, Fernandez E (2013) A low 
fractional excretion of Phosphate/Fgf23 ratio is associated with severe abdominal Aortic 
calcification in stage 3 and 4 kidney disease patients. BMC Nephrol 14: 221
49. Dominguez JR, Kestenbaum B, Chonchol M et al (2013)Relationships between serum and 
urine phosphorus with all-cause and cardiovascular mortality: the Osteoporotic Fractures in 
Men (MrOS) Study. Am J Kidney Dis 61: 555-563


Chapter 4SHORT-TERM EFFECT OF 
SEVELAMER-CARBONATE 
ON FIBROBLAST GROWTH 
FACTOR 23 AND PULSE WAVE 
VELOCITY IN PATIENTS WITH 
NORMOPHOSPHATEMIC 
CHRONIC KIDNEY DISEASE
A. Bouma - de Krijger, T. Hoekstra, F.J. van Ittersum, 
P.M. ter Wee, M.G. Vervloet 
Clinical Kidney Journal, 2019 Mar 25;12(5):678-685
Institutions:
¹ Department of Nephrology, VU University Medical Center 
Amsterdam, De Boelelaan 1117, 1081 HV Amsterdam, 
The Netherlands (https://www.vumc.nl)
2 Amsterdam Cardiovascular Sciences Institute (ACS), O2 | Building 






High concentrations of both phosphate and Fibroblast Growth Factor 23 (FGF23), 
observed in chronic kidney disease (CKD) are associated with an increased risk of 
cardiovascular morbidity and mortality. Pulse wave velocity (PWV) is a surrogate marker 
for cardiovascular events and all-cause mortality. It is not known whether a reduction of 
FGF23 or phosphate alters cardiovascular risk. Sevelamer has shown to have the ability 
to reduce both phosphate and FGF23 concentrations. Furthermore reduction of PWV 
is reported by sevelamer use as well, but it is unclear if this is mediated by decline of 
phosphate or FGF23. We investigated if sevelamer induced a decline in PWV and if this 
was associated with a reduction in FGF23.
Methods
In all, 24 Normophosphatemic CKD stage 3 patients started treatment with a fixed 
dose of sevelamer-carbonate (Renvela ®) 2.4 gram twice daily with their usual diet for 
8 weeks in a single arm study. PWV was measured and blood samples were obtained 
before, during and after wash out of treatment with sevelamer. Vascular calcification was 
quantified using the Kauppila Index (KI). The primary outcome was the change of PWV 
from baseline to 8 weeks of treatment and the secondary endpoint was the difference 
of FGF23 following treatment with sevelamer. One of the linear mixed models was used 
to analyse the association between treatment and outcome. Mediation analysis was 
performed as a sensitivity analysis. The study was registered in the Dutch trial register 
(http://www.trialregister.nl: NTR2383).
Results 
A total of 18 Patients completed 8 weeks treatment with sevelamer and were analysed. 
Overall, treatment with sevelamer did not induce a significant reduction of PWV (β -0.36, 
p= 0.12). However, in patients with less vascular calcification (lower KI score) there was 
a statistically significant reduction of PWV, adjusted for mean arterial pressure, after 
treatment (β 0.63, p= 0.02). Addition of FGF23 to do model did not alter this association. 
Mediation analysis yielded similar results. FGF23 did not decrease during treatment with 
sevelamer. 
Conclusion
In this short-term pilot-study in normophosphatemic CKD patients, treatment with 
sevelamer did not improve PWV. In subgroup analysis however, PWV improved in 
patients with no or limited abdominal aorta calcifications. This was not associated by 
a decline of FGF23.




Chronic kidney disease (CKD) is a major public health concern given its high prevalence 
and its associated increased risk for cardiovascular morbidity and mortality.1 This elevated 
risk cannot be fully explained by traditional Framingham risk factors. Emerging evidence 
points towards CKD-mineral bone disorder (CKD-MBD), in particular phosphate and 
Fibroblast Growth Factor 23 (FGF23) as independent cardiovascular risk factors, in 
haemodialysis patients,2,3 as well as in CKD patients.4,5 Both factors are associated with 
left ventricular hypertrophy,6,7 vascular calcification8 and disturbed vascular function.9
An established predictor for cardiovascular outcome is arterial stiffness, as measured 
by pulse wave velocity (PWV) since it is strongly associated with cardiovascular events 
and all-cause mortality in hypertensive patients 10,11 as well as in patients with CKD12 and 
end-stage renal disease.13 
PWV is the velocity at which the arterial pulse wave propagates through the arterial 
system and is a highly reproducible method to asses arterial stiffness.14 FGF23, a bone-
derived hormone involved in controlling serum phosphorus concentrations by enhancing 
its renal excretion,15,16 is associated with vascular stiffness and endothelial dysfunction 
through mechanisms currently not fully elucidated.17,18 Recent data suggest that vascular 
endothelium is a direct target for the klotho-FGF23 complex, possibly through the nitric 
oxide system enhancing vascular stiffness.19-21 Vascular stiffness in turn is considered to 
contribute to increased cardiovascular morbidity.17 22 
If FGF23 plays a causal role in arterial stiffness, then active targeting FGF23 would be 
a legitimate goal. Although several studies do demonstrate that FGF23 concentrations 
could be lowered by the use of non-calcium based phosphate binders,23-25 it is unknown 
what would be the impact on intermediate cardiovascular endpoints, such as PWV. 
Besides FGF23, hyperphosphatemia is also associated with impaired endothelial 
function and vascular smooth muscle cell calcification leading to increased arterial 
stiffness.26-29 To evaluate the independent role of FGF23 on PWV, we studied CKD patients 
with normophosphatemia, but increased FGF23.
In this pilot study in patients with CKD stage 3, we tested whether eight weeks of 
treatment with sevelamer lowered pulse wave velocity compared to baseline, and if this 
presumed change was associated with a decline in FGF23 concentration. We also tested 
if the presence of calcification influenced the effect of sevelamer treatment on PWV. 
MATERIALS AND METHODS
Patients and study design
Twenty four CKD stage 3 (eGFR 30-60 ml/min/1.73 m2) patients were recruited in 
a prospective single arm pilot study. Additional inclusion criteria were age >18 years, 
and serum phosphate concentration between 0.9 and  1.49 mmol/L. Exclusion criteria 
consisted of a known allergy or intolerance for sevelamer-containing drugs, heart failure, 
current phosphate binder therapy use, unstable kidney function, dependency on tube-
feeding or presence of a malabsorption syndrome, and a history of kidney transplantation.
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Following an observation period of two weeks, in all patients a fixed dose of sevelamer-
carbonate (Renvela ®provided by Genzyme/Sanofi ) 2.4 gram twice daily was initiated 
and continued for eight weeks. During the duration of the study patients kept their 
regular diet and further medication was unchanged. 
The primary outcome was change of PWV from baseline to eight weeks of treatment 
with sevelamer and the secondary endpoint was change of FGF23 following eight weeks 
of treatment. For safety reasons serum phosphate concentration was measured after 
one week of treatment and treatment was stopped if serum phosphate  declined <0.70 
mmol/L, the lower limit of normal. Patients who dropped out of the study were not 
analysed. This was because effect of treatment could not be evaluated in patients who 
stopped treatment. 
Data collection and Measurements
Patient visits were two weeks prior to baseline, at baseline (start of sevelamer carbonate 
treatment), following eight weeks of treatment and two weeks after cessation of 
treatment. After one week of treatment a single blood sample was obtained for 
measurement of serum phosphate. At all other visits physical examination, laboratory 
assessment and pulse wave velocity (PWV) measurements were performed. Physical 
examination consisted of measurement of height, weight and an office blood pressure 
measurement in supine position. Laboratory assessment included creatinine, calcium, 
phosphorus, PTH and plasma FGF23. C-terminal FGF23 was measured using sandwich 
ELISA (Immutopics San Clemente, CA, USA). The intra- and inter-assay coefficient of 
variation of this assay are <5% and <16%, respectively.30 Glomerular filtration rate (eGFR) 
was estimated using the four-point MDRD formula.31 Twenty-four hour urine samples 
were collected and creatinine, calcium, phosphate and proteinuria were measured using 
standard automated techniques. Fractional excretion of phosphate was calculated as 
(urine phosphate x serum creatinine)/(serum phosphate x urine creatinine) and expressed 
as percentage.  
Arterial stiffness was determined by measurement of PWV using the SphygmoCor® 
device. Transducer pulse waves were measured at the carotid artery and femoral artery 
(CF-PWV) by a specially trained research nurse following standardized procedures. 
The SphygmoCor applies an internal general transfer function to calculate measures of 
arterial stiffness and vascular properties. Three sequences of pulse waves of 10 seconds 
were recorded and analysed, but only readings with a standard deviation of <10% of 
the PWV were kept, averaged, and used in the analyses.  PWV values <8 m/s are defined 
as normal. Values above match progressive vascular stiffness of the aorta. 
The presence and extent of abdominal aortic calcification was obtained from a lateral 
lumbar spine X-ray and scored using the Kauppila Index (KI) as previously described (scores 
0-3 at each site, with a total range from 0 to 24).32 All X-ray images were evaluated by 
the same expert radiologist. Information on medication was obtained from questionnaires 
and cross-checked with medical records. 




A Generalized Estimating Equations (GEE) model (IBM SPSS Statistics version 22®) was used 
to compare the PWV and FGF23 concentration within each patient at the different time 
points of the study. The main analysis was  the comparison of PWV during the treatment 
compared to baseline. Baseline in the analysis was defined as the measurement direct 
at the start of intervention. The treatment value consisted of the measurement after 
eight weeks of treatment. The wash-out measurement was performed two weeks after 
cessation of therapy. All measurements were included in the model. To evaluate whether 
the potential effect of the use of sevelamer on PWV was affected by FGF23, FGF23 was 
added to the model. The analyses for PWV were expanded by stratification for baseline 
KI score (below or above median). Stratification was applied since vascular calcification 
contributes to arterial stiffness and this component will unlikely be modifiable with short-
term intervention as applied in this study. 
In addition, we performed a plain mediation analysis (Stata version 14.2®) using 
a causal step approach to analyse the causal pathway of treatment with sevelamer on 
PWV and mediation by FGF23.  Again beside the crude analysis, a MAP adjusted analysis 
and stratification for KI score was performed. Assuming changes in FGF23 will have in 
short term an effect on PWV, we used GEE in this analysis.
The second analysis consisted of a comparison of the FGF23 concentrations at different 
time points. Again all measurements were included in the model. FGF23 concentrations 
following eight weeks of treatment were compared with concentrations at baseline. 
Because FGF23 showed a non-normal distribution, FGF23 was log-transformed 
(natural logarithm) if used as dependent variable. Confounders added to the analysis 
consisted of known confounders for FGF23 and PWV, which could be subjected to change 
during study period. For FGF23 these were:  eGFR, serum calcium, serum phosphate, PTH, 
1,25(OH)₂ vitamin D and proteinuria. Possible confounders of PWV were mean arterial 
pressure (MAP) and eGFR. Furthermore, we analysed whether other laboratory parameters 
changed during the study. If this was the case, then we added those as confounders in 
the model to evaluate if change of these parameters had an influence. In addition to 
these analyses, we evaluated if change of FGF23 (the difference between two subsequent 
values) was associated with the change of PWV using Pearson’s correlation analysis. 
Data are given as mean and standard deviation (± SD) or median with interquartile 
range (IQR). The threshold for statistical significance was a p-value of 0.05. For all GEE 
models an exchangeable correlation structure was used. 
Ethics approval and consent to participate
The study was performed in accordance with the Declaration of Helsinki and was approved 
by the local medical ethics committee. In this case the ‘METc VUmc’, (address;  METc 
VUmc, kamer H-565,Postbus 7057.1007 MB  Amsterdam, +3120 -44 45585). 
All participants provided informed written consent to participate. The study was 




Course of inclusion of patients
Of 24 patients, 18 patients completed the study (Figure 1). In three patients, treatment 
was stopped as per protocol after one week, because of a phosphate concentration 
below the threshold of the normal value (0.7 mmol/L), after which it returned to normal. 
The measured serum phosphate concentrations in these patients were  0.68, 0.42 and 
0.64 mmol/L, and all patients were asymptomatic. In addition, three patients stopped 
treatment  because of gastro-intestinal side effects possibly related to sevelamer use. 
Analysis of the effect of treatment with sevelamer on PWV and FGF23 was performed in 
the remaining 18 patients. 
Baseline characteristics 
Baseline characteristics of all 24 patients who started the study are presented in 
Supplementary Table S1. The mean age of the 18 analysed patients was 52 years and 
61% were female (Table 1). Four patients had diabetes (two type 1 and two type 2 
diabetes). Mean eGFR was 43.5 (SD ± 9.6) ml/min/1.73m2.
Mean baseline PWV was 9.2 (SD ± 2.3) m/s. The KI score ranged from 0 in seven 
patients to scores above 7 in five patients. The median KI score was 1.5 (IQR 0.0-8.0). 
The median FGF23 concentration was 167 (IQR 121-234) RU/ml. MAP was 99.5 
(SD ± 11.8) mmHg. Additional baseline characteristics are depicted in Table 1.
Effect of Sevelamer on PWV 
Overall PWV did not change during treatment and was 9.2 (SD ± 2.3) before treatment 
and 8.7 (SD ± 2.4) m/s after treatment (p=0.12). Median change of PWV was -0.10 
(SD-0.85 to 0.35) m/s (Table 2 and Supplementary Figure S1). This was unchanged after 
addition of MAP and FGF23 to the model. Also after stratification for  baseline FGF23 
concentrations above or below the median, the decline of PWV did not differ from 
baseline to end of treatment (analysis not shown in table).  However, when stratified for 
KI, there was a statistically significant improvement of PWV, after correcting for MAP, 
in patients with KI scores below the median (Table 2). PWV did not change in patients 
with higher KI.  In the mediation analysis, performed as a sensitivity analysis, an effect of 
sevelamer  on PWV was again found in patients with low Kauppila scores, however there 
was no association with possible mediation of FGF23 (analysis not shown). No statistically 
significant association was found between eGFR or 1,25(OH)₂ vitamin D with PWV during 
treatment (analysis not shown in table). 
Effect of Sevelamer on phosphate balance, FGF23 and other parameters
The mean reduction of 24-h phosphate excretion from baseline to end of treatment was 
9.78 mmol/24-h (p=0.008), indicating significant reduction of phosphate absorption with 
sevelamer treatment. Serum phosphate concentration did not change during this period. 
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The median change of FGF23 was -1.5 (IQR-33.8 to 16.0) RU/ml from baseline to week 
8. This was no significant reduction (β -0.03 ,95% CI -0.19 to 0.12, p= 0.68) . Additional 
stratification for FGF23 baseline concentrations above or below the median did not 
change this absence of effect on FGF23. Besides, FGF23 change did not differ between 
patients with a reduction of urinary phosphate excretion above or below the median 
(analysis not shown). 
During treatment there was a statistically significant decline of eGFR , MAP and of 
1,25(OH)₂Vitamin D (Supplementary Figure S1), which returned towards baseline values 
 
Figure 1. Study consort diagram. Diagram of the number of patients screened, recruited, participated 
and dropped-out of the study
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Table 1. Baseline characteristics of 18 patients treated with Sevelamer Carbonate
Age (year) 52.0 ± 13.8
Sex (m/f) 7/11
Diabetes type 1 or 2  (%) 11.1
Body Mass Index (kg/m2) 27.4 (24.8-32.9)
Race (% Caucasian) 72.2
eGFR (ml/min/1.73m2) 43.5 ± 9.6
PWV (m/s) 9.2 ± 2.3
Kauppila index score (0-12) 1.5 (0.0-8.0)
FGF23 (RU/ml) 167 (121-234)
PTH (pmol/l) 7.2 (6.1-10.0)
25 OH vitD3 (nmol/l) 69.6 ± 30.6
1,25(OH)₂Vitamin D (pmol/l) 82.6 ± 21.2
Phosphate (mmol/l) 1.12 ± 0.18
Calcium (mmol/l) 2.30 ± 0.12
Urinary PO4 excretion (mmol/24 h) 25.4 (16.4-35.0)
Urinary Ca excretion (mmol/ 24 h) 1.5 (0.9-2.2)
Fractional PO4 excretion (%) 23.5 (14.4-36.4)
Proteinuria (g/24 h) 0.34 (0.0-1.66)
Haemoglobin (mmol/l) 8.1 (7.5-9.2)
Albumin (g/l) 37.0 ± 3.9
Cholesterol (mmol/l) 4.8 ± 0.8
LDL cholesterol (mmol/l) 2.48 ± 0.65
Mean Arterial Pressure (mmHg) 99.5 ± 11.8
Smoking  (yes/no) 5/13
Use Angiotensin-converting enzyme  
or Angiotensin receptor blocker  (%)
72.2
Use cholecalciferol (%) 27.8
Use active vitamin D (%) 33.3
Baseline values expressed as mean ± SD or median (IQR) 
after the wash-out period. The decline of 1,25 (OH)₂ vitamin D concentrations appeared 
in both vitamin D users and non-users. All other baseline parameters did not change 
significantly (analysis not shown in table).
In the analysis of the association between treatment with sevelamer and FGF23 
concentration, adjustment for parameters potentially affecting FGF23 concentrations 
was performed (Supplementary Table S2 ). After correcting for eGFR and 1,25(OH)₂ 
vitamin D, a statistically significant decline of FGF23 concentration was found following 
treatment with sevelamer. 
To study if any change of FGF23 was associated with a change in PWV, regardless 
of effect of sevelamer treatment, measurements from all time points of these two 
parameters were pooled.   The change, or delta, was calculated from all subsequent 
values of FGF23 and PWV. We found no association between changes of FGF23 with 
Short-term effect of sevelamer-carbonate on fibroblast growth factor 23 and pulse wave velocity
131
4
Table 2. Effect of  8 weeks treatment with Sevelamer Carbonate on PWV (m/s) 
Treatment compared to baseline β 95% Confidence Interval p-value
All
crude -0.36 -0.82 to 0.09 0.12
Model 1: crude + MAP -0.24 -0.58 to 0.10 0.17
Model 2: model 1 + FGF23 -0.22 -0.58 to 0.13 0.22
KI score < median
crude -0.71 -1.43 to 0.01 0.05
Model 1: crude + MAP -0.63 -1.13 to -0.12 0.02
Model 2: model 1 + FGF23 -0.58 -1.04 to -0.12 0.01
KI score > median
crude 0.05 -0.37 to 0.46 0.82
Model 1: crude + MAP 0.13 -0.22 to 0.48 0.47
Model 2: model 1 + FGF23 0.28 -0.07 to 0.62 0.11
Values of PWV  following treatment compared to PWV baseline. Generalized Estimating Equations (GEE) 
was used to analyze the difference between treatment and baseline PWV values. All PWV measurements 
(of all time points) were included in the model, depicted is only the difference between treatment and 
baseline PWV. Stratification for KI score above and below the median was performed. PWV: Pulse Wave 
Velocity, FGF23; Fibroblast Growth Factor 23, MAP; Mean Arterial Pressure.
corresponding change in PWV.  However, the absolute differences of consecutive values 
of both PWV and FGF23 were very small, as shown in Supplementary Figure S2.
DISCUSSION
Effect of Sevelamer on PWV 
We hypothesized that a sevelamer-induced reduction of FGF23 would lead to improved 
vascular function as assessed by PWV. This hypothesis is based on previous observations 
that sevelamer can lower PWV and its use is associated with a reduction in FGF23 
concentration.23-25 It is not known if lowering PWV is mediated by a reduction in FGF23 
concentrations. Overall we found no significant improvement in PWV after treatment with 
sevelamer (Table 2).  A secondary analysis in patients with high versus low baseline KI score 
was performed since increased PWV may in part the consequence of (non-modifiable) 
vascular calcification. This revealed noteworthy results. A statistically significant reduction 
of PWV during treatment with sevelamer was observed in patients with low KI scores 
after correction for MAP (Table 2). This suggests that in patients with low calcification 
score, PWV is more amenable for improvement. The latter was also observed in a study 
in peritoneal dialysis patients in which lower PWV was associated with lower aortic 
calcification scores and was more likely to change during the observation period.33
The overall findings of our study are generally in line with those of Chue et al,34 in 
which 109 patients with normophosphatemic CKD stage 3 were randomized to sevelamer 
or placebo for 40 weeks. Despite the considerably longer intervention period compared to 
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our study, these authors also found no effect of sevelamer on PWV or on FGF23. However, 
in contrast to our study, in the study of Chue no difference in PWV between placebo and 
sevelamer was observed when patients with aortic calcifications were excluded.34 This 
different outcome may result by the fact that in the study by Chue the PWV results were 
not corrected for blood pressure, which is a key determinant for PWV. 
Previous studies by Takenaka35 and Othmane et al.36 studying patients on dialysis with 
hyperphosphatemia, noted a significant decline of PWV following sevelamer treatment. 
These studies were performed in  patients at a different stages of CKD than our study 
and the duration of treatment in these studies was six and eleven months respectively, 
compared to eight weeks in our study. None of these studies measured FGF23. 
The short-term use of sevelamer in our study however was part of our hypothesis that 
FGF23-dependent arterial stiffness (assessed by PWV) can alter in a short period of time, 
unless there is outspoken vascular calcification. The possibility for short term modification 
of PWV is described in several studies ( e.g. studies in which statins or L–Arginine (through 
the nitric oxide pathway) affected PWV within days or weeks).37-39 
Effect of Sevelamer on FGF23
The original premise of our study was that the use of sevelamer would induce a decline 
in FGF23 concentrations, which subsequently would improve PWV. Sevelamer, like other 
non-calcium based phosphate binders, reduces phosphate absorption and has shown to 
have the potential to reduce FGF23 concentrations as is shown in a number of studies.23-
25,40,41 In our study FGF23 concentrations did not decrease during treatment with sevelamer, 
despite an effective reduction of phosphate absorption (reflected by a significant decline 
in 24-h phosphate excretion). The latter indicates that the dosage of the phosphate binder 
was adequate. The fact that we failed to reduce FGF23 concentrations may, at least in 
part, be attributed to an unforeseen transient decline in eGFR during the treatment phase. 
This decline potentially masked the effect of sevelamer treatment on FGF23. Following 
treatment there was also a reduction of 1,25(OH)₂ vitamin D and mean arterial pressure 
(MAP), which returned to pre-treatment levels after cessation of sevelamer.  A possible 
explanation is that during the study the patients adherence to medication, especially 
antihypertensive drugs,  improved leading to a decline of MAP which then induced 
a reduction of eGFR.  Interestingly, this phenomenon was also observed in the run-in 
phase of study of Chue.34 During that period, where the adherence to sevelamer was 
the highest, a decline in 1,25(OH)₂ vitamin D, blood pressure and eGFR (latter not 
significant) was observed as well. All in all, our study does not support the concept that 
phosphate binder therapy in normophosphatemic patients with CKD can lower FGF23.
Influence of FGF23 on PWV
One component of our hypothesis was that the presumed effect of sevelamer on PWV 
was mediated by FGF23.  However, the effect of treatment on PWV did not change by 
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adding FGF23 to the GEE model, excluding FGF23 as confounder in this analysis (Table 2). 
In the mediation analysis, the additional sensitivity test performed,  an effect of sevelamer 
on PWV was found; however this was not affected by FGF23.
Our inability to demonstrate an effect of FGF23 on PWV might be explained by the fact 
that the absolute change of FGF23 was minimal. Therefore our study lacks discriminatory 
power to reveal a potential impact of change of FGF23 on arterial stiffness assessed by 
PWV. Although it cannot be ruled out that more substantial decline of FGF23 would 
have improved PWV, Chue et al.’s recent data favour absence of any effect of FGF23 on 
PWV.34 In a subgroup analysis of this study, in the patients in whom FGF23 reduction was 
achieved, they observed that even more profound reduction of FGF23 concentration had 
no effect on PWV. In addition, in another study, patients with CKD stage 3 randomized 
to either lanthanum carbonate or placebo, the observed decline of FGF23 had no effect 
on PWV.42 Finally, a recent animal study in which mice were treated with sevelamer for 
eight weeks a decline of both FGF23 and PWV was found,43 yet the effect of sevelamer on 
PWV preceded the reduction of FGF23, and thus  the reduction of PWV could also not be 
attributed to change of FGF23. Altogether we conclude that although FGF23 is reported 
to be closely associated to vascular function, our study does not support the hypothesis 
that lowering FGF23 concentrations could improve PWV.
Strengths and weaknesses of the study
Strength of our study was that we performed the study in normophosphatemic CKD 
stage 3 because elevated FGF23 concentrations are observed, yet serum phosphate 
concentrations are usually still in the normal range at this stage of CKD. This enabled 
us to limit the potentially confounding effect of normalization of serum phosphate 
during the intervention period. Moreover in our study, patients had well-controlled blood 
pressure and so the possible beneficial effect of sevelamer was evaluated in a setting 
of optimized standard of care. In addition we measured abdominal calcification score, 
enabling us to study the potential of effect modification by this structural abnormality of 
the aorta.
Our study also has several  limitations. First, there was no control group. In the study 
design however, there was a baseline period, enabling individual patients to serve as 
their own control Because of the pilot design, the study was performed in only a small 
group of patients based on the amount of patients in the earlier study by Oliveira et al.23 
Although this is a limitation, one could also reflect that if an effect of sevelamer on either 
FGF23 or PWV is only detectable in a large population, this would also implicate a large 
number to treat to improve these intermediate endpoints. In this regard, it is encouraging 
that in the subgroup with low KI scores, a statistically significant effect of treatment 
on PWV was found.  Another limitation of our study is that no attempts were made 
to standardize intake of phosphate, calcium or other dietary components in the study 
population. This, however, is a better reflection of the real-life situation. Moreover, by 
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measuring 24-h phosphate excretion we were able to quantify dietary phosphate intake. 
In our study, three patients dropped out because of hypophosphatemia. It is possible 
that in those patients a different effect on PWV during treatment would have occurred. 
Another possible limitation is that we chose PWV as a proxy for vascular disease. PWV 
reflects function of the conduit arteries, not of the microcirculation. We cannot exclude 
that sevelamer treatment may have different effects on other segments of the circulation. 
Finally, our study was performed in a single centre, which might limit the external validity 
of our findings.
Conclusions 
In summary, in our study in 18 normophosphatemic patients with CKD stage 3, treatment 
with sevelamer did not improve PWV or FGF23. However, in patients with low KI  scores, 
sevelamer improved PWV, but this was not associated with an decline of FGF23. Our 
findings do not support the assumption of beneficial effects of early treatment of 
phosphate exposure in order to improve cardiovascular risks in all CKD stage 3 patients. 
Future studies aiming to improve cardiovascular risk by modifying PWV through lowering 
of FGF23 should focus on patients with limited vascular calcification.
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Supplementary Table 1. Patient characteristics of patients started treatment with Sevelamer Carbonate 
versus patients finished treatment with Sevelamer Carbonate.





Age (year) 50.3 ± 14.0 52.0 ± 13.8
Sex (m/f) 9 v 15 7/11
Diabetes type I or II (%) 16.7 22.2
Body Mass Index 27 (24-32) 27.4 (24.8-32.9)
race (% caucasian) 75 72.2
eGFR (ml/min/1.73m2) 42.8 ± 10.6 43.5 ± 9.6
FGF23 (RU/ml) 160 (123-207) 167 (121-234)
PTH (pmol/l) 7.5 (6.0-9.6) 7.2 (6.1-10.0)
25 OH vitD3 68.3 ± 29.7 69.6 ± 30.6
1.25 OH vit D (pmol/l) 79.1 ± 22.8 82.6 ± 21.2
Phosphate (mmol/l) 1.11 ± 0.20 1.12 ± 0.18
Calcium (mmol/l) 2.27 ± 0.14 2.30 ± 0.12
Urinary PO4 excretion (mmol/24 h) 22.1 (16.4-34.6) 25.4 (16.4-35.0)
Urinary Ca excretion (mmol/ 24 h) 1.4 (0.7-1.8) 1.5 (0.9-2.2)
Fractional PO4 excretion (%) 23.7 (14.8-34.0) 23.5 (14.4-36.4)
Proteinuria (g/24 h) 0.34 (0.0-1.36) 0.34 (0.0-1.66)
Hemoglobin (mmol/l) 8.1 ± 1.0 8.1 (7.5-9.2)
Albumin (mmol/l) 36.1 ± 6.1 37.0 ± 3.9
Cholesterol (mmol/l) 5.1 (4.3 -5.8) 4.8 ± 0.8
LDL cholesterol (mmol/l) 2.70  ± 1.05 2.48 ± 0.65
Mean Arterial Pressure (mmHg) 98.6 ± 11.4 99.5 ± 11.8
Smoking yes/no 7 v 24 5 v 13
Use ACE or ARB (%) 66.7 72.2
use  cholecalciferol 20.8 27.8
Use 1.25 OH vit D (%) 37.3 37.5
Kaupilla index score (0-15) 1.5 (0-8) 1 (0-8)
PWV (m/s) 9.0 ± 2.4 9.2 ± 2.3
Baseline values expressed as mean ± SD or median (IQR)  
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Supplementary Figure 1. Time course of different parameters  during study period. Time course 
of PWV, FGF23, Urinary phosphate excretion, eGFR, MAP and 1.25 OH₂Vitamin D during the study 
period. Depicted are the mean and standard deviation of PWV (m/s) ,24- hour Urinary Phosphate 
Excretion, eGFR, MAP and 1.25 OH₂Vitamin D concentrations on different time points during 
the study. FGF23 concentrations are depicted as median and interquartile range on the different 
time points because of a non-normal distribution. Generalized Estimating Equation models (GEE) 
were used to calculate the differences between subsequent time points. Only statistical significant 
differences (p value below 0.05) are shown
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Crude -0.032 (-0.187 to 0.123) 0.684
Model 1: adjusted for eGFR and serum 
1,25(OH)₂Vitamin D
-0.221 (-0.406 to -0.035) 0.020
Model 2:  Model 1 + adjusted for serum phosphate -0.256 (-0.438 to -0.074) 0.006
Model 3: Model 2 + adjusted for PTH -0.252 (-0.436 to -0.069) 0.007
Generalized Estimating Equations (GEE) was used to calculate the difference between treatment and 
baseline FGF23 concentrations. FGF23 values of all time points were included in the model, depicted is 
only the difference between treatment and baseline. FGF23 was log transformed because of non-normal 
distribution. FGF23, Fibroblast Growth Factor 23; eGRF, estimated glomerular filtration by the MDRD 
formula; PTH, parathyroid hormone; 1,25(OH)₂Vitamin D, calcitriol.
Supplementary Figure 2. delta FGF23 to delta PWV. Delta FGF23 plotted against delta PWV 
off all measurements during the study (with and without Sevelamer treatment). The change, 
or delta, was calculated from all subsequent values of FGF23 and PWV. The association is 
the calculated relation coefficient.
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Previous studies in patients on haemodialysis (HD) have shown an association of FGF23 
with all-cause mortality. As of yet, the result of FGF23 lowering on mortality is unknown 
in this population. 
Methods
FGF23 was measured in a subset of 404 patients from the CONTRAST study (a randomized 
trial in prevalent dialysis patients comparing HD and haemodiafiltration (HDF) on clinical 
outcome) at baseline and months 6 and 12. A substantial decline of FGF23 change over 
time was anticipated in patients randomized to HDF, since HDF induces higher dialytic 
clearance of FGF23. The associations of both baseline FGF23 and 6 months change 
in FGF23 with all-cause mortality were analysed. In addition, the difference in FGF23 
change between HD and HDF was explored. Furthermore, the role of dialysis modality in 
the association between FGF23 change and outcome was analysed.
Results
No association was observed between quartiles of baseline FGF23 and all-cause mortality. 
Over 6 months, FGF23 declined in patients on HDF, whereas FGF23 remained stable 
in patients on HD. A decrease in FGF23 was not associated with improved survival 
compared to a stable FGF23 concentration. However, increasing FGF23 was associated 
with a significant higher mortality risk, both in crude and fully adjusted models (hazard 
ratio [HR] 2.01 [95% confidence interval 1.30 to 3.09] ). 
Conclusion
Whereas no association between a single value of FGF23 and all-cause mortality was 
found, increasing FGF23 concentrations did identify patients at risk for mortality. 
Since lowering FGF23 did not improve outcome, this study found no argument for 
therapeutically lowering FGF23. 




Mortality rates in patients treated with haemodialysis (HD) remain unacceptably high, 
despite contemporary medication and modern dialysis equipment. Besides classical risk 
factors for cardiovascular disease (CVD), such as smoking, diabetes and hypertension, 
non-classical risk factors such as fluid overload and chronic kidney disease associated 
mineral bone disease (CKD-MBD), contribute to this high mortality risk.1-3 However, 
intervention studies targeting these CKD-MBD components generally failed to show 
a beneficial effect on CVD morbidity and mortality.4-8 More recently, fibroblast growth 
factor 23 (FGF23) has emerged as a key player in MBD pathophysiology. FGF23 is a bone 
derived-hormone maintaining phosphate balance by enhancing its renal excretion.9-11 
During the course of CKD, FGF23 values rise, reaching the highest levels in end stage 
renal disease (ESRD) patients on dialysis.12 Although this physiological adaptation is 
crucial for maintaining phosphate balance in early CKD, prolonged exposure in advanced 
CKD may have deleterious effects.13-15 Several observational studies have shown an 
independent association between increased FGF23 levels and mortality through all stages 
of CKD, including dialysis.16-19 However, it is debated whether interventions that lower 
FGF23 lower mortality risk. Previous studies in patients on HD are merely performed in 
incident dialysis patients and merely lack longitudinal FGF23 measurements, or observed 
the natural history of FGF23 evolution over time.20,21 In the current study, we explored 
the association between change of FGF23 over time and all-cause mortality in a cohort of 
patients treated with either low-flux HD or hemodiafiltration (HDF).22 This is of interest as 
convective transport has been shown to effectively lower FGF23.23-25 
MATERIALS AND METHODS
Study design and patient population
For the present study, data from the CONTRAST study (clinicaltrials.gov NCT00205556) 
were used. CONTRAST was a randomized controlled clinical trial evaluating the effect of 
online post-dilution HDF versus low-flux HD on mortality and cardiovascular outcomes. 
Methods of CONTRAST study have been described elsewhere.22,26 In short, data were 
collected in 29 dialysis centers in the Netherlands, Canada and Norway between 2004 
and 2010. Adult patients with ESRD on HD two or three times weekly for at least 2 
months were eligible for inclusion. Exclusion criteria were treatment with HDF or 
high-flux HD in the 6 months prior to randomization, an expected lifespan >3 months, 
severe incompliance to dialysis treatment or participation in another clinical intervention 
trial. CONTRAST was conducted in accordance with the declaration of Helsinki and Good 
Clinical Practice guidelines and was approved by central and all local medical ethics review 
boards. Before enrolment, written informed consent was obtained from all participants.26
Of the original 714 patients enrolled in CONTRAST, stored plasma samples from 
baseline were available in 404 patients for measurement of FGF23. Those samples 
originated from 17 out of the 29 participating centers in the CONTRAST study of which 
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it was logistically feasible to collect and store extra plasma samples at -80 °C.27 Of 
these, plasma samples were available at month 6 in 341 patients and at 12 months in 
291 patients.  
Data collection
At baseline, data on demographic characteristics, medical history, medication and duration 
of dialysis were recorded. Every 3 months laboratory values, medication, treatment 
characteristics and information on clinical events were obtained. Blood samples were 
drawn at the beginning of dialysis. The mean delivered convection volume (substitution 
volume plus net ultrafiltration) was in HDF estimated with the following formula: mean 
delivered convection volume = (HDF treatments / total number of treatments) x mean 
convection volumes of the three treatments preceding the quarterly visit.22
Laboratory measurements
All routine laboratory measurements were analyzed locally by the participating hospitals 
using standard laboratory techniques.  From the stored samples at -80 °C, the c-terminal 
FGF23 was measured using sandwich ELISA assay (Immutopics® San Clemente, CA, 
USA). The intra- and inter-assay coefficient of variation of this assay are <5% and <16%, 
respectively.28 If values were >16.000 RU/ml additional dilution was performed in order to 
optimize validity of the test results.
Statistical analysis
Baseline characteristics were presented as proportions, means with their corresponding 
standard deviations (± SD), or as medians with interquartile ranges (IQRs) when data had 
a skewed distribution.
For all mortality analyses, an intention-to-treat approach was applied. Follow-up for 
survival was complete as patients who discontinued the randomized treatment (e.g. due 
to renal transplantation, a switch to peritoneal dialysis or moving to a non-participating 
centre) were still followed for cause-specific mortality until the end of the study. Since 
transplantation during follow-up is a competing treatment affecting  mortality, all models 
were adjusted for transplantation by adding transplantation as a time-varying covariate, 
as recently suggested.29 Adjusted models were corrected for: age, diabetes, history of 
CVD, dialysis vintage, residual kidney function and serum phosphate concentration. 
First, the relation between quartiles of baseline FGF23 concentration and all-cause 
mortality was analysed using Cox proportional hazard models. 
Secondly, we explored the possible difference in rate of change of FGF23 in HDF 
compared with HD using generalized Linear Mixed Models with an interaction term 
between treatment modality and time. When appropriate, stratified models were fitted 
subsequently. For these analyses, models with a random slope, random intercept, or both 
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were used depending on the lowest Akaike’s Information Criterion. Change in FGF23 
concentrations in 6 months’ time were calculated as absolute and relative change. 
In a supplemental analysis we investigated whether the relative change in FGF23  over 
6 months was different for different tertiles of the mean reached convention volume. For 
this, a p-value for trend was calculated. Convective volume for the HD group was set to 
zero, assuming differences in net ultrafiltration between study arms did not differ.
Third, the association between change in FGF23 concentrations over 6 months and 
all-cause mortality was analysed. An interaction term was used to evaluate if the 6 months 
change in FGF23 differed between HD and HDF in a Cox regression model. Since no 
interaction was found we continued with the pooled cohort. Patients were categorized 
into tertiles with either declining, relatively stable or increasing FGF23 concentrations as 
determined by the absolute difference between FGF23 concentration from baseline to 
Month 6. Stable FGF23 concentrations were set as the reference and defined by the mid-
tertile range. Both crude and adjusted models were fitted with identical confounders as 
described above. In addition, baseline FGF23 was added in a model. Lastly, treatment 
modality was added to the model in a final Cox regression model. 
Hazard ratios (HRs) are reported with a 95% confidence interval (CI). All p-values are 
two-sided and considered statistically significant <0.05.
Sensitivity analysis
In a sensitivity analysis, crude and adjusted Cox regression models were fitted for baseline 
FGF23 quartiles using an ‘on treatment’ approach 
In addition, a Cox regression model with time-varying covariate analysis was performed 
at baseline and at 12 months, with the quartiles of baseline FGF23 concentrations. 
RESULTS
Baseline characteristics
Baseline characteristics for the entire CONTRAST cohort and the subgroup of 404 patients 
with FGF23 measurements are shown in Table 1. In the FGF23 cohort, mean age was 
63.5 ± 13.9 years, 38.1% were female and 43.1% had a history of CVD. No calcimimetics 
were used. Median FGF23 was 4384 (IQR 1829 to 12 210) RU/mL. No remarkable 
differences were observed between patients randomized to HD of HDF at baseline, 
including baseline FGF23 (p for difference 0.54). 
Baseline FGF23 and risk for all-cause mortality
Median follow-up of 404 patients in the FGF23 cohort was 3.0 (IQR 1.5 to 4.4) years. 
In total, 156 patients died during follow-up. The results of the survival analyses are 
shown in Table 2. The HR for all-cause mortality did not differ between quartiles of 





























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































(on-treatment analysis and time-varying covariate analysis) yielded similar results 
(supplementary Table S1 and S2). 
FGF23 over time: impact of HDF 
The rate of change of FGF23 was statistically significant different between HD and HDF (p 
for interaction <0.001). In patients on HDF, FGF23 decline was 432 RU/mL/month ([95% 
CI -663 to -201], p < 0.001), while FGF23 concentrations in patients on HD did not change 
(103 [95% CI -83 to 290] RU/mL/month, p= 0.276). Additional analysis on convection 
volume showed a positive relation between the decline in FGF23 and convection volume 
(p for trend 0.02, as shown in supplementary Figure S1). 
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Cox Regression, intention to treat analysis. Results are shown as hazard ratios (HRs) with 95% confidence 
intervals. All models are adjusted for transplantation by adding transplantation as a time-varying covariate.
a Model 1 = Adjusted for age 
b Model 2 = Model 1 plus adjustment for sex, diabetes,  history of cardiovascular disease, dialysis vintage, 
residual kidney function and phosphate
Table 3. Hazard ratios for all-cause mortality of tertiles of FGF23 change during 6 months. 
Tertiles Stable FGF23 Decreasing FGF23 Increasing FGF23
n=115 n=114 n=114
Median change of FGF23# -275 (-825 to 33) -4972 (-14418 to -2582) 3339 (1226 to 7310)
ref HR 95% CI HR 95% CI
Crude ref 0.96 0.61 to 1.50 1.56 1.03 to 2.35*
Model 1a ref 1.26 0.79 to 2.01 2.01 1.32 to 3.07*
Model 2b ref 1.25 0.78 to 2.02 2.01 1.32 to 3.07*
Model 3c ref 1.25 0.78 to 2.02 2.00 1.30 to 3.09* 
Results are shown as hazard ratios (HRs) with 95% confidence intervals. All models are adjusted for 
transplantation by adding transplantation as a time-varying covariate.
# Depicted are median change of FGF23 concentrations (RU/ml) in 6 months with Interquartile range (IQR)
a Model 1 = Adjusted for age, sex, diabetes, history of cardiovascular disease, dialysis vintage, residual 
kidney function and phosphate 
b Model 2 = Model 1 plus adjustment for baseline FGF23 concentration.
c Model 3 = Model 2 plus adjustment for dialysis modality
* Indicates a statistically significant difference in hazard at the level of p≤0.05. 




























Figure 1. Course of FGF23 over time divided to patients on HD and on HDF. Course of FGF23 
concentrations over time in patients on hemodialysis and hemodiafiltration. FGF23 concentrations 
are depicted as medians and corresponding 95% confidence interval at baseline, 6 months 
and 12 months.
Change in FGF23 concentrations and risk of all-cause mortality 
The 341 patients of whom measurements of both baseline and Month 6 were available, 
were divided into tertiles of change in FGF23. Table 3 demonstrates HRs for all-cause 
mortality for the tertiles of FGF23 change. Figure 2 shows the survival curve of tertiles 
FGF23 change in 6 months’ time. Decreasing FGF23 was not associated with all-cause 
mortality (HR 0.96 [95% CI 0.61 to 1.50]) whereas increasing FGF23 was associated 
with an increased mortality risk (HR 1.56 [95% CI 1.03 to 2.35] p-value 0.03). Adjusted 
analyses yielded similar results (HR 2.01 [95% CI 1.32 to 3.07], p-value 0.001).
HDF induced reduction of FGF23 and its association with all-cause 
mortality
Adding dialysis modality to the model (Table 3, Model 3), to explore the potential 
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Figure 2. Survival curve of tertiles FGF23 change in 6 months’ time. Kaplan Meier: log rank p 0.015 
(indicates a difference between three groups)
(HR 2.01 [95% CI 1.30 to 3.09] p-value 0.002). Furthermore, no significant interaction 
was found between treatment modality and FGF23 change (p-value 0.11), indicating that 
the relation between FGF23 decrease or increase is not different between HD or HDF. 
DISCUSSION
In this study we found no association between baseline FGF23 concentration and all-cause 
mortality among prevalent dialysis patients. Next, we confirmed that HDF is capable to 
substantially reduce plasma FGF23 concentrations. Most remarkable, we found that 
only increasing FGF23 concentrations over 6 months were associated with an increased 
all-cause mortality risk, while decreasing FGF23 concentrations did not associate with 
mortality, both compared with rather stable FGF23 concentrations. Treatment modality 
did not modify these risks. 
The absence of an association between a single FGF23 measurement and mortality 
risk is in contrast with some previous findings, which showed that FGF23 in patients on 
HD was independently associated with all-cause mortality.18,30 However, those studies 
were performed among incident HD patients or patients initiating dialysis, compared 
with the prevalent HD patients in our study.  In turn, the results of a recent analysis of 
the large Japanese DOPPS cohort were in line with our findings. This study found no 
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association between FGF23 and all-cause mortality in the adjusted model of patients 
with a dialysis vintage of >3,5 years).31 In our study, median dialysis vintage was 1.8 
(IQR 0.9 to 3.3) years. In addition, two other studies in prevalent HD patients found no 
association of baseline FGF23 with all-cause mortality as well.32,33 Moreover, this absence 
of an association between FGF23 and all-cause mortality was recently confirmed in 
patients treated by either HD or peritoneal dialysis.34 Collectively, these data, together 
with our current analysis, suggest that the association between a single value of FGF23 
and long-term outcome may disappear with dialysis duration. These observations may be 
explained by survival bias; those patients surviving on dialysis may be less susceptible for 
detrimental effects of FGF23 (assuming direct causality) or the processes causing FGF23 to 
rise. However, two other studies in prevalent HD patients did demonstrate an association 
between FGF23 and all-cause mortality.19,35 In the study by Nowak, among 239 patients, 
the average dialysis vintage was 59 months while the mean FGF23 concentration was 
883 RU/ml,35 which is exceptionally low, thereby possibly limiting the external validity 
of that finding. In comparison, in our current study median baseline FGF23 was 4384 
RU/mL. In the study by Jean, a relatively small single center study, phosphate control 
was exceptionally good (in part due to 5 to 8-hour dialysis sessions).19 These findings 
complicate the interpretation of the divergent effects of FGF23. 
In general, FGF23 declined in patients treated with HDF while FGF23 in most patients 
on HD remained stable. Although this difference between HD and HDF was not adjusted 
for change in the use of phosphate binders, it was previously demonstrated in this cohort 
that patients on HDF used slightly less phosphate binders. Thus, if any, the absence of 
data on phosphate binders in the present analysis induces a bias towards the zero.36 
FGF23 reduction in HDF is most likely explained by its middle-molecule size (32 kDa), 
which therefore can be cleared by HDF and not by low-flux HD.37 Previous studies showed 
a reduction ratio of serum FGF23 within a single HDF session of around 50% (± 25%), 
with FGF23 present in dialysate samples.23-25 Our study is the first study to show that 
FGF23 in patients on HDF decline over time and that this reduction increases with 
higher convection volume. 
The primary finding from our study was the association of increasing FGF23 
concentration in 6 months with all-cause mortality as compared with stable FGF23, while 
a decline and stable FGF23 did not differ in terms of mortality risk. These findings were 
unaltered after adjustment for all relevant confounders. The increased mortality risk of 
increasing FGF23, is in line with a recent report from the CRIC cohort, a large population 
of nearly 4000 patients with CKD stage 2 to 4,20 and extends these findings to patients 
with CKD 5D.
In turn, we did not find that a decline of FGF23 was associated with improved survival. 
This finding seems to contradict a post hoc analysis of the EVOLVE trial. Here, a > 30% 
reduction of FGF23 in 20 weeks among participants allocated to cinacalcet was associated 
with a reduced risk on the composite outcome of cardiovascular mortality, sudden cardiac 
death and heart failure.38 However, in the placebo-treated group there were also (yet 
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fewer) patients with >30% FGF23 reduction in whom no association with cardiovascular 
events was found. This suggests that not the decline of FGF23 itself, but the way it 
was achieved, determined the incidence of the composite endpoint. In addition, another 
study examining trajectories of FGF23 in HD patients found no benefit for patients with 
decreasing levels compared with the group with high stable levels of FGF23.21
Since our study showed that FGF23 concentrations can be lowered with HDF, while 
increasing FGF23 concentrations associated with increased mortality, it is tempting to 
speculate that HDF may prevent this from happening. However, a decline of FGF23 did 
not confer improved mortality risk as outlined above, and addition of dialysis modality 
to the model did not alter the elevated mortality risk associated with increasing FGF23 
concentrations. In addition, change of FGF23 in relation to all-cause mortality was not 
different between HD and HDF. The latter finding suggests that the effect of FGF23-
change on mortality is not affected by dialysis modality. This finding resembles previous 
observations of beta-2-microglobulin during HDF, a protein of comparable molecular 
weight to FGF23 and of resembling kinetics . Despite its association with cardiovascular 
outcome, the superior reduction of beta-2-microglobulin by HDF as compared with 
low-flux HD, did also not associate with a survival benefit.39,40
So despite the substantial variability of FGF23 in our study, a dose-response association 
between change in FGF23 and mortality was absent. Only patients with an increase of 
FGF23 were at risk, suggesting that FGF23 is more likely merely a tell-tale of a high-risk 
phenotype instead of a direct uremic toxin, which is in line with the conclusion of 
a recent meta-analysis of studies that addressed the association of FGF23 and mortality 
and other endpoints.41 
The present study has several limitations: our analysis of FGF23 change in 6 months 
was necessarily limited to patients who had survived these six additional months. We 
evaluated the course of FGF23 concentrations in 6 months because we anticipated 
the largest effect of dialysis modality on FGF23 levels in this short time window, with 
limited additional diverging effects after this time point. However, a longer time window 
might have induced an even more substantial decline of FGF23. In addition, the high 
FGF23 concentrations in our study may simply be too high to induce a beneficial 
treatment effect on mortality, even with moderate lowering. A possible beneficial effect 
of lowering of FGF23 might also be masked by exposure to stronger competing risks. 
This would explain the discrepancy with the study by Isakova in CKD Stages 2-4, in which 
the median FGF23 was much lower when compared with our study. Another limitation is 
that this study was performed in countries with a mainly Caucasian population that may 
reduce the applicability of our conclusions to other populations. However, no important 
interaction between FGF23 and race has been demonstrated in previous studies. Lastly, 
since this is a post hoc analysis, we cannot rule out the possibility that titrating treatments 
on change in FGF23 concentration may yield different results, and residual confounding 
cannot be excluded.
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An important strength of the present study is the use of serial measurements for 
FGF23 in the survival analyses. In addition, we performed separate sampling handling 
for the higher FGF23 concentrations, since ELISA loses precision in the extreme values. 
Furthermore, we performed several sensitivity analyses to increase the validity of our 
findings and competing risk by renal transplantation was taken into account by a time-
varying analysis. Another merit of the study is the strongly diverging FGF23 concentrations 
in this population. HDF has shown to be an efficacious manner to lower FGF23 in patients 
on dialysis, which created the unique opportunity to study the impact of a substantial 
decline of FGF23 on outcome. Furthermore, this study was performed in a well-defined 
cohort of patients on HD(F), in which the data were collected meticulously and follow-up 
for mortality was complete.
In conclusion, in prevalent dialysis-dependent patients, baseline FGF23 value is not 
associated with all-cause mortality, suggesting that the association between FGF23 and 
long-term outcome may disappear with dialysis duration. Furthermore, decreasing FGF23 
concentrations over time are not associated with a lower mortality risk. This observation 
argues against a benefit of interventions that lower FGF23 in prevalent patients on HD. 
Finally, since increasing FGF23 does associate with increased risk for all-cause mortality, 
serial FGF23 measurements could identify dialysis-dependent patients at highest risk.
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Supplementary Table 1. Hazard Ratios  of  quartiles of FGF23 for mortality. Sensitivity analysis with 
Cox regression on-treatment analysis. 
Crude Model 1a Model 2b
All-cause mortality
Quartile 2 versus Quartile 1 
Quartile 3 versus Quartile 1 










Results are shown as hazard ratios (HRs) with 95% confidence intervals. HRs are calculated with Cox 
models with censoring of patients at the time of discontinuation of randomized treatment (i.e. due to 
switch to PD, renal transplantation, etc.)
a Model 1 = Adjusted for age 
b Model 2 = Model 1 plus adjustment for sex, diabetes, history of cardiovascular disease, dialysis vintage, 
residual kidney function and phosphate
Supplementary Table 2. Hazard Ratios of  quartiles of FGF23 for all-cause mortality. Sensitivity 
analysis with time varying analysis. 
Crude Model 1a Model 2b
Lowest quartile FGF23= reference 
2e quartile of FGF23 
3e quartile of FGF23 














Time varying analysis; events occurred one year after baseline line where associated with baseline FGF23 
concentrations. Events occurring after year one where associated with FGF23 concentrations measured 
at 1 year. Events after two years of follow-up where discarded (to keep the period at risk the same for 
the two time points of FGF23 measurement, limiting the maximum follow-up time to 2 years in this 
analysis).  Results are shown as hazard ratios (HRs) with 95% confidence intervals. 
a Model 1 = Adjusted for age 
b Model 2 = Model 1 plus adjustment for sex, diabetes,  history of cardiovascular disease, dialysis vintage, 
residual kidney function and phosphate












Supplementary Figure 1. Change from baseline of FGF23 over 6months’ time in patients on HDF 
for each tertile of convection volume. Change of FGF23 concentrations from baseline to month 6 
in four groups of HD and the tertiles of convection volume. Change is depicted percentage change 
from baseline. From the first to the third tertile of convection volume a decline of respectively 12.6% 
(IQR -50.5 to 29.5%), 32.3% (IQR -59.4 to 7.3%) and 40.8% (IQR -57.2 to 54.1%) was observed 
respectively, while in patients treated with HD no change was observed (p for trend 0.02).
1: Course of FGF23 divided by HD versus tertiles of convection volume of HDF
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Patients with chronic kidney disease (CKD) have a strongly enhanced risk for cardiovascular 
morbidity and mortality.1 Over the past decades it has become clear that besides 
traditional risk factors, such as hypertension, dyslipidemia and  diabetes, disturbances in 
calcium-phosphate metabolism are at least partially accountable for this additional risk.2 
Especially Fibroblast Growth Factor 23 (FGF23) appears to a play role in the development 
of cardiovascular disease (CVD). Numerous observational studies showed an independent 
association between FGF23 levels  and mortality in healthy persons as well as in patients 
with CKD.3-8 Furthermore FGF23 is associated with left ventricular hypertrophy,9-11 
cardiovascular events,12-14 progression of kidney failure6,15-17 and with several cardiovascular 
risk factors such as endothelial dysfunction and arterial stiffness.18-21  These associations 
are observed in the general population and throughout all stages of CKD. Until today 
the mechanisms whereby FGF23 may induce complications is not fully elucidated. 
Studies performed in the general population, lacking the metabolic derangements which 
are typical for CKD, show an unaltered  association of FGF23 with adverse outcome, 
suggesting a specific effect of FGF23.3,4,19,22 Importantly, FGF23-associated risk for adverse 
outcome has shown to be independent of phosphate and the other components of 
CKD-MBD.7 Furthermore, the magnitude of the risk associated with elevated FGF23 levels 
is higher than associated risks of the other biomarkers of the Chronic Kidney Disease 
Mineral and Bone Disease (CKD-MBD) axis.7 From this observation the hypothesis arises 
that FGF23 might be, independent of its role as a phosphate regulator, in the causal 
pathway to the development of CVD. This hypothesis is supported by experimental 
studies, demonstrating FGF23 involvement in several pathophysiological processes  seen 
in CKD, unrelated to the classical role of FGF23 physiology  in phosphate homeostasis. 
This thesis focused on the question whether it is beneficial to modify FGF23 levels, 
in order to improve patient outcome. If lowering of FGF23 leads to a reduced risk for 
adverse outcome, then interventions should aim at lowering FGF23 as short-term goal of 
treatment, with long-term goals obviously being patient-level outcomes. 
In chapter 1 an introduction to the thesis is given. The chapter provides a broader 
perspective on the possible clinical usefulness of FGF23 in the near future. Several aspects 
concerning the clinical use of FGF23 measurement are discussed. If FGF23 measurement 
is going to be used in clinical practice, then it is required that this biomarker can be 
measured accurately and reproducibly. Therefore, this chapter discusses the reliability 
of currently available FGF23 assays. Furthermore, an overview is provided of studies 
examining FGF23 as a tool for improving patient risk classification. Most importantly, 
this chapter discusses on the main question of this thesis, namely whether lowering 
FGF23 might be beneficial. For this, the current evidence indicating that FGF23 may or 
may not be in the causal pathway to cardiovascular pathology is discussed, including 
epidemiological studies as well as mechanistic studies. In this discussion the results from 
this thesis were integrated. Lastly, chapter 1 describes different strategies to lower FGF23. 
Up to date there are no prospective intervention studies in humans aiming to reduce 
FGF23 concentrations and testing whether cardiovascular morbidity and mortality is 
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improved by this approach. The rationale of such a study however is challenged by  studies 
in CKD animal models using FGF23 antibodies. These studies demonstrated that this 
strategy may even be detrimental because these animals developed hyperphosphatemia, 
soft tissue calcification leading to increased mortality, underlining the relevance of 
the physiological role of FGF23 to avoid serum phosphate levels to rise. Ahead developing 
long and costly clinical trials aiming to lower FGF23 we studied in chapter 2.1 the natural 
course of FGF23 levels on clinical outcome. We explored to what extend the spontaneous 
change of FGF23 levels over time outperforms a single measurements as indicator of future 
cardiovascular events and mortality. For this the average of two FGF23 measurements 
in two years’ time, reflecting exposure to FGF23 during the 2 years, was compared to 
a single measurement. Likewise, the rate of change of FGF23 (in absolute values and 
in percentages) as a potential marker for progressive disease was evaluated. However, 
we did not found that multiple FGF23 measurements are more strongly associated with 
outcome than a single measurement. This may be explained in part by the fact that on 
average only a marginal change of FGF23 was observed in two years’ time in this cohort 
of CKD stage 3 and 4. We concluded that a greater amplitude of change, achieved 
by specifically targeting FGF23 and or a longer follow up in this stage of CKD would 
be necessary to prove or disprove this concept. This study however did confirm earlier 
studies by demonstrating that a single FGF23 measurement is an important risk factor 
for cardiovascular disease, as FGF23 was significantly associated with a composite of 
cardiovascular events, all-cause mortality and the initiation of renal replacement.  
In chapter 2.2 a meta-analysis of FGF23 and several clinical events is described. This 
study compared the associations of FGF23 with different outcomes and in the different 
populations, from the general population to non-dialysis CKD, and  to dialysis populations. 
For myocardial infarction, stroke and heart failure, there were consistently higher risks among 
participants in the top versus bottom tertile of the FGF23 distributions. However, neither 
the strengths of these associations nor the effect size differed across these populations, 
despite the wide range of severity of renal insufficiency and the absolute differences in 
FGF23 across these populations. Furthermore, associations were of the same magnitude 
for cardiovascular mortality and non-cardiovascular mortality indicating non-specificity of 
the association. The absence of an exposure-response relationship of FGF23 with outcome 
and the similarity of associations for both cardiovascular outcomes and all-cause mortality 
argue against a cause and effect relation of elevated FGF23 concentrations and outcome, 
implying that targeting FGF23 alone may not reduce these risks.
However, clear absence of an exposure –response relation may be due to a nonlinear 
association of FGF23 with outcome or because in higher FGF23 ranges the association 
between FGF23 and adverse outcome is lost. Another possibility is that very high FGF23 
concentrations, as occurs during progression of CKD towards ESRD, merely reflect a state 
of resistance to FGF23. FGF23 resistance can be defined as a state in which the kidney 
and the parathyroid glands, the primary sites of FGF23 action, do not respond optimally 
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to FGF23, reflected by mitigated ability to excrete phosphate and suppression of PTH, 
which drives FGF23 to increase. In chapter 3 we investigated if the association of FGF23 
with risk might be partially the result of this FGF23 resistance instead of FGF23 perse. 
FGF23 induces higher fractional excretion of phosphate and therefore resistance to 
FGF23 can be defined as the ratio of FGF23 levels over fractional phosphate excretion 
(FePi). In this study of a cohort of patients with CKD stage 3-4, FGF23 was indeed 
independently associated with increased risk for the composite endpoint (consisting of 
death, cardiovascular events, renal replacement therapy or doubling of serum creatinine). 
However, the association of FGF23 with outcome did not change after adjustment for 
FePi and no interaction between FGF23 and FePi was found, suggesting that resistance 
itself does not contribute to the adverse outcome related to elevated FGF23 levels. 
As observational studies can only hint at a cause-effect relation between FGF23 and 
outcome, studies that specifically target FGF23 and evaluate the effect of this intervention 
on outcome are needed. Therefore, we performed a prospective clinical intervention 
study as described in chapter 4. This study investigated an intervention assumed to 
lower FGF23 and its effect on pulse wave velocity (PWV). PWV, a well-established marker 
for arterial stiffness, was chosen as a surrogate endpoint for CVD since arterial stiffness 
is strongly associated with cardiovascular events and all-cause mortality, and might be 
in the causal path. Previous studies have observed that sevelamer, an oral phosphate 
binder, can lower FGF23, and its use is associated with a decline in pulse wave velocity 
(PWV). However, it is not known if this effect on PWV is mediated by a reduction in FGF23 
concentrations. The hypothesis of this study therefore was that a sevelamer–induced 
reduction of FGF23 would lead to improved vascular function as assessed by PWV. 
Unexpectedly however, in this study no significant improvement of PWV after 
treatment with sevelamer was found. Interestingly, in a subgroup of patients with no 
or limited vascular calcification at baseline, the use of sevelamer actually was associated 
with a decline in PWV. Notably, no significant reduction of FGF23 was found, despite 
an effective reduction of phosphate absorption due to the use of sevelamer. A finding 
also present in the subgroup of patients with low baseline calcification, suggesting that 
the effect of sevelamer on PWV was not mediated by FGF23. 
Although the effect of changing FGF23 on clinically relevant outcome parameters 
can be analyzed to some extent from the spontaneous change over time of FGF23 in 
observational studies, several reports (amongst one in this thesis) described that FGF23 
concentrations in patients with CKD remain quite stable over time. To prove if actively 
lowering FGF23 leads to improved patient outcomes, a strategy to substantially lower 
FGF23 is needed, ideally in trials designed with that goal, but these trials have not 
been performed yet. In chapter 5 the effect of lowering FGF23 by hemodiafiltration 
(HDF) on outcome was studied, as a posthoc analysis comparing low flux HD with HDF 
(The CONTRAST trial). Previous studies have shown that convective transport, the modus 
operandi in HDF, can effectively lower FGF23. In turn, FGF23 cannot be cleared by 
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low-flux hemodialysis due to its middle-molecule size. In this study very high levels of 
FGF23 were observed and over time strongly diverging FGF23 concentrations were seen 
due to the difference in dialysis modality. In particular a strong decline of FGF23 over  6 
up to 12 months’ time was observed among those allocated to HDF, as was expected. 
However, this reduction of FGF23 in 6 months’ time was not accompanied by a decreased 
risk for all-cause mortality. On the other way, increasing FGF23 concentrations were 
associated with an increased risk for all-cause mortality. Treatment modality (HD or HDF) 
did not modify this risk. This study therefore argues against the rationale to actively lower 
FGF23 in patients on hemodialysis of hemodiafiltration, in order to improve all-cause 
mortality risk. Only patients with increasing FGF23 were at higher risk, suggesting that 
increasing FGF23 merely identifies patients with a certain phenotype with a higher-risk 
for mortality. Interestingly, this study found no association between baseline FGF23 value 
and all-cause mortality, suggesting that the association between FGF23 and all-cause 
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Although several studies showed an association  of FGF23 with cardiovascular morbidity 
and  cardiovascular and all-cause mortality, it is up to today still uncertain if FGF23 plays 
a causal role in the development of cardiovascular disease. However, increasing FGF23 
during the progression of CKD precedes the sequence of pathological changes leading 
to cardiovascular morbidity, indicating temporal plausibility.1 Besides, some mechanistic 
studies point to FGF23 being a direct inductor of the development of left ventricular 
hypertrophy (LVH) and other unfavorable conditions such as  inflammation, activated 
renin-angiotensin-aldosterone system (RAAS), lowered αKlotho levels and anemia.2-9 
The association of FGF23 with cardiovascular events and mortality
In the population with CKD stage 3-4, described in two studies of this thesis, we found 
an association between FGF23 and cardiovascular disease and mortality. In the study 
presented in chapter 2.1 FGF23 was associated with an increased hazard for all-cause 
mortality, initiation of renal replacement and congestive heart failure. In the study 
presented in chapter 3 FGF23 was independently associated with the composite endpoint 
of death renal failure and cardiovascular events. Both studies were performed in a sub 
cohort of the Masterplan study. The finding of an association of FGF23 and outcome 
is consistent with other studies in CKD stage 3-4 in which a single value of FGF23 is 
associated with an increased risk for cardiovascular events, congestive heart failure, 
progression of kidney disease and mortality.10-15
However, we found no association between quartiles of baseline FGF23 and 
mortality in prevalent patients on hemodialysis (or hemodiafiltration) in the CONTRAST 
study. Although in contrast with some previous findings, mostly among incident HD 
patients,10,16 our results were in line with other studies performed in prevalent dialysis 
patients.17-19 Also in the meta-analysis presented in this thesis, the pooled analysis 
consisting of eight studies in hemodialysis patients, showed no significant risk  for  all-cause 
mortality and for cardiovascular mortality. It is at least remarkable that the association 
of FGF23 with outcome is more apparent or stronger in CKD patients not on dialysis 
compared to prevalent patients on dialysis, despite much lower absolute levels of FGF23 
in the former population .  Absence of such an exposure –response relation may be due 
to a nonlinear association of FGF23 for outcome, or because in ESRD the association is 
lost because of more competitive risks in this population. Another explanation might be 
survival bias; prevalent patient on the dialysis are the ones surviving, identifying patients 
less susceptible for detrimental effects of FGF23 (assuming direct causality) or other 
processes causing FGF23 to rise. One of these processes might be resistance to FGF23, 
leading to the very high levels observed in patients on dialysis. 
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FGF23 resistance and adverse outcomes
During progression of CKD there is a decline of the total of phosphate ultra-filtered 
by the glomeruli. In order to keep serum phosphate in balance the fractional excretion 
of phosphate (FePi) increases. This means that the tubular re-uptake of phosphate is 
reduced through down regulation of the Sodium-phosphate 2a and 2c co-transporters 
secondary to increased FGF23 concentrations.20-22 
FGF23 resistance can be defined as a state in which the kidney and the parathyroid 
glands, the primary sites of FGF23 action, do not respond optimally to FGF23 by excreting 
less phosphate and suppressing PTH less efficiently, which drives FGF23 to further increase. 
It has been suggested that high FGF23 is merely reflecting FGF23 resistance and that this 
condition, and not so much the elevated FGF23 level itself, is associated with adverse 
outcome. FGF23 resistance may occur in the setting of α-klotho deficiency since α-klotho 
is the co-factor required for binding of FGF23 to its main target receptor.23 
In this scenario increased FGF23 is combined with a relatively low FePi, reflecting 
impaired tubular responsiveness to FGF23 signaling. In chapter 3, we investigated in 
a group of patients with CKD stage 3-4 the modifying effect of FePi on the association 
between FGF23 and outcome. However, we found no association of FePi with outcome 
while FGF23 itself was an independent predictor of the composite endpoint (consisting of 
death, cardiovascular events, renal replacement therapy or doubling of serum creatinine). 
This study therefore shows that the increased FGF23 concentration itself drive its 
association with adverse outcome, but not FGF23 resistance. 
Nevertheless, it is conceivable that FGF23 resistance may occur (partly) independently 
of glomerular function, as was suggested by Vervloet et al,24 for instance through 
the toxicity of proteinuria on the tubuli.25,26 A process  likely accelerated through α-Klotho 
deficiency, as decreasing Klotho expression is a process already starting in early CKD. These 
diminishing klotho levels are due to loss of renal tissue and through active downregulation 
of klotho secondary to inflammation and increased oxidative stress in uraemia.6,27,28 
Further contributing to this resistance are the increased concentrations of the C-terminal 
FGF23 fragments, due to reduced renal clearance, as there is evidence that the C-terminal 
FGF23 fragments competitively bind to the FGFR-klotho receptor, further impairing FGF23 
signaling.29  In our study in patients with ESRD on dialysis from the Contrast cohort, we 
found, despite substantial diverging FGF23 concentrations as a consequence of dialysis 
modality, no dose-response association between change in FGF23 and mortality. One 
of the possible explanations for this might be that the extremely high levels of FGF23 
observed reflect a state of  FGF23 resistance. In this situation the association of FGF23 
with outcome becomes lost, again proving that the state of FGF23 resistance does not 
determine the positive association between FGF23 and mortality.
FGF23 possibly just a confounding factor?
Another hypothesis is that FGF23 might be a confounder for other pathological processes, 
instead of a direct uremic toxin. Several metabolic changes seen in CKD may play a part 
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in the development of cardiovascular morbidity and mortality associated with increased 
FGF23. In healthy individuals and in patients with CKD,  higher serum phosphate is 
associated with vascular calcification and with mortality.30-32 In addition, experimental 
models show that in FGF23 knockout mice high levels of phosphate and active Vitamin 
D lead to arterial medial calcification, observations also found in klotho deficiency.33,34 An 
argument for an more important role of phosphate over FGF23 in advanced CKD (when 
both FGF23 and serum phosphate are elevated), is that in hypophosphataemic rickets and 
also in tumor induced osteomalacia, conditions characterized by primary elevated FGF23, 
no cardiovascular phenotype is observed.35 On the other hand, in healthy individuals and 
in early CKD, FGF23 is not accompanied with a higher serum phosphate, yet in these 
populations this elevated FGF23 is associated with adverse outcome.36-38 Besides, most 
studies investigating the association between FGF23 and adverse outcome, including 
the ones in this thesis, adjusted for serum phosphate, making it unlikely that FGF23 is 
confounded by serum phosphate concentration.10 
In addition, the pilot study in this thesis shows that FGF23 and phosphate are, although 
closely connected in physiology, not interchangeable in the relation to cardiovascular 
outcome and mortality. While serum phosphate is strongly associated with vascular 
calcification leading to vascular stiffness, we found in chapter 4 no association between 
FGF23 and vascular stiffness (measured by PWV), suggesting elevated FGF23 is not 
just a proxy for phosphate toxicity leading to vascular calcification. Still, as both serum 
phosphate and FGF23 are associated with cardiovascular outcome, the combination of 
both factors might not only sum up but may even have a synergistic toxic effect on 
the cardiovascular system.
 Besides  FGF23 being a possible confounder for high serum phosphate, increased 
phosphate intake, or klotho deficiency (discussed in the previous paragraph), it is also 
possible that FGF23 reflects tissue malperfusion, including bone, the tissue from which 
FGF23 originates. In the latter situation, not necessarily accompanied with CKD, elevated 
FGF23 concentrations are observed as was shown in several studies in which increased 
FGF23 levels identified patients with compromised organ perfusion.39-41 In these studies 
increased FGF23 was observed before kidney damage (due to diminished oxygenation) 
became manifest. The other way around, in CKD often situations with hemodynamic 
instability occur (for example during cardiovascular events, complicated hemodialysis or 
during infectious complications) leading to tissue malperfusion. It is therefore conceivable 
that severely elevated FGF23 concentrations, as occurring in ESRD,  might also reflect 
a situation of impaired organ perfusion and that high FGF23 is a confounder of this 
condition associated with an increased risk for morbidity and mortality. Further discussion 
on this hypothesis lies beyond the scope of this thesis as this situation was not accounted 
for in our studies. Finally, there may be even more confounding factors which are unknown.
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Causality between increased FGF23 and adverse outcome
Several studies proposed mechanisms by which FGF23 itself may play a causal role in 
the development of cardiovascular disease and mortality. One mechanism might be 
through its effect on arterial stiffness. Increased vascular stiffness can be caused by 
(accelerated) vascular calcification and endothelial dysfunction and, regardless of its 
cause, increased PWV. The review in chapter 1.2 provides an overview of the studies 
investigating the role of FGF23 in the development of arterial stiffness. These studies 
suggest FGF23 might induce arterial stiffness, most likely through endothelial dysfunction 
and not likely through increased calcification. 
The suggested mechanisms provide a rationale for FGF23 targeted therapy. In the pilot 
study presented in chapter 4 we investigated the effect of lowering FGF23 by the use of 
Sevelamer Carbonate (an oral phosphate binder) on arterial stiffness measured by pulse 
wave velocity, a well-established surrogate end-point for CVD.42,43 We found however 
overall no improvement of vascular stiffness in this study among patients with CKD stage 
3 during treatment with Sevelamer Carbonate. Interestingly, in the subgroup of patients 
with no or limited existing vascular calcification an reduction of PWV was found during 
the use of Sevelamer Carbonate, however this was not mediated by a decrease in FGF23. 
The absence of effect of FGF23 can be simply explained by the fact that the absolute 
change of FGF23 during treatment was minimal. Although several studies have shown 
that FGF23 can be effectively lowered by non-calcium-containing phosphate binders, we 
found no reduction of FGF23 by the use of sevelamer. One explanation is that we measured 
c-terminal FGF23 instead of intact FGF23. From  the overview of studies investigating 
the use of phosphate binders in order to decrease FGF23 concentrations, presented in 
chapter 1.2 it has become clear that non-calcium containing phosphate binders are able 
to lower intact FGF23 concentrations,  however this reduction is not seen when c-terminal 
FGF23 is measured. Another limitation of this pilot study is the small number of patients 
and its relatively short duration (the study was performed as proof of principle study). It is 
not certain if a reduction of FGF23 would have been observed when intact FGF23 would 
have been measured and if the study was performed in a larger cohort and for a longer 
period of time, and if so what the effect would have been on PWV. 
Another possible mechanism by which FGF23 might be linked with adverse outcome 
is the induction of LVH.2,3,44 In chapter 2, in which the value of serial measurements of 
FGF23 in CKD stage 3-4 was investigated, we found that exposure to FGF23 in two 
years’ time (presented by the average FGF23 level over two years’ time) was a better 
predictor for congestive heart failure than a single time point, indicating that prolonged 
exposition to high FGF23 might increase the risk of developing congestive heart failure 
(CHF), a clinical condition that can result from LVH. 
Besides investigating intermediate cardiovascular outcomes which may be in 
the pathophysiological route of FGF23’s effect on clinical outcome, we sought further 
arguments from epidemiological data if FGF23 should be a target for treatment. For 
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this we investigated if FGF23 concentrations over time would influence clinical outcome. 
The exposure to FGF23 levels in the two years’ time period (represented by the average 
FGF23) and the rate of change of FGF23, a potential marker for progressive disease was 
evaluated in a cohort of CKD patients in relation to clinical outcome. We found that 
the predictive value for the average FGF23 over 2 years’ time on subsequent clinical 
events (composite endpoint and all-cause mortality after this two year period) was not 
higher compared to a single time point measurement of FGF23. Because this study 
showed that change of FGF23 over time is not a better predictor for cardiovascular risk, 
this study found no additional arguments in favor of targeting FGF23. However this 
conclusion is hampered by the low variability of FGF23 levels over time within subjects 
found in the population of this study. To demonstrate that changing levels of FGF23 in 
the natural course of disease modify outcome, longer follow-up, a larger sample size 
and more events would have been required. Indeed, in a more recent analysis of a large 
population of patients with a comparable stage of CKD with also in general very stable 
FGF23 levels, increasing levels of FGF23 over time increased the risk for cardiovascular 
outcome.45 Still, observing the natural course of FGF23 levels over time will not likely 
show the effect of decreasing FGF23 levels, as in general CKD progresses over time. 
Therefore, trials specifically targeting FGF23 levels is needed to provide a definite answer.
In chapter 5 we investigated if actively lowering of FGF23 improved patient outcome 
in a post-hoc analysis. This study, performed in patients with end stage renal disease on 
dialysis (CKD stage 5 D), a decline of FGF23 was anticipated in patients allocated to HDF 
because previous studies have shown that FGF23 with its 32 kDA middle molecular size 
can be effectively cleared by HDF and not by low-flux HD.46-48 Indeed in patients allocated 
to HDF, a greater reduction of FGF23 was observed compared to patients on HD, increasing 
with increasing convection volume. Furthermore over-all very high and over time strongly 
diverging FGF23 levels were observed. However, we found no improvement in outcome 
in patients with a decline of FGF23 over time compared to patients with stable FGF23 
concentrations. In contrast, increasing FGF23 was associated with a higher mortality risk. 
The latter finding is in line with a previous study in patients with CKD stage 2-4 in which 
increasing FGF23 identified patients with an increased risk for adverse outcome,45 and 
extends these findings to patients with CKD stage 5 D. As our study showed no dose-
response relation of FGF23 with all-cause mortality, it rejects targeting FGF23 to improve 
outcome. The study does however show that increasing FGF23 concentrations might be 
a good way to identify patients with an increased mortality risk.  The most important 
finding was however, that FGF23 reduction by applying HDF did not confer benefit, 
a conclusion drawn with caution, because it is based on a post-hoc analysis.
FUTURE PERSPECTIVES
Since this thesis found no compelling evidence for improved patient outcome if FGF23 
decreases (treatment targeted or during the natural course),  the question arises if 
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the concept of FGF23 as a potential target of therapy should be abandoned.  The studies 
in this thesis add to a vast amount of studies on FGF23 and clinical outcome and improved 
our understanding of CKD-MBD. However, there are still conflicting results concerning 
the association between FGF23 and outcome. Furthermore, the studies investigating 
FGF23 in the causal pathway leading to cardiovascular disease and mortality provide only 
circumstantial evidence in this direction. 
Therefore further research is needed, especially because a prospective study designed 
to lower FGF23 and investigating its effect on clinical endpoints is still lacking. This 
prospective clinical trial has obviously not been performed yet since these trials are costly 
and time-consuming. However, the availability of several interventions capable to lower 
FGF23 concentrations should set the stage to do so. The next question is therefore, how 
should this clinical trial be designed. Which strategy to lower FGF23 should be used 
(considering its shortcomings, see chapter 1.2) and what should be the best timing to 
target FGF23? 
For patients with end-stage CKD on dialysis, calcimimetics, non-calcium containing 
phosphate binders and HDF have shown to be effective modes to substantially lower 
FGF23.49-53 However, in this stage of CKD the risk of cardiovascular morbidity and mortality 
is very high implying that different kind of pathological changes have already taken place, 
or at least play a prominent role that may overwhelm effects of FGF23.54 Therefore it 
makes sense to target FGF23 in more early stages of CKD. However, in healthy and CKD 
stage II  elevated FGF23 concentrations are most likely adaptive and beneficial. Therefore 
it seems most appropriate to target FGF23 in stage III and IV, the stages in which both 
CKD and FGF23 becomes a stronger marker for cardiovascular disease and mortality.55 
Besides, in this stages there is more evidence for possible pathophysiological action of 
FGF23 such as inflammation, RAAS activation and the development of LVH and anemia. 
Both dietary phosphate restriction and non-calcium containing phosphate binders are 
capable to lower FGF23 concentrations in CKD stage III-IV.56-59 However it is challenging 
to persevere on a low-phosphate diet and only phosphate binders may be less effective.60 
Probably more effective are FGF23 antibodies and FGF23 receptor blockers, however 
their use leads to hyperphosphatemia promoting vascular calcification and increased 
mortality as was shown in experimental studies.61,62An option is therefore the use of 
FGF23 antibodies combined with non-calcium containing phosphate binders to prevent 
the development of hyperphosphatemia. Additional to this combined strategy klotho 
supplementation might be beneficial, since experimental studies showed that klotho 
overexpression or administration of recombinant-Klotho protein leads to enhanced 
Phosphaturia and prevents vascular calcification.63,64 Another possibility is the use of 
a more selective FGFR-4 blocker to block the klotho-independent actions of FGF23 to 
prevent the development of LVH, without affecting its phosphate lowering capacity.65 
Long-term exogenous supplementation of a selective FGFR-4 blocker or the klotho protein 
has not been performed neither in clinical nor in experimental setting. The proposed 
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strategies should first be tested on safety and on the ability  to effectively lower FGF23 
concentrations or effectively block specific FGF23 actions before applying in a prospective 
trial investigating its effect on clinical outcome. In addition to clinical studies, experimental 
studies are at the same time needed to unravel the different components of CKD-MBD to 
understand the role of FGF23 in the development of adverse outcome as clinical studies 
cannot test its causality to clinical outcome.
In conclusion, it currently is too preliminary to use FGF23 concentrations as target for 
therapy since there is no compelling evidence yet to demonstrate that FGF23 reduction 
leads to improved outcome. Furthermore, the role of FGF23 in the pathway to adverse 
outcome is still under debate. In turn, an important causal role for FGF23 cannot be 
excluded either. The results of this thesis confirm that elevated FGF23 concentration 
in CKD indicate an increased risk for cardiovascular disease and mortality and adds to 
the knowledge that may be used to make the next step in future research, which could be 
testing the impact of FGF23-targeted interventions for prolonged period in intermediate 




1. Isakova T, Wahl P, Vargas GS, et al. Fibroblast growth factor 23 is elevated before parathyroid 
hormone and phosphate in chronic kidney disease. Kidney Int 2011;79:1370-8.
2. Faul C, Amaral AP, Oskouei B, et al. FGF23 induces left ventricular hypertrophy. J Clin 
Invest 2011;121:4393-408.
3. Grabner A, Amaral AP, Schramm K, et al. Activation of Cardiac Fibroblast Growth Factor 
Receptor 4 Causes Left Ventricular Hypertrophy. Cell Metab 2015;22:1020-32.
4. Singh S, Grabner A, Yanucil C, et al. Fibroblast growth factor 23 directly targets hepatocytes to 
promote inflammation in chronic kidney disease. Kidney Int 2016;90:985-96.
5. de Borst MH, Vervloet MG, ter Wee PM, Navis G. Cross talk between the renin-angiotensin-aldosterone 
system and vitamin D-FGF-23-klotho in chronic kidney disease. J Am Soc Nephrol 2011;22:1603-9.
6. Koh N, Fujimori T, Nishiguchi S, et al. Severely reduced production of klotho in human chronic 
renal failure kidney. Biochem Biophys Res Commun 2001;280:1015-20.
7. Sun CY, Chang SC, Wu MS. Suppression of Klotho expression by protein-bound uremic toxins 
is associated with increased DNA methyltransferase expression and DNA hypermethylation. 
Kidney Int 2012;81:640-50.
8. Coe LM, Madathil SV, Casu C, Lanske B, Rivella S, Sitara D. FGF-23 is a negative regulator of 
prenatal and postnatal erythropoiesis. J Biol Chem 2014;289:9795-810.
9. Agoro R, Montagna A, Goetz R, et al. Inhibition of fibroblast growth factor 23 (FGF23) signaling 
rescues renal anemia. FASEB J 2018;32:3752-64.
10. Gutierrez OM, Mannstadt M, Isakova T, et al. Fibroblast growth factor 23 and mortality among 
patients undergoing hemodialysis. N Engl J Med 2008;359:584-92.
11. Isakova T, Xie H, Yang W, et al. Fibroblast growth factor 23 and risks of mortality and end-stage 
renal disease in patients with chronic kidney disease. JAMA 2011;305:2432-9.
12. Alderson HV, Ritchie JP, Middleton R, Larsson A, Larsson TE, Kalra PA. FGF-23 and 
Osteoprotegerin but not Fetuin-A are associated with death and enhance risk prediction in 
non-dialysis chronic kidney disease stages 3-5. Nephrology (Carlton) 2016;21:566-73.
13. Munoz Mendoza J, Isakova T, Cai X, et al. Inflammation and elevated levels of fibroblast growth 
factor 23 are independent risk factors for death in chronic kidney disease. Kidney Int 2017;91:711-9.
14. Levin A, Rigatto C, Barrett B, et al. Biomarkers of inflammation, fibrosis, cardiac stretch and 
injury predict death but not renal replacement therapy at 1 year in a Canadian chronic kidney 
disease cohort. Nephrol Dial Transplant 2014;29:1037-47.
15. Seiler S, Reichart B, Roth D, Seibert E, Fliser D, Heine GH. FGF-23 and future cardiovascular 
events in patients with chronic kidney disease before initiation of dialysis treatment. Nephrol 
Dial Transplant 2010;25:3983-9.
16. Scialla JJ, Parekh RS, Eustace JA, et al. Race, Mineral Homeostasis and Mortality in Patients with 
End-Stage Renal Disease on Dialysis. Am J Nephrol 2015;42:25-34.
17. Olauson H, Qureshi AR, Miyamoto T, et al. Relation between serum fibroblast growth 
factor-23 level and mortality in incident dialysis patients: are gender and cardiovascular disease 
confounding the relationship? Nephrol Dial Transplant 2010;25:3033-8.
18. Sugimoto H, Ogawa T, Iwabuchi Y, Otsuka K, Nitta K. Relationship between serum fibroblast growth 
factor-23 level and mortality in chronic hemodialysis patients. Int Urol Nephrol 2014;46:99-106.
19. Komaba H, Fuller D, Taniguchi M, et al. FGF23 and Mortality in a Large Cohort of Prevalent 
Hemodialysis Patients: Results from the J-DOPPS. .  ASN Kidney Week, Abstract 
20. Saito H, Kusano K, Kinosaki M, et al. Human fibroblast growth factor-23 mutants suppress Na+-
dependent phosphate co-transport activity and 1alpha,25-dihydroxyvitamin D3 production. J 
Biol Chem 2003;278:2206-11.
21. Baum M, Schiavi S, Dwarakanath V, Quigley R. Effect of fibroblast growth factor-23 on 
phosphate transport in proximal tubules. Kidney Int 2005;68:1148-53.
185
6
22. Gattineni J, Bates C, Twombley K, et al. FGF23 decreases renal NaPi-2a and NaPi-2c expression 
and induces hypophosphatemia in vivo predominantly via FGF receptor 1. Am J Physiol Renal 
Physiol 2009;297:F282-F91.
23. Kurosu H, Ogawa Y, Miyoshi M, et al. Regulation of fibroblast growth factor-23 signaling by 
klotho. J Biol Chem 2006;281:6120-3.
24. Vervloet MG. FGF23 measurement in chronic kidney disease: What is it really reflecting? Clin 
Chim Acta 2020;505:160-6.
25. Fernandez-Fernandez B, Izquierdo MC, Valino-Rivas L, et al. Albumin downregulates Klotho in 
tubular cells. Nephrol Dial Transplant 2018;33:1712-22.
26. de Seigneux S, Courbebaisse M, Rutkowski JM, et al. Proteinuria Increases Plasma Phosphate 
by Altering Its Tubular Handling. J Am Soc Nephrol 2015;26:1608-18.
27. Shimamura Y, Hamada K, Inoue K, et al. Serum levels of soluble secreted alpha-Klotho are 
decreased in the early stages of chronic kidney disease, making it a probable novel biomarker 
for early diagnosis. Clin Exp Nephrol 2012;16:722-9.
28. Sakan H, Nakatani K, Asai O, et al. Reduced renal alpha-Klotho expression in CKD patients and 
its effect on renal phosphate handling and vitamin D metabolism. PLoS One 2014;9:e86301.
29. Goetz R, Nakada Y, Hu MC, et al. Isolated C-terminal tail of FGF23 alleviates hypophosphatemia 
by inhibiting FGF23-FGFR-Klotho complex formation. Proc Natl Acad Sci U S A 2010;107:407-12.
30. Covic A, Kothawala P, Bernal M, Robbins S, Chalian A, Goldsmith D. Systematic review of 
the evidence underlying the association between mineral metabolism disturbances and risk 
of all-cause mortality, cardiovascular mortality and cardiovascular events in chronic kidney 
disease. Nephrol Dial Transplant 2009;24:1506-23.
31. Foley RN. Phosphate levels and cardiovascular disease in the general population. Clin J Am Soc 
Nephrol 2009;4:1136-9.
32. Dhingra R, Sullivan LM, Fox CS, et al. Relations of serum phosphorus and calcium levels to 
the incidence of cardiovascular disease in the community. Arch Intern Med 2007;167:879-85.
33. Hu MC, Shi M, Zhang J, et al. Klotho deficiency causes vascular calcification in chronic kidney 
disease. J Am Soc Nephrol 2011;22:124-36.
34. Shimada T, Kakitani M, Yamazaki Y, et al. Targeted ablation of Fgf23 demonstrates an essential 
physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest 2004;113:561-8.
35. Takashi Y, Kinoshita Y, Hori M, Ito N, Taguchi M, Fukumoto S. Patients with FGF23-related 
hypophosphatemic rickets/osteomalacia do not present with left ventricular hypertrophy. 
Endocr Res 2016:1-6.
36. Westerberg PA, Tivesten A, Karlsson MK, et al. Fibroblast growth factor 23, mineral metabolism 
and mortality among elderly men (Swedish MrOs). BMC Nephrol 2013;14:85.
37. Arnlov J, Carlsson AC, Sundstrom J, et al. Higher fibroblast growth factor-23 increases the risk 
of all-cause and cardiovascular mortality in the community. Kidney Int 2013;83:160-6.
38. Mirza MA, Hansen T, Johansson L, et al. Relationship between circulating FGF23 and total body 
atherosclerosis in the community. Nephrol Dial Transplant 2009;24:3125-31.
39. Leaf DE, Christov M, Juppner H, et al. Fibroblast growth factor 23 levels are elevated and associated 
with severe acute kidney injury and death following cardiac surgery. Kidney Int 2016;89:939-48.
40. Zhang Q, Doucet M, Tomlinson RE, et al. The hypoxia-inducible factor-1alpha activates ectopic 
production of fibroblast growth factor 23 in tumor-induced osteomalacia. Bone Res 2016;4:16011.
41. Hanudel MR, Wesseling-Perry K, Gales B, et al. Effects of acute kidney injury and chronic 
hypoxemia on fibroblast growth factor 23 levels in pediatric cardiac surgery patients. Pediatr 
Nephrol 2016;31:661-9.
42. Zoungas S, Cameron JD, Kerr PG, et al. Association of carotid intima-medial thickness and indices 
of arterial stiffness with cardiovascular disease outcomes in CKD. Am J Kidney Dis 2007;50:622-30.
186
6
43. Blacher J, Safar ME, Guerin AP, Pannier B, Marchais SJ, London GM. Aortic pulse wave velocity 
index and mortality in end-stage renal disease. Kidney Int 2003;63:1852-60.
44. Di Marco GS, Reuter S, Kentrup D, et al. Treatment of established left ventricular hypertrophy 
with fibroblast growth factor receptor blockade in an animal model of CKD. Nephrol Dial 
Transplant 2014;29:2028-35.
45. Isakova T, Cai X, Lee J, et al. Longitudinal FGF23 Trajectories and Mortality in Patients with 
CKD. J Am Soc Nephrol 2018;29:579-90.
46. Cernaro V, Lucisano S, Canale V, et al. Acetate-free biofiltration to remove fibroblast growth 
factor 23 in hemodialysis patients: a pilot study. J Nephrol 2018;31:429-33.
47. Choo SZ, Polkinghorne KR, Kerr PG. Biochemical Comparison of 8-hour Haemodialysis and 
4-hour Haemodiafiltration, and Two Dialysis Membranes, in a Randomised Cross-over Trial. 
Nephrology (Carlton) 2018.
48. Humalda JK, Riphagen IJ, Assa S, et al. Fibroblast growth factor 23 correlates with volume 
status in haemodialysis patients and is not reduced by haemodialysis. Nephrol Dial 
Transplant 2016;31:1494-501.
49. Koizumi M, Komaba H, Nakanishi S, Fujimori A, Fukagawa M. Cinacalcet treatment and serum 
FGF23 levels in haemodialysis patients with secondary hyperparathyroidism. Nephrol Dial 
Transplant 2012;27:784-90.
50. Moe SM, Chertow GM, Parfrey PS, et al. Cinacalcet, Fibroblast Growth Factor-23, and 
Cardiovascular Disease in Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower 
Cardiovascular Events (EVOLVE) Trial. Circulation 2015;132:27-39.
51. Ketteler M, Sprague SM, Covic AC, et al. Effects of sucroferric oxyhydroxide and sevelamer 
carbonate on chronic kidney disease-mineral bone disorder parameters in dialysis patients. 
Nephrol Dial Transplant 2018.
52. Patrier L, Dupuy AM, Granger Vallee A, et al. FGF-23 removal is improved by on-line high-efficiency 
hemodiafiltration compared to conventional high flux hemodialysis. J Nephrol 2013;26:342-9.
53. Bouma-de Krijger A, de Roij van Zuijdewijn CLM, Nubé MJ, Grooteman MPC, Vervloet MG, Group 
obotCS. Change in FGF23 concentration over time and its association with all-cause mortality in 
patients treated with haemodialysis or haemodiafiltration. Clinical Kidney Journal 2020.
54. de Jager DJ, Grootendorst DC, Jager KJ, et al. Cardiovascular and noncardiovascular mortality 
among patients starting dialysis. JAMA 2009;302:1782-9.
55. Marthi A, Donovan K, Haynes R, et al. Fibroblast Growth Factor-23 and Risks of Cardiovascular 
and Noncardiovascular Diseases: A Meta-Analysis. J Am Soc Nephrol 2018;29:2015-27.
56. Di Iorio B, Di Micco L, Torraca S, et al. Acute effects of very-low-protein diet on FGF23 levels: 
a randomized study. Clin J Am Soc Nephrol 2012;7:581-7.
57. Goto S, Nakai K, Kono K, et al. Dietary phosphorus restriction by a standard low-protein diet 
decreased serum fibroblast growth factor 23 levels in patients with early and advanced stage 
chronic kidney disease. Clin Exp Nephrol 2014;18:925-31.
58. Gonzalez-Parra E, Gonzalez-Casaus ML, Galan A, et al. Lanthanum carbonate reduces FGF23 
in chronic kidney disease Stage 3 patients. Nephrol Dial Transplant 2011;26:2567-71.
59. Yilmaz MI, Sonmez A, Saglam M, et al. Comparison of Calcium Acetate and Sevelamer on 
Vascular Function and Fibroblast Growth Factor 23 in CKD Patients: A Randomized Clinical 
Trial. Am J Kidney Dis 2012;59:177-85.
60. Bouma-de Krijger A, Vervloet MG. Fibroblast growth factor 23: are we ready to use it in clinical 
practice? Journal of Nephrology 2020;33:509-27.
61. Shalhoub V, Shatzen EM, Ward SC, et al. FGF23 neutralization improves chronic kidney disease-
associated hyperparathyroidism yet increases mortality. J Clin Invest 2012;122:2543-53.
62. Yanochko GM, Vitsky A, Heyen JR, et al. Pan-FGFR inhibition leads to blockade of FGF23 signaling, 
soft tissue mineralization, and cardiovascular dysfunction. Toxicol Sci 2013;135:451-64.
187
6
63. Kuro-o M, Matsumura Y, Aizawa H, et al. Mutation of the mouse klotho gene leads to 
a syndrome resembling ageing. Nature 1997;390:45-51.
64. Chen TH, Kuro OM, Chen CH, et al. The secreted Klotho protein restores phosphate retention 
and suppresses accelerated aging in Klotho mutant mice. Eur J Pharmacol 2013;698:67-73.
65. Grabner A, Schramm K, Silswal N, et al. FGF23/FGFR4-mediated left ventricular hypertrophy is 
reversible. Sci Rep 2017;7:1993.

Addendum &LIST OF ABBREVIATIONS









FGF23  fibroblast growth factor 23 
iFGF23   intact FGF23
cFGF23  c-terminal fragment of FGF23
PTH   parathyroid hormone
CKD  chronic kidney disease
CVD  cardiovascular disease 
CKD-MBD CKD-mineral bone disorder
ESRD  end stage renal disease 
eGFR  estimated glomerular filtration rate
MAP   mean arterial pressure
LVH  left ventricular hypertrophy
CHF  congestive heart failure
PWV   pulse wave velocity 
KI   Kauppila index 
AAC   abdominal aortic calcification
FePi  fractional excretion of phosphate
HD  hemodialysis
HDF  hemodiafiltration
RRT  renal replacement therapy
GEE models  generalized estimating equations models
MDRD formula four-point modification of diet in renal disease formula
SD  standard deviation




NEDERLANDSE SAMENVATTING VOOR NIET 
INGEWIJDEN
Een patiënt met een verminderde nierfunctie heeft een sterk verhoogd risico op het 
ontwikkelen van een hart- of vaataandoening  en een verhoogd risico op vroegtijdig 
overlijden. Het is bekend dat dit komt doordat een chronische verminderde nierfunctie, 
oftewel wel chronische nierschade, vaak gepaard gaat met een aantal risicofactoren voor 
het ontwikkelen van hart- en vaatziekte (HVZ),   zoals het hebben van suikerziekte, hoge 
bloeddruk of een verhoogd cholesterol. Er is echter naast  deze risicofactoren nog een 
bijkomende factor nodig die het veelvuldig voorkomen van HVZ en de oversterfte bij 
patiënten met een chronische nierschade kan verklaren. Er zijn steeds meer aanwijzingen 
uit wetenschappelijk onderzoek dat een verstoorde calcium-fosfaathuishouding bij 
patiënten met chronische nierschade zo’n bijkomende risicofactor is. Calcium en fosfaat 
zijn nodig voor allerlei processen in het lichaam, zoals voor de energiehuishouding, 
de werking van spieren en zenuwen en voor de opbouw en het herstel van botten. 
Verstoring hiervan leidt  tot nadelige effecten in het lichaam.
Een belangrijk hormoon dat zorgt voor een stabiele calcium en fosfaathuishouding 
is ‘Fibroblast Growth Factor 23’ (FGF23). Dit hormoon wordt gevormd in de botten en 
staat onder andere onder invloed van andere hormonen zoals het bijschildklierhormoon, 
de vitamine D concentratie en de concentraties van calcium en fosfaat.
 Schade aan de nieren leidt tot een verminderde capaciteit van de nieren om het bloed 
te filteren en te zuiveren (de klaring). Bij een verminderde nierfunctie zou ook de klaring 
van fosfaat in het gedrang komen, maar compensatoire mechanismen voorkomen dat 
grotendeels .  Bij achteruitgang van de nierfunctie wordt er compensatoir meer FGF23 
aangemaakt, en dit FGF23 zet de nier aan om meer fosfaat per nog werkende nier-
eenheid (nefron) uit te scheiden. Dat mechanisme is gunstig, want een verhoogd fosfaat 
in het bloed leidt onder andere tot bloedvatenverkalking. 
Een verhoogd FGF23, en vooral een heel sterk verhoogd FGF23, is echter mogelijk ook 
nadelig. Uit talloze onderzoeken blijkt namelijk dat een verhoogde FGF23 concentratie 
in het bloed is geassocieerd met een verhoogd risico op het optreden van verdikking 
van de hartspier, stijve bloedvaten, een hartaandoening (zoals een hartinfarct). Mede 
hierdoor geeft het een verhoogd risico op vroegtijdig overlijden. Dit verband tussen een 
verhoogd FGF23 en deze nadelige effecten blijft aanwezig ook als in deze onderzoeken 
gecorrigeerd wordt (met statistische methoden) voor andere bijkomende risicofactoren 
en voor een hoger fosfaat. Ook wordt de associatie tussen FGF23 en deze verhoogde 
risico’s gezien bij zowel mensen met een nierschade als bij gezonde mensen. 
Uit deze waarneming volgt de hypothese dat een hoog FGF23 mogelijk leidt tot 
ziekmakende processen die (deels) HVZ veroorzaken die kunnen leiden  tot voortijdig 
overlijden. Ook laten experimentele laboratoriumonderzoeken  nadelige effecten zien 
van FGF23 op de bloedvaten en de hartspier die deze hypothese ondersteunen. Een 
hypothese die in de praktijk nog bewezen moet worden.  
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Het doel van dit proefschrift is om te onderzoeken of verlaging van FGF23 bij mensen 
met een chronische nierschade gunstige effecten laat zien en of een verlaging van FGF23 
daadwerkelijk leidt tot een verlaging van het risico op HVZ en sterfte. Dit is nodig om 
te bepalen of er in de toekomst een therapie moet komen die gericht is op het laten dalen 
van FGF23 in patiënten met nierschade. Dit met als doel om de behandeling van patiënten 
met een chronische nierschade te verbeteren en zo het risico op HVZ te verminderen.
In hoofdstuk 1 wordt een aantal aspecten onderzocht van de vraag of het bepalen 
van FGF23 nuttig kan zijn voor de klinische praktijk. Deze review begint met de vraag 
of de meting van FGF23 betrouwbaar is. Uit onderzoeken blijkt dat FGF23 nauwkeurig 
bepaald kan worden mits het bloed na afname tijdig gecentrifugeerd wordt, anders 
degradeert het FGF23 eiwit. Na centrifugeren blijkt het eiwit goed stabiel en ook is het 
stabiel als het materiaal wordt opgeslagen bij -80 °C. Er zijn verschillende kwantitatieve 
analyse tests (assays) beschikbaar om FGF23 te meten. Bepaalde assays meten het totale 
eiwit (intact of iFGF23), andere meten alleen fragmenten van het eiwit (c-terminale 
fragment of c-FGF23). Onderzoeken laten zien dat het intacte FGF23 binnen het individu 
een biologische variabiliteit heeft, waarbij de concentratie in de ochtend hoger is dan 
in de middag. Verder staat de concentratie van iFGF23 -met enige vertraging- onder 
invloed van de fosfaat inname in het dieet. Daarmee lijkt iFGF23 een betere reflector 
te zijn van het biologisch effect van FGF23 dan cFGF23.  Vergeleken met iFGF23, zijn 
de waarden van cFGF23 veel stabieler binnen het individu en laten weinig biologische 
variabiliteit zien. Ook heeft cFGF23 een sterkere relatie met uitkomst dan iFGF23. Welk 
FGF23 je het beste kan meten hangt dus af van het doel waarvoor je het wilt meten en 
dat bepaalt ook wanneer je het moet meten en welke assay je moet gebruiken. Hier moet 
nog meer onderzoek naar gedaan worden. Daarnaast zijn de verschillende FGF23 assays 
weliswaar goed getest op reproduceerbaarheid en nauwkeurigheid, maar ze zijn nog niet 
goed met elkaar vergeleken. Ook zijn er nog geen leeftijdsafhankelijke en nierfunctie 
afhankelijke normaalwaarden vastgesteld. Dit is nog een obstakel om FGF23 te meten in 
de klinische praktijk.
Voor wat betreft de bruikbaarheid van FGF23 om het risico op ziekte en sterfte voor een 
individuele patiënt beter in te schatten is er ook nog onduidelijkheid. Uit de onderzoeken 
die in hoofdstuk 1 op een rij zijn gezet blijkt dat FGF23 geen toegevoegde waarde heeft 
als deze marker wordt toegevoegd aan de bestaande risicomodellen om de achteruitgang 
van de nierfunctie en de start van de dialyse te voorspellen. Bij patiënten met chronische 
nierschade geeft toevoeging van FGF23 aan de bestaande modellen wél een verbetering 
van de risico inschatting op sterfte. Iets wat overigens niet meer wordt gezien bij patiënten 
met vergevorderde ziekte, namelijk bij het eindstadium van nierfalen als patiënten zijn 
gestart met dialyse.   
Wat betreft de vraag of FGF23 gebruikt moet worden in de klinische praktijk, 
analyseerde deze review de argumenten voor mogelijke toxiciteit van FGF23 uit 
epidemiologische studies en uit experimenteel onderzoek. Hoofdstuk 1 zette hiervoor 
195
&
verschillende onderzoeken op een rij en laat zien dat FGF23 een associatie toont met 
sterfte, dat matig sterk is bij gezonde personen, sterk is bij patiënten met chronische 
nierschade maar minder duidelijk aantoonbaar is bij patiënten aan dialyse. Daarnaast 
is er bij patiënten met chronische nierschade ook een associatie tussen de hoogte van 
FGF23 en optreden van HVZ. Verder is er een associatie tussen FGF23 en het optreden 
van een verdikte hartspier (linker ventrikel hypertrofie, LVH). Experimenteel onderzoek 
heeft mogelijke mechanismen ontdekt waardoor een hoog FGF23 nadelig kan zijn. Dit is 
onderzocht voor LVH, maar ook zijn er verstorende processen beschreven die een verband 
aantonen tussen verhoogd FGF23 en een verstoorde vaatwand functie. 
Vervolgens is de vraag, of we FGF23 kunnen laten dalen. Dit hoofdstuk behandelt 
studies die dit onderzocht hebben. Hoewel de resultaten van deze studies divers zijn, lijkt 
het beeld te overheersen dat gebruik van niet-calcium-houdende fosfaatbinders FGF23 
kunnen doen laten dalen, mits de dosering en de tijdsduur van deze medicatie voldoende 
is. Ook zijn er studies die aantonen dat de concentratie van FGF23 kan dalen door de stof 
te klaren met hemodiafiltratie (een vorm van dialyse) en waarschijnlijk ook door het 
remmen van de bijschildklier met het medicijn cinacalcet.
Dit alles leidt tot de hoofdvraag: Is een daling van FGF23 gunstig?  Er zijn nog 
geen prospectieve studies gedaan waarbij er onderzocht is of een daling van FGF23, 
bijvoorbeeld via één van de bovengenoemde therapieën,  effect heeft op het risico op 
HVZ en sterfte. De onderzoeken in dit proefschrift zetten stappen in de richting om deze 
vraag te beantwoorden.
In hoofdstuk 2 is het epidemiologisch onderzoek beschreven waarin FGF23 wordt 
gerelateerd aan  klinische uitkomsten. In hoofdstuk 2.1 werd onderzocht in hoeverre 
het natuurlijke beloop van FGF23 bij patiënten met chronische nierschade invloed heeft 
op het optreden van HVZ en sterfte. De vraag hierbij was of een stijging van FGF23 een 
hoger risico en een spontane daling een verlaagd risico geeft op nadelige uitkomsten. 
Daarvoor werd gekeken naar het gemiddelde FGF23 waarden over twee jaar tijd als 
maat voor blootstelling aan FGF23 (de mogelijk ‘toxische stof’). Daarnaast werd er 
gekeken naar de verandering van FGF23 over twee jaar tijd, uitgedrukt in percentage 
en als absolute stijging of daling, als maat voor progressie van ziekte. Het gemiddelde 
FGF23 en de verandering van FGF23 werd vergeleken met een enkel meetmoment van 
FGF23. Uit het onderzoek kwam naar voren dat FGF23 waarden bij chronische nierschade 
over het algemeen heel stabiel zijn over tijd en dat, waarschijnlijk als gevolg daarvan, 
meerdere meetmomenten geen betere inschatting maken van het risico op complicaties 
en sterfte vergeleken met een enkele meting. Wel bevestigde dit onderzoek eerdere 
onderzoeksresultaten, namelijk dat FGF23 een sterke associatie heeft met het optreden 
van HVZ en sterfte. 
In hoofdstuk 2.2 is een meta-analyse beschreven waarbij de resultaten van 
eerder gepubliceerde onderzoeken naar de relatie van FGF23 en klinische uitkomst, 
samengevoegd werden en geanalyseerd werden. Deze analyse betrof onderzoeken onder 
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de gezonde populatie, onder patiënten met chronische nierschade en onder patiënten 
met eindstadium chronische nierschade aan dialyse. Uit de analyse blijkt dat in alle 
onderzoeksgroepen de kans op een hartinfarct, herseninfarct en hartfalen verhoogd was 
voor de groep met de hoogste FGF23 waarden. Een bijzondere uitkomst daarbij is dat 
het risico in gelijke mate verhoogd was voor zowel de verschillende uitkomstmaten als 
voor de verschillende populaties, terwijl de nierfunctie tussen de groepen en de daarbij 
passende absolute hoogte van FGF23 aanzienlijk verschilde. Dat de relatie tussen FGF23 
en uitkomst niet-specifiek lijkt en dat er geen duidelijke blootstelling-effect relatie is, pleit 
tegen een oorzakelijke relatie tussen verhoogd FGF23 en uitkomst. 
Toch is een oorzakelijke relatie tussen verhoogd FGF23 en uitkomsten nog steeds 
mogelijk, zonder een duidelijke relatie tussen de hoogte van FGF23 en de hoogte van het 
risico op HVZ. Het kan namelijk zijn dat de relatie tussen FGF23 en HVZ een niet-rechtlijnige 
verdeling heeft, waardoor bij hogere waarden de associatie minder sterk wordt. Dit zou 
kunnen komen doordat er bij hogere FGF23 waarden FGF23 resistentie optreedt. FGF23 
resistentie is dan de situatie waarbij de nier en de bijschildklier niet meer goed reageren 
op FGF23. Tenslotte wijst een eerder onderzoek onder patiënten met matig verminderde 
nierfunctie op de mogelijkheid dat juist FGF23 resistentie verantwoordelijk zou kunnen 
zijn voor de relatie tussen FGF23 en nadelige klinische uitkomst.
Hoofdstuk 3 beschrijft  het onderzoek naar de vraag of FGF23 resistentie de 
verklaring kan zijn voor het hogere risico op HVZ bij chronische nierschade. FGF23 
verhoogt de uitscheiding van fosfaat per nog werkende nier-eenheid, oftewel de 
fractionele fosfaatexcretie (FePi). FGF23 resistentie kan dus gedefinieerd worden als een 
hoog FGF23 gecombineerd met een lage FePi. In het onderzoek, onder patiënten met 
een matig verminderde nierfunctie (chronische nierschade stadium 3-4) werd gevonden 
dat FGF23 geassocieerd was met een samengestelde uitkomstmaat (de combinatie van 
sterfte , HVZ of achteruitgang van de nierfunctie). Echter, de relatie tussen FGF23 en 
uitkomst veranderde niet bij statistische correctie voor FePi. Ook was er geen interactie 
tussen FGF23 en FePi, dat wil zeggen dat deze variabelen samen niet het effect op de 
uitkomst versterken, iets dat wel het geval zou zijn als FGF23 resistentie verantwoordelijk 
zou zijn voor het verhoogde risico op een nadelige klinische uitkomst.  
Voorgaande onderzoeken zijn gebaseerd op observationele data en daaruit kunnen 
alleen indirecte bewijzen voortkomen voor de aard van de relatie tussen FGF23 en klinische 
uitkomst. Prospectief klinisch onderzoek met als doel het effect van therapeutische FG23 
verlaging  op klinische uitkomst te bestuderen, is daarom nodig. Hoofdstuk 4 beschrijft 
de prospectieve studie verricht onder patiënten met matige nierschade (stadium 3) waarin 
werd onderzocht of  acht weken behandeling met sevelamer, een niet-calcium-houdende 
fosfaatbinder, FGF23 kon laten dalen en wat het effect daarvan zou zijn op vaatstijfheid. 
De vaatstijfheid werd gemeten met de polsgolfsnelheid (Pulse Wave Velocity, PWV), 
aangezien dit een gevalideerde methode is om vaatstijfheid te meten en omdat PWV een 
bewezen sterke relatie heeft met een verhoogd risico op HVZ en sterfte. Vaatstijfheid 
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wordt bepaald door structurele vaatwandeigenschappen maar ook door de functionele 
vaatfunctie, dit laatste is beïnvloedbaar door kortdurende interventies zoals ook toegepast 
in deze studie. Eerdere studies hebben laten zien dat sevelamer gebruik mogelijk leidt tot 
een verlaging van de PWV. Tevens zijn er studies gedaan waarbij aangetoond werd dat 
sevelamer FGF23 kon laten dalen. Onbekend is of de sevelamer geïnduceerde verlaging 
van PWV wordt veroorzaakt door een daling in FGF23.  Echter, in ons onderzoek werd er 
geen daling van FGF23 geobserveerd na een acht-weekse behandeling met sevelamer, 
ook was er geen verbetering van PWV. Bijzonder was dat in een subgroep van deze 
studie, namelijk bij patiënten met geen tot weinig vaatwandverkalking (een structurele 
vaattoestand leidend tot hoge stijfheid), wél een verlaging werd gevonden van de PWV 
na behandeling met sevelamer. In deze subgroep werd overigens geen daling van FGF23 
gevonden, hetgeen suggereert dat het effect van sevelamer op PWV niet gemedieerd 
werd door een daling van FGF23. 
Evenals het onderzoek in dit proefschrift, hebben eerdere studies laten zien dat FGF23 
concentraties bij stabiele chronische nierschade matig verhoogd zijn en ook vrij stabiel 
over tijd. Het is mogelijk dat er een meer substantiële daling van FGF23 nodig is om 
het effect op klinische uitkomsten aantoonbaar te maken. Daarvoor zijn langere studies 
nodig, of behandelingen die het FGF23 sterker laten dalen, of misschien zijn er hogere 
uitgangsconcentraties van FGF23 nodig om een effect meetbaar te maken. Heel hoge 
concentraties FGF23 worden gezien bij patiënten met eindstadium chronische nierschade 
langdurig aan dialyse. Idealiter zou prospectief onderzocht moeten worden of substantiële 
FGF23 daling in deze groep tot een verlaging van het risico op HVZ en sterfte leidt, maar 
dergelijke studies zijn nog niet verricht. Hoofdstuk 5 beschrijft het effect van FGF23 
daling bij patiënten met eindstadium nierschade aan dialyse. Dit werd onderzocht door 
middel van een post hoc analyse van een eerdere studie, de zogenaamde CONTRAST 
studie. Deze studie is een gerandomiseerde studie onder eindstadium nierfalen patiënten 
waarbij hemodialyse (HD) werd vergeleken met hemodiafiltratie (HDF) op klinische 
uitkomsten. Eerder onderzoek heeft laten zien dat convectief transport, de methode van 
klaring gebruikt bij HDF, effectief het FGF23 kan verlagen. Conventionele HD kan dit niet, 
aangezien FGF23 met zijn midden-moleculaire grootte het dialyse membraan niet kan 
passeren. In het onderzoek werden hoge concentraties FGF23 gevonden waarbij er over 
de tijd sterk uiteenlopende concentraties werden gevonden. In de groep patiënten aan 
HDF werd er gemiddeld een daling van FGF23 gezien, dit zoals verwacht. Indien werd 
gekeken naar een stijgend of een dalend versus een gelijkblijvend FGF23, werd gezien 
dat een daling van FGF23 (t.o.v. een gelijkblijvend FGF23) niet gepaard ging met een 
verlaagd risico op sterfte. Daarentegen was een stijgend FGF23 wel geassocieerd met 
een verhoogd risico op sterfte. Het ontbreken van een lineaire respons op verandering 
suggereert dat er geen oorzakelijke relatie is tussen FGF23 en klinische uitkomst, en dat 
een stijgend FGF23 slechts personen identificeert met een verhoogd risico. Opvallend is 
dat dit onderzoek geen associatie vond tussen baseline FGF23 en sterfte. Een mogelijke 
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verklaring hiervoor is dat de associatie tussen FGF23 en sterfte verdwijnt als FGF23 
waarden heel hoog worden, zoals bij patiënten die langdurig dialyseren. 
Hoofdstuk 6 biedt een samenvatting en discussie van de resultaten van de studies die 
in dit proefschrift beschreven worden. 
De onderzoeken beschreven in dit proefschrift hebben een bijdrage geleverd aan de 
reeds bestaande kennis op het gebied van FGF23 onderzoek en met name op het gebied 
dat de relatie onderzoekt tussen een verstoorde calcium-fosfaathuishouding en klinische 
uitkomst. De studies in dit proefschrift hebben bevestigd dat FGF23 bij patiënten met 
een chronisch verminderde nierfunctie gerelateerd is aan een verhoogd risico op HVZ 
en sterfte. Bij patiënten met matig chronische nierschade lijken de veranderingen 
van FGF23 concentraties tijdens het natuurlijk beloop van ziekte deze relatie echter 
niet te beïnvloeden. Hierbij moet worden opgemerkt, dat bij deze groep patiënten, 
FGF23 concentraties over tijd heel stabiel blijken te zijn. Dit is anders bij patiënten met 
vergevorderde nierschade die al langere tijd dialyseren. In deze groep patiënten werd 
geen duidelijke relatie gevonden tussen FGF23 en sterfte. Dit komt mogelijk doordat deze 
patiënten een heel hoog risico hebben op overlijden door andere bijkomende factoren, 
waardoor het risico van verhoogd FGF23 wordt overschaduwd. Bij deze patiënten is een 
stijgend FGF23 echter wel gerelateerd aan een hoger risico op voortijdig overlijden. 
Al met al lijkt FGF23 een veelbelovende biomarker bij patiënten met chronische 
nierschade. FGF23 kan patiënten identificeren met een hoog risico op HVZ en/of 
overlijden. Het is alleen nog onduidelijk of dit risico verlaagd kan worden en op welke 
manier dit moet gebeuren. Ook is niet zeker of FGF23 een oorzakelijke rol speelt in 
de ontwikkeling van HVZ en het risico op sterfte. De studies in dit proefschrift hebben 
geen bewijs gevonden dat het laten dalen van FGF23 een gunstig effect heeft op deze 
uitkomsten. Op dit moment is het te voorbarig om FGF23 te gebruiken als doel van 
behandeling, maar meer onderzoek is nodig. Het feit dat diverse onderzoeken hebben 
laten zien dat het wel haalbaar lijkt om FGF23 te laten dalen, schept de mogelijkheid 
voor onderzoek dat gericht is op FGF23 daling en evalueert wat het effect daarvan is op 
HVZ en sterfte. Dit onderzoek is zeer gewenst, gezien de hoge prevalentie van chronische 
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Nu er een einde is gekomen aan de leerzame en uitdagende periode van promotietraject 
rest mij nog een aantal mensen te bedanken. Dit proefschrift is niet het werk van mij alleen, 
maar velen hebben direct en indirect een rol gespeeld in de totstandkoming hiervan. 
Allereerst dank aan alle patiënten die geparticipeerd hebben in de onderzoeken. In het 
bijzonder de patiënten die meededen in de pilotstudy ben ik dankbaar dat ze een aantal 
maanden belangeloos studiemedicatie wilden gebruiken en naar het ziekenhuis kwamen 
voor de vele onderzoeken. Mijn hoop is dat dit proefschrift mag bijdragen aan betere 
zorg en gezondheid voor patiënten met chronische nierschade. 
Zeer geleerde professor dr. Vervloet, beste Marc, zonder jou had ik dit proefschrift niet 
kunnen maken. Jij liet mij vrij om mijn eigen pad bewandelen en bracht me zo nu en dan 
weer op koers met de aanmoediging niet te veel naar links of naar rechts uit te wijken. 
Dat was niet altijd gemakkelijk voor iemand zoals ik die graag het avontuur van zijpaden 
opzoekt, maar uiteindelijk lukte dat steeds beter. Ik bewonder je enorme parate kennis, je 
sterke analytische vermogen en je doelgerichte harde werken. Jij hebt mij mede gevormd 
als nefroloog en blijft mijn elektrolyten vraagbaak.
Hooggeachte professor dr. Ter Wee, beste Piet, mijn eerste baan na de opleiding kreeg ik 
van jou; een mooie plek om mij als jonge klare te ontwikkelen. Jij zorgde dat mijn ambitie 
om mij te ontwikkelen op onderzoeksgebied vorm kreeg door het ontwerp en de subsidie 
van mijn eerste onderzoek. De goede werksfeer op de afdeling nefrologie van het VUmc 
werd door jou gezet. 
Geachte leden van de leescommissie, prof. dr. Van Ittersum, prof. dr. Zillikens, dr. 
De Jongh en prof. dr. De Borst, hartelijk dank voor het lezen en het beoordelen van dit 
proefschrift. Ik zie er naar uit u te ontmoeten bij de verdediging. Dear professor Olauson, 
I am honoured that you took the effort to review this thesis and become a member of 
the doctorate committee.
Veel dank ook aan de Masterplan onderzoekers voor hun vertrouwen om de studie 
data te mogen gebruiken. Professor dr. Wetzels, Beste Jack, bedankt voor het prettige 
meedenken en het laagdrempelig overleg. Als iemand het boegbeeld is van de nefrologie 
in Nederland, ben jij dat. Je bent een voorbeeld door je kennis en kunde op klinisch en 
wetenschappelijk gebied en je scherpe analytische blik die ook mijn onderzoek naar een 
hoger niveau heeft getild. 
Professor dr. Bots, beste Michiel. Mijn eerste artikel schreef ik in samenwerking met jou. Een 
heel prettige samenwerking door jouw vriendelijke, no-nonsens houding en je inbreng die 
altijd verrassend vernieuwend en heel bijdragend was. Heel veel dank daarvoor.
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prof dr. F van Ittersum, beste Frans, bedankt voor het meedenken met de analyse van het 
klinische onderzoek. Het was best een puzzel om te zoeken welke analyse recht deed aan 
de onderzoeksvraag en vaker dan eens moest het roer weer om, een hele klus. Toch is het 
juist hierdoor beter geworden. Jij zorgde voor tijd om aan mijn onderzoek te werken en 
jouw eerlijke en rationele werkwijze heb ik altijd erg gewaardeerd.
Tiny Hoekstra, wat was het leuk om met jou samen te werken! Je bent laagdrempelig 
meedenkend en je hebt me enorm fijn geholpen met een deel van de statistiek. Na een 
middagje SPSS-en, wat overigens altijd eindigde in een melige sfeer, was ik elke keer weer 
wat verder gekomen. Bedankt daarvoor. 
Veel dank ook aan de onderzoeksverpleegkundigen van het Niercentrum voor alle 
ondersteuning. Marion en Hiske, veel dank voor de metingen die jullie als research 
verpleegkundigen voor mij deden. Marieke, wij brachten heel wat uren door in een vreemde 
wereld achter hekken met sleutels en codes, die van droogijs, handschoenen-in-de-zomer 
en -80 °C vriezers. Het monnikenwerk van samples uitzoeken werd zo toch gezellig. 
Het onderzoek naar de invloed van FGF23 verandering bij patiënten aan hemodialyse 
en de rol van HDF daarin is mogelijk geworden dankzij de contrast studie groep. Zeer 
gewaardeerde dr. Grooteman, beste Muriel, ik heb je langzamerhand steeds beter leren 
kennen als een mooie, warme persoonlijkheid. Niet alleen heb ik op wetenschappelijk gebied 
van jou geleerd en kon ik mij laven aan jouw kennis over hemodialyse en hemodiafiltratie, 
en passant kreeg ik van jou ook veel levenswijsheden mee. Weledelzeergeleerde Camiel 
de Roy van Zuijdewijn, beste Camiel, zo relaxed als jij razendsnel statistiek uit jouw 
mouw schudt! Altijd optimistisch en relativerend, dank voor de leuke samenwerking! 
Professor Nube, beste Menso, met pretoogjes toonde jij mij de vrijheid van nieuwsgierige 
gedachtenvorming. Jouw prikkelende humor was relativerend en zorgde dat er ook nog 
wat gelachen werd. 
Beste Anneke Bech, we schreven samen het stuk over FGF23 resistentie, waarbij jij goed 
de vaart er in hield. Jij was van de grote stappen, ik meer van de details. Dat bleek mooi 
complementair en dat hebben we ondanks de afstand toch mooi samen gedaan!
Hooggeleerde –inmiddels professor, gefeliciteerd!- Annemieke Heijboer, bij een vraag 
over de FGF23 bepalingen kon ik altijd bij jou terecht en kreeg ik altijd een antwoord 
waar ik wat aan had. Hartelijk dank voor je hulp en advies. Zo’n vaagbaak als jij wens ik 
iedere onderzoeker!
Mijn collega nefrologen van het VU Medisch Centrum wil ik bedanken voor de goede 
werksfeer. In de begin tijd Brigit, Muriel, Azam, Marc, Piet, Frans, Joost, Wim, Carolien, 
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Neelke en Karima, jullie hebben mij mede gevormd als nefroloog, en later ook Joris, 
Aegida, Janneke, Fenna, Catherine, Yu-sok en Frederiek, bedankt voor de collegialiteit en 
gezelligheid. Karima en Carolien, onze Spaarne tijd - met het kletspraatje met Eva als begin 
van de dag (heel gezellig!) - is een warme herinnering. Brigit, dank voor de ruimte die jij 
mij gaf in Diapriva. Na corona wordt het hoog tijd voor weer eens een kippenhok etentje! 
Ook dank aan de verpleegkundigen van het VUmc voor de heel prettige samenwerking. 
En misschien, wie weet, ga ik ook nog eens ergens landen. Michaela, Bart, Marc en Rik en 
de collega-internisten uit het CWZ, bedankt voor het warme onthaal bij jullie.
Veel dank aan mijn paranimfen, Jedidja en Kaatje. Dat jullie mij willen bijstaan, betekent 
veel voor mij. Jedidja, vanaf het tweede jaar Geneeskunde trekken we met elkaar op en 
we kennen elkaar door en door. Wat fijn om zo’n goede vriendin te hebben met wie ik 
over van alles kan sparren. Fijn dat jij nu je plek hebt gevonden als psychiater. Kaatje, 
vanaf dag 1 in de opleiding tot internist was jij er. Van Zaandam, met daar overvolle 
afdelingen runnen, hectische spoedsituaties het hoofd bieden en wat al niet meer, naar 
samen in de academie als het (misschien minder dan verwachte) walhalla van kennis, tot 
het internist worden; we hebben heel de opleiding gezamenlijk doorlopen. Prachtig hoe 
jij van alles in mooie beeldtaal weet te vangen!
Lieve vrienden, bedankt voor jullie hulp en raad al deze jaren, maar vooral dank voor 
de broodnodige ontspanning en gezelligheid. Meiden (Wu, Es, Jed), na dit proefschrift 
gaan we weer eens pokeren! En wanneer naar Oerol? Laten we de traditie van jaarlijkse 
(-helaas nu minder-) weekendjes weg volhouden tot 80+! Hopelijk na dit proefschrift 
meer tijd voor etentjes, verjaardagen, bijkletsen en gezellige borrels; Marianka, Rosalinde, 
Akke, Erica, Daan en Lian, we zien elkaar te weinig, maar elke keer is het goed!
Ineke en Truus bedankt voor jullie flexibiliteit en bereidheid om op onze kinderen 
te passen. Ineke, jij stond om half 8 op de stoep vanaf dat Alette vier maanden oud was. 
Ik kon met een gerust hart naar mijn werk in de wetenschap dat ze bij jou in veilige en 
liefdevolle handen was. Truus, dank dat we op jou zo vaak een beroep mogen doen, zelfs 
bij nacht en ontij! Als ik weer eens tot laat moest werken was het fijn dat Alette ‘s avonds 
op de boerderij kon mee-eten. 
En wat is het goed om fijne buurtgenoten te hebben! Agnes, heerlijk om bij jou even 
langs te fietsen voor een kop koffie, samen schilderen –moet ook gebeuren- gaat niet 
alleen sneller maar is ook erg gezellig! Ineke, bedankt voor alle raad en daad. René 
en Annemiek dank voor jullie gastvrijheid en de mogelijkheid om mijn laatste artikel 
te schrijven in jullie tuinhuis en huis. Maria, Joris, Ben, Deborah en Tjalling, jullie 
organiseerden de gezamenlijke thuisschool tijdens de eerste corona lockdown- wat een 
203
&
goede oplossing! Jaqualine, Jan, Nicolien en met jullie nog velen, wat is het goed om in 
Postwijck een stevige basis te hebben.
Lieve schoonfamilie, jullie huis is een fijn thuis. Wat een heerlijke luxe om af en toe neer 
te kunnen ploffen en verzorgd te worden. Dank voor jullie liefde, interesse en meeleven. 
Henk, Elmarie, Froukje, Chris, Herman en Naomi ik heb het getroffen met jullie als 
extended family. 
Lieve familie; Greet, Henk, Jacobien en Anke en natuurlijk ook Dan, Sandra, Erik-Jan 
en Roelof, ik ben blij met jullie! Lieve papa en mama, jullie liefde, harde werken, 
zorgzaamheid en verantwoordelijkheid hebben mij mede gevormd tot wie ik ben. Mama, 
je bent hier niet meer bij en ik blijf je missen, maar ik ben er zeker van dat je trots op mij 
zou zijn. Lieve papa, jij leerde mij Nil Volentibus Arduum, en dat heb ik onthouden! 
Aller, aller, allerliefste Alette en Thijs, jullie brengen behalve af en toe ongewenste afleiding 
vooral een heel veel vrolijke, onbevangen gezelligheid die ik niet voor mogelijk had 
gehouden. Alette, dank voor je mooie tekeningen en lieve briefjes ‘(‘Mamma omdat jij zo 
hart werkt voor ons allemaal♥ krijg jij dit mooie schilderij’). Thijs bedankt voor je knuffels en 
zoentjes. Julie zijn voor mij een blijvend wonder en ik dank God voor jullie bestaan. 
Lieve Tjalling, jij bent altijd in voor iets nieuws ondernemen. De afgelopen jaren waren 
wat dat betreft zeker een avontuur! De combinatie van beiden een baan, beiden een 
proefschrift schrijven en samen een gezin hebben heeft ons wel eens tot wanhoop 
gedreven! Ik had dit proefschrift niet kunnen schrijven zonder jouw steun en liefde, 
waarvoor oneindig veel dank. En nu tijd voor een ander avontuur!
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